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 The current work establishes novel heme sensing technology to quantitate 
intracellular labile heme (LH) and provides new information concerning the amount and 
dynamics of LH pools. Though methods to detect both total and exchange inert 
intracellular heme exist, measuring exchange LH in intact cells, the pool of heme 
accessible for heme dependent processes and signaling, has not been possible until the 
development of fluorescent based genetically encoded sensors like that put forth by this 
work2. The nature of the regulatory heme pool, how it is controlled, as well as the means 
by which heme can be propagated to activate heme-based signals have remained 
mysterious phenomena. However, this body of work demonstrates the means to measure 
the dynamics of heme mobilization and trafficking, conditions that dynamically mobilize 
heme, proteins involved in buffering or controlling LH availability, and demonstrate the 
subsequent effects of altered LH levels on heme dependent transcription. 
 Before starting this thesis work, tools to monitor intracellular LH levels to 
investigate what controls LH availability and mobilization did not yet exist. The 
objective, therefore, was to develop and extensively characterize a tool to quantitate 
intracellular LH and apply it in multiple cell lines starting with the easily genetically 
tractable model eukaryote Saccharomyces cerevisiae. As a lab, we collectively showed 
that by using the heme sensors characterized in this body of work, we could measure and 
identify factors that induce dynamic heme mobilization and identify new heme 
trafficking proteins that control LH availability.  
 xxviii 
 After using the heme sensor to demonstrate the first reported case that heme could 
be dynamically mobilized by signaling molecules like nitric oxide (NO), further stress 
conditions that may cause dynamic shifts in heme mobilization were investigated. 
Investigated stresses included heme starvation, heme chelation, and Pb2+ poisoning in 
Saccharomyces cerevisiae. Indeed, fluxes in LH availability under these stress conditions 
resulted in changes in heme dependent signaling evincing a role for this regulatory pool 
of heme in controlling heme signaling. Of the investigated stresses, Pb2+ poisoning, 
which was originally hypothesized to induce heme signaling in the form of a 
mitochondrial retrograde signal, was shown to have the most adverse effects on heme 
homeostasis. Our extensive characterization of our yeast model of Pb2+ poisoning and its 
effects on labile and total heme motivated the development of a heme affinity assay using 
hemin agarose beads to be used with quantitative mass spectrometry to identify proteins 
that dynamically lose or gain heme in response to Pb2+ poisoning. The identification of 
these proteins was hypothesized to shed light on new heme signaling networks activated 
under Pb2+ poisoning. 
 The other main goal of this thesis was to fully characterize the heme sensors in a 
mammalian cell line. After describing the use of our heme sensors in HEK293 cells and 
developing calibration protocols to quantitate LH in these cells, the sensors were used to 
interrogate compartment specific LH availability. Using the heme sensors, we identified 
how both synthesis and import of extracellular heme each impact cytosolic, nuclear, and 
mitochondrial heme pools. In this investigation, we discovered a preference for 
synthesized heme in the mitochondrial LH pool and that nuclear and cytosolic LH pools 
were more sensitive to exogenous heme availability than mitochondria. Next, given that 
 xxix 
overexpressed heme oxygenase 2 (HO2) was ascribed cytoprotective roles under 
oxidative stress that were independent of its catalytic activity, we sought to test if HO2 
overexpression had an impact on labile and total heme availability. Quite surprisingly, we 
found that both WT HO2 and catalytic mutants, but not heme binding mutants of HO2, 
sequester LH in HEK293 cells without effecting total heme availability. This unexpected 
result ultimately elucidated a cytoprotective role for HO2 acting as a heme sequestering 
or heme buffering factor. In total, the work done in HEK293 cells puts forth the means to 
quantify subcellular pools of LH that should be adapted to other mammalian cell lines 
and demonstrate the use of our heme sensors to uncover previously undescribed effectors 
of LH availability like HO2. 
 Altogether, completion of this body of work poises others to use the developed 
fluorescent sensor technology to shed more light on questions relevant to heme 
trafficking and transport, as well as LH’s roles in heme related pathologies. In addition, 
proteins identified by the investigation in the hemin agarose mass spectrometry studies 
represent a new putative heme binding proteome, and the screening and characterization 
of these proteins may demonstrate their involvement in regulating LH availability and 




CHAPTER 1. INTRODUCTION 
 Iron protoporphyrin IX, or heme, is an iron-containing macrocycle required for all 
aerobic life that functions as a protein prosthetic group to most porphyrin binding 
proteins2, 3. Heme is an extremely well characterized molecule that serves as a cofactor in 
numerous proteins and is involved in controlling signaling in a myriad of different ways. 
Even so, little is known about how heme is trafficked throughout the cell after being 
synthesized in the mitochondria4. Beyond heme being essential for life, understanding 
how heme is partitioned throughout the cell to be acquired by hemoproteins and control 
heme dependent processes is crucial to understanding the contributions of aberrant heme 
trafficking in several disease states5-9. Our understanding of heme trafficking and its 
involvement in pathogenesis is quite limited, largely in part by these two factors: First, 
there is a dearth of proper chemical and genetic tools to identify and characterize heme 
transporters4. Secondly, heme is such a promiscuous molecule that many candidate 
proteins could bind to it at low affinity to transport it throughout the cell, adding 
difficulty to designing screens for heme trafficking factors4. These points were large 
motivations to our approach to develop a ratiometric heme sensor and a more quantitative 
means to identify new heme trafficking factors with hemin agarose beads and mass 
spectrometry. This introduction will serve as a brief review of heme, its roles in cell 
biology as both a static cofactor and exchange labile molecule, describe the current 
knowledge concerning heme trafficking and transport, and provide a brief summary of 
heme in pathogenesis all while highlighting crucial points that motivated this body of 
work. 
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1.1 Heme in Cell Biology 
 Heme is an indispensable metallo-nutrient utilized in cells to facilitate a diverse 
set of functions that span energy production, regulating metabolism, and facilitating 
redox biochemistry. Heme can adapt many different conformations when bound to  
proteins that are often associated with the function of the associated hemoprotein3. The 
iron atom of the heme is typically in one of two oxidation states, either ferrous, Fe2+ or 
ferric, Fe3+. There are 4 main types of heme; heme a, b, c, and o, which are distinguished 
by their side chains around the porphyrin ring3. Heme b is the most common form and is 
the cofactor of most globins like hemoglobin and myoglobin3. Heme a is solely known 
for its role as a cofactor in cytochrome c oxidase3. Heme o is similar to heme a but is only 
found in Escherichia coli10. Lastly, heme c is different from the other hemes in that it 
forms a covalent attachment to hemoproteins via a thioether linkage like in cytochrome c 
and the cytochrome bc1 complex3. The work in this dissertation is focused on the most 
abundant form, protoheme or heme b. 
 Most organisms including mammals, fungi, and α-proteobacteria, synthesize 
heme via the Shemin pathway, a highly conserved eight-step process, starting with the 
condensation of glycine with succinyl-coenzyme A to form δ-aminolevulinic acid 
(ALA)11. The next four steps of the Shemin pathway occur in the cytosol following 
mitochondrial export of ALA3, 11. The cytosolic steps end with the biosynthesis of  
coproporphyrinogen III, which is shuttled back into the mitochondria for the remaining 
steps of heme synthesis12. The final step of the pathway is the insertion of Fe2+ into 
protoporphyrin IX by ferrochelatase (FECH) to form heme b12. After its terminal step of 
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synthesis in the mitochondria, heme is shuttled by unknown mechanisms to virtually 
every subcellular compartment where there are heme dependent processes13, 14. 
 The most commonly known roles of heme are as a static protein cofactor or 
prosthetic group in globins and cytochrome proteins11. As a cofactor in globins, heme 
serves multifaceted roles in gas sensing, transport, and scavenging14, 15. Regarding gas 
sensing, differential gas binding to heme regulates many metabolic switches and 
signaling processes15-19.  In gas transport, hemoglobin is well known to bind and deliver 
diatomic oxygen and carbon dioxide via heme, but was also recently shown to control the 
transport of nitric oxide to regulate vasodilation20, 21. Finally, concerning heme’s role in 
gas scavenging, many bacteria rely on specific globin proteins to detoxify nitric oxide 
imposed by environmental stresses22, 23. In cytochromes, heme is required as a prosthetic 
group to shuttle electrons in respiratory and photosynthetic pathways that require the use 
of an electron transport chain11. Additional roles for heme as an essential cofactor include 
in enzymatic reactions where it facilitates as part of cytochrome p450 enzymes and its 
involvement in scavenging hydrogen peroxide (H2O2) when bound to catalase or in 
clearing H2O2 in disproportionation reactions as a cofactor in peroxidases
11, 14, 24-26. 
Altogether, heme is indispensable as a protein cofactor for its use in regulating signaling 
and metabolism, adapting to oxidative stress, and facilitating many enzymatic reactions. 
  Even though heme is mostly thought of as a static protein cofactor buried deep 
within the core of tight binding hemoproteins, more recent genetic and biochemical 
evidence have indicated that heme may act as a dynamic signaling molecule that 
regulates cell metabolism and physiology 2, 27-29. In fact, heme dependent nuclear 
transcription factors, like HAP1, p53, Bach1, and Reverb, collectively serve to regulate 
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diverse functions from oxygen sensing, iron homeostasis, antioxidant stress response, 
energy metabolism, circadian rhythms, apoptosis, and cell proliferation, and are 
conserved from yeast to man 29-35. Additional roles for heme in signaling extend 
beyond regulating metabolism and physiology via direct modulation of transcription. For 
instance, ferric heme has been shown to regulate the activity of the RNA-binding protein 
DGCR8 for primary microRNA processing36. Furthermore, heme transport from 
cytochrome c peroxidase in response to H2O2 produced as cells switch to respiratory 
metabolism is required for cells to undergo proper mitohormesis37, and KATP channels are 
regulated by binding of both heme and heme degradation product, carbon monoxide 
(CO), to a KATP CXXHX16H heme-binding motif
38, 39. Beyond direct effects of heme on 
signaling, variable heme transport and heme availability affect the stores of different 
signaling molecules. For example, heme availability to inducible nitric oxide synthase 
(iNOS) and cytosolic catalase, as regulated by the heme chaperone GAPDH40, will alter 
intracellular levels of nitric oxide (NO) and hydrogen peroxide (H2O2), which are two 
vital signaling molecules41-43. These are some of many examples of heme dependent 
regulation that exists outside of heme directly regulating transcription. 
1.2 Heme Trafficking and Transport 
 The roles for heme in regulating cell metabolism and signaling are exhaustive. 
Even so, the factors involved in mobilizing heme from its site of synthesis in the 
mitochondria to all these client hemoproteins that exist in virtually every subcellular 
compartment is poorly understood14 (Figure 1.1). When conceptualizing the number and 
the diversity of heme regulated processes, it is clear that heme transport and trafficking 
must be tightly regulated to ensure that this metallo-nutrient is available as needed by the 
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cell’s plethora of heme dependent functions. Even so, the dearth of knowledge regarding 
how heme is partitioned leaves us in the dark on whether there are distinct cellular 
mechanisms that actively deliver heme from where it’s synthesized or from a heme store 
directly to different client hemoproteins or if heme is transported more passively as a 
passenger of heme-binding proteins that are themselves trafficked throughout the cell. 
The former notion points to there being a direct transfer method from synthesis or from a 
regulatory pool of heme that could regulate heme-dependent processes and signaling. The 
latter idea of heme as a passenger with heme-binding proteins describes a means to 
allocate heme more passively through the exchange of heme between several proteins 
that are themselves trafficked in a way that gets heme to equilibrate to different locales 
and client hemoproteins throughout the cell. Each method, active transport or passive 
exchange between proteins could distribute heme to meet cellular demands while 
buffering heme to low levels as mandated by its apparent hydrophobicity and cytoxicity. 
Even so, complete pathways for heme portioning throughout the cell by either means 
have yet to be elucidated in detail as there as the technology to monitor heme levels and 
heme mobilization in cells was recently developed2, 44. Regardless of the means for heme 
allocation throughout the cell,  the cytotoxicity of misregulated heme dictates that the 
acquisition of heme by these client hemoproteins and transcription factors to regulate 
metabolism and signaling is ultimately reliant on the ability of cells to safely mobilize 
heme and use an exchange-labile source of heme, and the underlying mechanisms and 
proteins involved in heme trafficking and transport must be elucidated2, 29, 45. 
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Figure 1.1 – Model of eukaryotic heme transport and trafficking. The final step of heme 
synthesis occurs in the mitochondrial matrix, and heme must be transported out of the 
mitochondria and incorporated into a multitude of hemoproteins found in different 
compartments. This process is likely mediated by heme chaperones and transporters. 
Proteins previously implicated in heme transport, trafficking, or buffering are identified, 
and trafficking pathways that are currently unknown are marked with question marks. 
Figure reproduced exactly as published by Hanna et al, Copyright © 2017 American 
Chemical Society2. 
 Exchange labile heme (LH) is a pool of chelatable, kinetically labile heme that 
can readily exchange between proteins and biomolecules to be used for heme dependent 
processes45. Exchange inert heme, on the other hand, represents the fraction of heme that 
is too tightly bound or buried within the core of a hemoprotein, like in cytochromes or 
globins, so that the heme is not readily available for new heme-dependent processes2, 29, 
45. These two pools of heme comprise the total heme within a cell, where the pool of 
exchangeable heme utilized for regulating heme dependent processes in non-erythroid 
cells has been estimated to be around 10% of a cell’s total heme quota44. In order to 
elucidate how the cellular demands for heme are met, the characterization of LH, 
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including its concentration, speciation, oxidation state, distribution, and dynamics must 
be understood29. However, these details regarding LH, including what proteins and 
biomolecules affect its availability, have remained mysterious mostly due to a lack of 
required tools to study LH availability and trafficking14, 28, 29. 
The relevance for studying heme transport goes beyond heme being an essential 
protein prosthetic group and signaling molecule. Heme is also a very cytoxic molecule 
due to its inherent peroxidase activity and its promiscuous, nonspecific binding 
interactions 13, 14, 46. Therefore, understanding the cellular mechanisms that underlie heme 
trafficking and transport will help elucidate mechanisms of aberrant heme trafficking 
apparent in different disease states like cardiovascular and neurological diseases 5, 47. 
These properties that make heme cytotoxic mandate the need of dedicated pathways to 
facilitate the safe transfer and mobilization of heme. In much the same way that 
“essential toxins” like copper and iron require transporters and chaperones to bind and 
deliver these metals safely, I propose that heme requires this as well 2, 13, 48. 
Heme is required by both membrane bound and soluble hemoproteins, requiring 
heme to be both soluble and able to cross membranes. However, heme is not readily 
soluble in aqueous media due to its hydrophobic character, and its hydrophilic propionate 
groups make heme unable to completely cross the lipid bilayer unassisted. Therefore, for 
both membrane and soluble hemoproteins to access heme, the assistance of a binding 
partner or heme chaperone is warranted 13, 14. Even so, the identities of such chaperones 
that assist in heme transfer are mostly unknown. In fact, how heme leaves the 
mitochondria to be acquired by hemoproteins in virtually all subcellular compartments is 
a mysterious phenomenon13, 14. 
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Although a complete list of required heme trafficking factors is lacking, there has 
been some success in identifying a number of heme transporters and chaperones within 
the past 10 years (Figure 1.1). Several of these heme trafficking factors were discovered 
using molecular genetics approaches to identify genes that were regulated differently by 
heme in the heme auxotroph C. Elegans49, 50. Of the identified heme responsive genes 
dubbed HRGs, several were characterized to have direct roles in heme trafficking and 
have elevated what we currently know about heme transport in cells and whole organisms 
(Figure 1.1)49-56. 
In addition to the identification of transporters and chaperones, small molecule 
oxidants like NO and H2O2 have proven key to facilitating heme transfer mechanisms. 
Recent studies have shown that H2O2 generated during the diauxic shift, when cells 
switch from fermentation to respiration, triggers a heme transfer from cytochrome c 
peroxidase (Ccp1) to mitochondrial catalase37. The peroxide labilizes heme from the 
otherwise exchange-inert cytochrome c peroxidase, which causes heme dissociation and 
heme transfer to catalase. Beyond regulating heme reallocation between these two 
mitochondrial hemoproteins, other instances of peroxide-dependent heme transfer have 
not been identified nor extensively studied45. Beyond peroxide based heme transfer, work 
by Stuehr and his colleagues has shown a more diverse set of roles for nitric oxide (NO) 
in regulating heme signaling and protein heme acquisition 41. In fact, S-nitrosylation of 
GAPDH, a recently discovered major heme buffer and chaperone, negatively regulates 
inducible nitric oxide synthase (iNOS) and excess NO blocks insertion of heme to a 
number of hemoproteins, including iNOS, hemoglobin, catalase, and cytochrome p450s 
40-43, 57, 58. On the other hand, NO can also help facilitate heme insertion as done with the 
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β-subunit of soluble guanylate cyclase59. Beyond NO regulating protein heme 
acquisition, NO has been postulated to regulate heme homeostasis for years60. In fact, 
different nitrosylation mechanisms have been shown to be regulated by heme, and vice 
versa, various heme cleavage and heme transfer mechanisms are regulated by NO29, 60-68. 
Indeed, heme and NO signaling appear to be intimately tied, but the extent to which NO 
availability regulates heme trafficking and availability is undetermined69. 
1.3 Heme Related Pathology 
 As mentioned, heme is essential for life, serving countless roles in both 
facilitating and regulating biological processes. Even so, heme is also cytotoxic and 
causes many deleterious effects when mishandled by cells3. Heme is pro-oxidant that 
catalyzes the formation of reactive oxygen species, has the potential for non-specific 
binding interactions, and is known to intercalate membranes14. Heme is also both 
hydrophobic and charged, and yet, must be able to cross membranes to be incorporated 
into soluble hemoproteins1. Taken together, these characteristics enable misregulated 
heme to cause the peroxidation of membrane lipids, as well as damage proteins and 
nucleic acids 1, 14, 70. Further, dysregulated “free heme” can act as a source of redox active 
iron that can facilitate the Fenton reaction to generate free hydroxyl radicals, ramping up 
oxidative damage and the generation of more reactive oxygen species that can negatively 
affect a wide-array of cellular processes (Figure 1.2)1. 
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Figure 1.2 – Diagram of free heme toxicity. Heme causes tissue injury by inducing 
oxidative damage, hemolysis, inflammation, and vascular dysfunction. This figure was 
reprinted with permission from Chiabrando et al. (2014) as part of Drug Metabolism and 
Transport, as section of the journal Frontiers in Pharmacology1 
 Natural ways for heme to be misregulated include defects in heme synthesis and 
catabolism by heme oxygenase (HO) enzymes, as well as hemoprotein breakdown1. 
Heme synthesis is a very well characterized and tightly regulated process but when 
misregulated induces a class of metabolic disorders called porphyria, characterized by the 
overproduction of porphyrin intermediates, porphyrins, and heme deficiency71-73. The 
toxicity associated with heme and its biosynthetic enzymes, along with increasing 
amounts of biochemical evidence, support the idea that there is a heme synthesis 
metabolon to ensure the efficient and safe production of heme and the shuttling of its 
intermediates between the cytosol and mitochondria71, 74. This heme metabolon comprises 
several of the cytosolic and mitochondrial heme synthesis enzymes, several heme related 
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proteins, and has the potential to serve as a scaffold for interactions with other pathways, 
signaling molecules, and organelles71. Therefore, understanding defects in heme synthesis 
may be crucial towards understanding how heme is directed out of the mitochondria and 
how heme may be misregulated in porphyria, anemias, and other heme related disorders1, 
4, 70, 71, 73. 
 Heme catabolizing HO enzymes serve a dual protective role by regulating heme 
levels while also controlling cytoprotective responses to stress1, 75. HO’s cytoprotective 
roles are usually attributed to its heme degradation products, biliverdin and CO, which 
have been shown to reduce several models of inflammation in the liver and brain75-77. 
Both free heme and the two main isoforms of HO, HMOX-1 (HO-1) and HMOX2 
(HO2), are associated in a number of neurological disorders78-81. In Parkinson’s disease, 
Alzheimer’s disease, and multiple sclerosis, HO-1 is upregulated presumably to help 
manage inflammation associated with neuroinflammation and continual cell injury82. For 
undetermined reasons, however, in human immunodeficiency virus (HIV) infections of 
the brain, HO-1 is downregulated82, 83. How heme oxygenase expression and its 
regulation of free heme act in heme related pathology is extremely important and needs to 
be better understood. 
 Although there are dedicated heme chaperones, transporters, buffering factors, 
and tightly controlled mechanisms to regulate heme synthesis and induce heme 
degradation, heme is still inappropriately handled in cells, and there are conditions that 
increase free heme to pathophysiological levels84. Regarding high heme levels, 
hemolysis, hemorrhage, and myolysis all cause the release of excesses of hemoproteins 
and free heme into the extracellular space that is often too much for scavenging proteins 
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like hemopexin and haptoglobin to handle and deliver for clearing by HO85. Under these 
contexts, endothelial cells become dysfunctional leading to vascular disease (Figure 
1.2)47, 86, 87. When heme is not in detrimental excess under hemolytic stress, heme likely 
acts as an alarmin to signal to TLR4 to ensure an adaptive response. However, under 
hemolytic conditions commonly associated with malaria, sepsis, and sickle cell disease, 
heme has been shown to activate innate immune receptors that contribute to lethality and 
the pathogenesis of these diseases (Figure 1.2)84, 85, 87, 88. Yet, the modes by which heme 
activates these extracellular signals, and specifically those contributing to lethality, are 
unknown and may lead to new therapeutic strategies for hemolytic diseases84, 85. 
 Heme is the focus of several other diseases, including infectious diseases like 
tuberculosis and malaria where these pathogens rely on their host’s heme as a source of 
iron for virulence. The mechanisms under which heme is regulated and acquired in these 
organisms is of high relevance in discovering new therapeutic drug targets that could 
selectively target the pathogen89-91. Therefore, in this context, understanding how heme is 
trafficked differently between the host and the pathogen is crucial to developing new 
therapeutic strategies. 
 Additionally, heme has been implicated in Alzheimer’s disease where it can 
associate with the Alzheimer’s disease hallmark, amyloid beta (ABeta), and intensify 
Abeta associated cytotoxicity with its peroxidase activity92, 93. Interestingly, a number of 
heme-associated proteins and heme degradation in Alzheimer’s disease models have their 
expression downregulated, potentially increasing the amount of free heme that can 
associate with ABeta94. In addition, studies in primary mouse astrocytes have shown that 
physiological doses of heme and hemoglobin can associate with particular ABeta species 
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and that through their interactions with ABeta, suppress inflammatory response by 
preventing the induction of pro-inflammatory cytokines and prevent ABeta uptake into 
the astrocytes95. Heme has not been a central focus of Alzheimer’s disease progression, 
but understanding the molecular mechanisms surrounding altered heme availability in the 
affected tissues as well as the downstream effects of heme on physiology are paramount 
in understanding the pathogenesis of this disease. 
 Before the start of this thesis, no tools existed for quantifying or monitoring 
dynamic changes in LH availability. Ideally, many of the questions underlying heme 
related pathologies relevant to mismanaged heme, disorders in heme synthesis, and 
perturbed regulation of HO enzymes can now be parsed out using some of the novel 
heme sensing technologies produced over the last several years. Now, using the heme 
sensors characterized as part of this dissertation, others are currently investigating heme’s 
role in infectious diseases like tuberculosis and parsing out more details relevant to heme 
in Alzheimer’s disease and traumatic brain injury models. Additionally, our lab is 
currently utilizing our heme sensors in genetic screens to identify new heme trafficking 
factors that will be paramount to understanding the molecular mechanisms that control 
heme’s availability in health and disease. 
1.4 Scope of Thesis 
 Chapter 2 describes the initial development and characterization of our genetically 
encoded ratiometric sensors for heme and their deployment in Saccharomyces cerevisiae 
to quantitate and reveal the nature and dynamics of LH. We found that there is cell to cell 
variability in cytosolic LH availability, that the subcellular distribution of LH is 
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heterogenous, and we revealed that the signaling molecule nitric oxide (NO) can initiate 
the rapid mobilization of heme in the cytosol and nucleus from certain thiol containing 
factors. Our heme sensing technology developed in Chapter 2 shed light on several 
factors regarding the nature of LH; however, the physiological importance of LH 
remained unclear. 
 Hence, in Chapter 3, we first sought to ascribe a physiological role for LH using a 
blend of site-specific heme chelators, molecular genetics approaches, and our fluorescent 
heme sensors. Using these combined approaches, we showed that LH has direct effects 
on physiology, and that cells rely on a LH heme pool for regulatory functions instead of 
solely relying on newly synthesized heme to modulate all their heme dependent 
processes. Additionally, in Chapter 3, we demonstrated that (1) yeast cells preferentially 
use LH in heme-depleted conditions; (2) sequestration of cytosolic LH suppresses heme 
signaling; and (3) lead (Pb2+) stress contributes to a decrease in total heme, but an 
increase in LH, which correlates with increased heme signaling. We also observed that 
the proteasome is involved in the regulation of the labile heme pool and that loss of 
proteasomal activity sensitizes cells to Pb2+ effects on heme homeostasis. All these 
observations motivated the development of methods to probe the binding and releasing of 
heme in response to stress to identify new heme signaling factors that may utilize and 
modulate LH availability. To this end, given that Pb2+ had severe effects on heme 
homeostasis and maintained heme dependent signaling, we employed hemin agarose 
bead chromatography approaches coupled to SILAC labeling and LC MS-MS to identify 
proteins that bind and release heme in response to our model of Pb2+ toxicity. 
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 Given the broader physiological relevance of heme in mammalian cells, in the 
following study outlined in Chapter 4, I employed our genetically encoded heme sensors 
in HEK293 cells and demonstrate the means to in situ calibrate the sensor for live cell 
quantitation of subcellular LH availability. The sensor was then used to interrogate 
compartment specific responses to endogenously produced or extracellularly supplied 
heme. Lastly, I employed our heme sensors to reveal a novel role for the constitutively 
expressed heme oxygenase 2 (HO2) in buffering LH, explaining previous reports of HO2 











CHAPTER 2. HEME DYNAMICS AND TRAFFICKING 
FACTORS REVEALED BY GENETICALLY ENCODED 
FLUORESCENT HEME SENSORS 
2.1 Thesis Attribution Statement for Chapter 2. 
Portions of this chapter are adapted from previously published work: “David A. 
Hanna; Raven M. Harvey; Osiris Martinez-Guzman; Xiaojing Yuan; Bindu 
Chandrasekharan; Gheevarghese Raju; F. Wayne Outten; Iqbal Hamza; and Amit R. 
Reddi. ‘Heme Dynamics and Trafficking Factors Revealed by Genetically Encoded 
Fluorescent Heme Sensors. Proc Natl Acad Sci, 2016;113:7539-7544.’”  
2.2 Introduction 
Heme (iron protoporphyrin IX) is an essential protein cofactor and signaling 
molecule1, 3, 27, 31, 34, 35, 96-100.The canonical view of heme is that it is a static cofactor 
buried in the active sites of hemoproteins. This view point is irreconcilable with the fact 
that all heme dependent processes, from heme acquisition by proteins to heme signaling, 
require the dynamic mobilization of heme. However, heme mobilization has never been 
monitored, and the mechanisms that mediate it are poorly understood. The 
hydrophobicity and cytotoxicity of heme necessitate that its concentration is tightly 
regulated and buffered to low levels, creating an apparent paradox when trying to 
conceptualize the movement of heme to client hemoproteins or for heme-based signal 
transduction1, 44, 101. The total heme quota is the sum of the exchange inert and labile 
heme (LH) pools. Inert heme, which is unavailable for new heme-dependent processes, is 
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more abundant and represents the large fraction of heme that is associated with high-
affinity hemoproteins like cytochromes and globins. The LH pool, which is available for 
hemoproteins and heme signaling, is far less abundant and buffered by unknown 
factors44. The properties of LH pools, including concentration, speciation, oxidation state, 
distribution, and dynamics, are paramount for understanding how cells assimilate this 
essential nutrient, but are poorly understood. The current lack of understanding of LH is, 
in large part, due to the dearth of tools available to probe it. Herein, we report genetically 
encoded ratiometric fluorescent heme sensors and deploy them in the unicellular 
eukaryote Saccharomyces cerevisiae (Baker’s yeast) to elucidate the nature and dynamics 
of LH. We find that LH is buffered at a concentration of 20–40 nM in the cytosol and less 
than 2.5 nM in the nucleus and mitochondria. Further, we find that the signaling molecule 
nitric oxide (NO) can initiate the rapid mobilization of heme in the cytosol and nucleus 
from certain thiol-containing factors. By integrating our heme sensors with genetic 
screens, we also find that the glycolytic enzyme glyceraldehyde phosphate 
dehydrogenase (GAPDH) is responsible for buffering intracellular heme and regulating 
the activity of the nuclear heme-dependent transcription factor heme activator protein 
(Hap1p). Altogether, these results reveal fundamental aspects of heme trafficking and 
dynamics, providing fresh insight into the cellular management of this essential nutrient. 
2.3 Design and Characterization of Heme Sensors 
The first-generation heme sensor, HS1, consists of a heme-binding domain, the 
His/Met coordinating 4-alpha-helical bundle hemoprotein cytochrome b562 (Cyt b562)
102, 
fused to a pair of fluorescent proteins, EGFP and Katushka 2 (mKATE2), that are 
expected to exhibit heme-sensitive and -insensitive fluorescence, respectively (Figure 
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2.1A). Holo-Cyt b562 is a fluorescence resonance energy transfer (FRET) acceptor for 
EGFP103, 104 [excitation (ex.) = 488 nm, emission (em.) = 510 nm] but not mKATE2105 
(ex. = 588 nm, em. = 620 nm) 29. Thus, HS1 was designed as an excitation-emission 
ratiometric probe 106 in which the ratio of heme-sensitive EGFP fluorescence to heme-
insensitive mKATE2 fluorescence provides a readout of cellular heme independent of 
sensor concentration. 
 
Figure 2.1 - Design and heme-dependent fluorescence properties of the heme sensors. 
(A) Molecular model and design principles of the heme sensor, HS1. The model is 
derived from the X-ray structures of mKATE [Protein Data Bank (PDB) ID code 3BXB] 
and CG6 (PDB ID code 3U8P). Ferric heme-dependent changes in the normalized 
fluorescence emission spectra of HS1 at pH 8.0 upon excitation of EGFP (B, ex.= 488 
nm) and mKATE2 (C, ex. = 588 nm) are illustrated. Normalized changes in EGFP (ex. = 
488 nm, em. = 510 nm) and mKATE2 (ex. = 588 nm, em. = 620 nm) fluorescence upon 
titration of heme into 0.5 μM HS1 (D) and HS1-M7A (E) at pH 8.0 are illustrated. (F) 
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Change in EGFP/mKATE2 fluorescence ratios for HS1 and HS1-M7A upon titration of 
heme. All titration data are fit to 1:1 heme/protein binding models. 
HS1 was adapted from a previously reported EGFP-Cyt b562 integral fusion protein, 
CG6, that exhibits >99% efficient FRET between EGFP and heme 107. mKATE2 was 
appended to the N terminus of CG6 with a GlySer linker. Titration of ferric and ferrous 
heme into an aqueous buffered solution [20 mM NaPi, 100 mM NaCl (pH 8.0)] of 0.5 
μM purified HS1 resulted in visible absorbance spectra indicative of heme coordination, 
and quenched EGFP fluorescence (∼10-fold decrease in signal), with minimal 
perturbation to mKATE2 fluorescence (∼20% decrease in signal) (Figure 2.1B-D). Both 
oxidized and reduced heme quench the fluorescence of EGFP and mKATE2 to similar 
degrees and the change in fluorescence as a function of [heme] evinces a 1:1 heme/HS1 
stoichiometry (Figure 2.1D,F). 
HS1-ferric heme dissociation constants, Kd
III, were determined by direct titration of 
hemin chloride into HS1 over a broad pH range (pH 5–8) and found to be 3 nM between 
pH 6.0 and 7.529. At pH 8.0, the 10 nM Kd
III value for HS1 is identical to the Kd
III values 
previously reported for Cyt b562 
102 and CG6 107. HS1-ferrous heme dissociation 
constants, Kd
II values, were too tight to measure by direct titration and are less than 1 nM. 
The approximate values of Kd
II can be estimated to be ~10 pM at pH 7.0 and by 
completing a thermodynamic cycle relating the reduction potential of free heme (-50 mV 
vs. NHE) and HS1-heme (assumed to be the reduction potential of Cyt b562, 170 mV vs 
NHE) and by using the Kd
III values that were determined here by direct titration in 
Equation (1)102, 108, 109. Em(bound) is the heme protein, HS1’s reduction potential, and 
Em(free) is the reduction potential of free heme
110. 
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Figure 2.2 - Molecular model of the heme sensors HS1 and HS1M7A. Models are 
derived from the X-ray structures of mKATE (PDB: 3BXB) and CG6 (PDB: 3U8P). 
Because previous estimates for the concentration of the LH pool are highly varied 
between nanomolar and micromolar values44, we generated heme sensors with altered 
heme binding affinities. One variant, HS1-M7A, which was generated by replacing the 
heme axial Met7 ligand of Cyt b562 with Ala (Figure 2.2), exhibits fluorescence properties 
similar to the fluorescence properties of HS1 and binds heme in a 1:1 stoichiometry 
(Figure 2.1E,F). HS1-M7A binds ferrous heme with a Kd
II value of 25 nM between pH 
6.0 and 7.529. The HS1-M7A Kd
III values are very weak, determined to be 0.5–2.0 μM 
over a pH range of 5.0–8.029. The Kd
II value of HS1-M7A is similar in magnitude to 
previous estimates of the “regulatory” heme pool, 10–100 nM44, 111, as well as the 
affinities of proteins that may respond to this pool, including the heme-dependent 
transcription factor Reverbβ112 and constitutive heme oxygenase-2 (HO-2)113. 
Both HS1 and HS1-M7A are selective for ferrous heme over other metals, 
protoporphyrin IX, and the heme degradation products bilirubin and biliverdin29. Further, 
apo- and ferrous heme-bound HS1 and HS1-M7A exhibit pH-independent 
EGFP/mKATE2 fluorescence ratios between pH 6.5 and 9.0 but are markedly pH-
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dependent below pH 6.529.The fluorescence ratio of HS1 and HS1-M7A is independent 
of protein concentration between 10 nM and 1 μM, suggesting that the sensors do not 
aggregate over these concentrations29. Ferrous heme binding to HS1 and HS1-M7A is 
reversible because competition with excess apo-Cyt b562 restores the fluorescence ratio to 
apo-sensor29. Further, in vivo, HS1 and HS1-M7A’s selectivity for heme over heme 
biosynthesis intermediates is shown by the EGFP:mKATE2 sensor fluorescence ratio 
being identical between hem1Δ and hem15Δ strains expressing HS1 (Figure 2.3). hem1Δ 
cells are heme deficient as they lack 5-aminolevulinic acid (5-ALA) synthase, the first 
enzyme in the heme biosynthetic pathway114. hem15Δ cells lack the ultimate enzyme in 
heme synthesis, which results in both heme deficiency and a build-up of heme synthesis 
intermediates, like protoporphyrin IX115. If HS1 bound heme intermediates in vivo, the 
EGFP:mKATE of hem15Δ cells expressing HS1 would be expected to be lower than 
hem1Δ cells expressing HS1 (Figure 2.3). 
 
Figure 2.3 - Comparison of HS1 sensor fluorescence in hem1Δ vs hem15Δ cells. 
Cytosolic HS1 does not bind heme synthesis intermediates in vivo. 
2.4 Cellular Heme Imaging: Cytosol 
Using fluorimetry (Figure 2.4A), flow cytometry (Figure 2.4B), and fluorescence 
microscopy (Figure 2.4C), we find that HS1 and HS1-M7A can be used to sense 
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endogenous LH in a quantitative manner. Fluorimetry (Figure 2.4A) and fluorescence 
microscopy (Figure 2.4C) of WT yeast cells expressing cytosolic HS1 and HS1-M7A 
indicate an EGFP/mKATE2 ratio that is markedly reduced in comparison to heme-
deficient hem1Δ cells. The difference in HS1 and HS1-M7A fluorescence ratios in WT 
cells reflects their differential heme binding affinities (vida infra). 
 
Figure 2.4 - Heme-dependent fluorescence ratios of HS1 and HS1-M7A in WT and 
hem1Δ yeast cells as measured by fluorimetry (A), flow cytometry (B), and confocal 
microscopy (C). Where indicated, cells were treated with SA or 5-ALA. Cells for 
microscopy experiments were treated with 0.2 mM SA or 1.5 mM 5-ALA. “Heme 
saturated” is the ratio recorded upon digitonin permeabilization of cells and incubation 
with excess heme as described in the main text for in situ calibration of the cytosolic 
sensors. Fluorimetry data represent the mean ± SD of triplicate cultures. The green bar 
indicates the eGFP/mKATE2 fluorescence ratio when the heme sensors are saturated 
with heme. The flow cytometry and microscopy data are representative of three 
independent mid-log-phase cultures grown in synthetic complete media lacking leucine 
and supplemented with ergosterol and tween-80 (SCE-LEU). 
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The HS1 and HS1-M7A EGFP/mKATE2 fluorescence ratios in hem1Δ cells 
decrease when heme synthesis is initiated due to supplementation with 5-ALA (Figure 
2.4A,C) in a dose-dependent manner (Figure 2.5C,D), which is consistent with increased 
heme binding. Excess 5-ALA does not reduce HS1-M7A fluorescence ratios to the same 
extent as HS1. This effect is because excess 5-ALA (1.5 mM) results in intracellular 
heme levels similar to WT cells29; strict control of heme biosynthesis does not allow for 
endogenous heme levels that are sufficient to saturate the low-affinity heme sensor HS1-
M7A. Conversely, the HS1 and HS1-M7A EGFP/mKATE2 fluorescence ratios in WT 
cells increase upon supplementation with the heme biosynthesis inhibitor succinylacetone 
(SA) (Figure 2.4A–C) in a dose-dependent manner (Figure 2.5A,B), which is consistent 
with decreased heme binding34. A variant of HS1 with His102 and Met7 heme-
coordinating ligands mutated to Ala, HS1-M7A,H102A, and an mKATE2-EGFP fusion 
protein lacking the Cyt b562 domain do not exhibit heme-dependent changes in 
fluorescence ratio, indicating that heme iron coordination to HS1 is required for cellular 
heme sensing (Figure 2.6). 
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Figure 2.5 - Heme dependence of cellular EGFP:mKATE2 fluorescence ratios. (A-B) 
WT cells expressing (A) HS1 or (B) HS1-M7A were cultured in SCE-LEU media for 15 
hours with the indicated concentrations of the heme biosynthesis inhibitor 
succinylacetone (SA) and EGFP:mKATE2 fluorescence ratios were recorded. (C-D) 
hem1∆ cells expressing (C) HS1 or (D) HS1-M7A were cultured in SCE-LEU media for 
15 hours with the indicated concentrations of 5-aminolevulinic acid (5-ALA) and 
EGFP:mKATE2 fluorescence ratios were recorded. The EGFP (ex. 488, em. 510) to 
mKATE2 (ex. 588, em. 620 nm) fluorescence ratio was recorded by a plate reader using 
100 µL of 6x107 cell/mL in PBS buffer. 
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Figure 2.6 - Heme-dependence of EGFP:mKATE2 fluorescence ratios of heme binding 
mutants and various N- and C-terminal mKATE2-CG6 fusion proteins expressed in 
hem1∆ cells cultured with the indicated concentration of 5-aminolevulinic acid (5-ALA). 
Only mKATE2-(GS)1-CG6 exhibits a heme dependent EGFP to mKATE2 fluorescence 
ratio. The EGFP (ex. 488, em. 510) to mKATE2 (ex. 588, em. 620 nm) fluorescence ratio 
was recorded by a plate reader from 100 µL of 6x107 cell/mL in PBS buffer. The data 
represent the mean ± SD of triplicate cultures. Cells were cultured to mid-exponential 
phase in SCE-LEU media prior to analyses. 
The heme sensor does not itself perturb heme metabolism and is a reliable reporter 
for endogenous LH. Titration of HS1-M7A expression using weak (prADH1), medium 
(prTEF1), and strong (prGPD) promoters on centromeric plasmids do not result in a 
change in the observed concentration of the bioavailable heme pool, and prGPD-HS1-
M7A does not affect cell growth or heme-regulated functions like total heme, catalase 
activity, or respiration29.  
For quantitative heme monitoring, an in situ method to calibrate the sensor was 
developed111. The concentration of [heme] accessible to the sensor is governed by the 
following expression116:  
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where Kd is the heme-sensor dissociation constant, Rexpt is the EGFP/mKATE2 
fluorescence ratio under any given condition, Rmin is the EGFP/mKATE2 fluorescence 
ratio when 0% of the sensor is bound to heme, Rmax is the EGFP/mKATE2 fluorescence 
ratio when 100% of the sensor is bound to heme, Fmin
mKATE2 is the mKATE2 emission 
intensity when 0% of the sensor is bound to heme, and Fmax
mKATE2 is the mKATE2 
emission intensity when 100% of the sensor is bound to heme. Determination of Rmax and 
Fmax
mKATE2 involves recording EGFP and mKATE2 fluorescence after digitonin 
permeabilization of cells and incubation with 50 μM heme. Determination of Rmin and 
Fmin
mKATE2 involves recording EGFP and mKATE2 fluorescence after cells are treated 
with SA or from hem1Δ cells cultured in parallel. Because the ferrous heme binding 
affinities are tighter than ferric affinities for both HS1 and HS1-M7A, Rmax and 
Fmax
mKATE2 are determined in the presence of the reducing agent ascorbate (1 mM) to 
drive heme saturation of the sensors. 
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Figure 2.7 - In-situ calibration of cytosolic HS1 and HS1-M7A. 6x107 cells were 
harvested after 15 hours of growth and resuspended in 1 mL of PBS buffer. 
EGFP:mKATE2 fluorescence ratios were recorded by exciting EGFP (ex. 488) and 
mKATE2 (ex. 588) and collecting their emission at 510 nm and 620 nm, respectively. To 
calibrate the sensor and determine the ratio when they are 100% bound to heme (Heme 
Saturated), 6x107 cells/mL were incubated for 30 minutes at 30 °C in PBS buffer 
containing 1 mM ascorbate, 200 µg/mL digitonin, and 50 µM hemin chloride. After 
incubation, cells were washed of excess heme and fluorescence ratios were recorded as 
described for non-permeabilized cells. The data represent the mean ± SD of triplicate 
cultures. Cells were cultured to mid-exponential phase in SCE-LEU media prior to 
analyses. 
Using fluorimetry, in situ calibration of HS1 in WT cells indicates that it is >95% 
saturated (Figure 2.4A, Figure 2.7), which is not ideal for imaging. On the other hand, 
HS1-M7A is typically 20–50% bound in exponential-phase WT cells and well poised to 
monitor changes in heme availability (Figure 2.4A, Figure 2.7). Estimation of the 
concentration of LH using equation (2) depends on assumptions made about its oxidation 
state. In the two limiting cases of LH being 100% reduced or oxidized, cytosolic LH can 
be estimated to be buffered between ∼30 nM and ∼1 μM, respectively, after considering 
the data depicted in Figure 2.4A and the Kd
II or Kd
III value of 25 nM or 1 μM at pH 7.029, 
which is the pH of the yeast cytosol117. Given the relatively reducing cellular 
environment, Em
Cytosol ∼−320 mV vs. normal hydrogen electrode (NHE)118, which is 
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governed by the ratio of oxidized-to-reduced glutathione, and the reduction potential of 
aqueous heme, estimated to be between −50 mV and −220 mV vs. NHE108, 109, we 
propose that LH is biased toward the reduced state and assume herein that LH is 100% 
reduced. However, the actual fraction of LH that is reduced is dependent on its speciation 
and the degree to which it equilibrates with the glutathione redox buffer, both of which 
are unknown. However, given the weak ferric heme affinities of HS1-M7A, if [LH] is 
<100 nM, HS1-M7A cannot sense oxidized LH29. 
Flow cytometry of log-phase WT cells expressing HS1-M7A reveals that there are 
three populations of cells with distinct concentrations of cytosolic LH; 40 nM, 20 nM, 
and <1 nM heme (Figure 2.4B). These LH concentrations correspond to 1,200, 600, and 
<30 molecules of heme, respectively, assuming a cytosolic volume (Vcyt) of 50 fL
119. By 
comparison, total cellular heme was determined to be ∼1 μM29. Although this trimodal 
distribution is highly reproducible, the relative abundance of cells with these three 
distinct heme levels is quite variable between experiments (Figure 2.8). This observation 
suggests that heme availability may be dynamically regulated. In contrast, HS1 exhibits 
only one population due to complete heme saturation as a result of its high heme binding 
affinity (Figure 2.4B, Figure 2.9). For details on how the analyzed cells were processed 
see the Appendix. 
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Figure 2.8 - Variation in the tri-modal distribution of labile heme as measured by HS1-
M7A. (A-F) Flow cytometry analysis of HS1-M7A EGFP:mKATE2 ratios in WT and 
hem1∆ cells in six independent trials. In each trial, cells were cultured in SCE-LEU 
media to mid-exponential phase before being subject to flow cytometry. (F and G) 
Replicate cell cultures indicate the low amount of variation in tri-modal distribution 
within one experimental trial (F), which is also indicated by the small deviation in the 
cell weighted average EGFP:mKATE2 ratio between the three replicates (G). 
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Figure 2.9 - Variation in HS1 EGFP:mKATE2 fluorescence ratios as measured by flow 
cytometry. (A-D) Flow cytometry analysis of HS1 EGFP:mKATE2 ratios in WT and 
hem1∆ cells in four independent trials. In each trial, cells were cultured in SCE-LEU 
media to mid-exponential phase before being subject to flow cytometry. 
 Given WT cells expressing HS1-M7A displayed three populations of cells with 
different concentrations of labile heme, we wished to ensure that each population was 
heme responsive. Validating this confirms that there are indeed three populations of LH 
in and the three populations do not arise from heme independent effects. To this end, we 
in situ calibrated triplicate samples of WT and hem1Δ cells expressing HS1-M7A, and 
indeed, each population in the WT cells collapsed onto the same value as in hem1Δ cells 
expressing HS1-M7A (Figure 2.10). 
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Figure 2.10 - Validation of in situ saturation protocol used in Figure 2.7 for HS1-M7A 
expressing cells analyzed by flow cytometry in triplicates. Like in Figure 2.7 both hem1Δ 
and WT cells expressing sensor have their EGFP levels quenched, resulting in minimized 
EGFP:mKATE2 ratios. 
2.5 Exogenous Heme Incorporation into Labile Heme Pools in Baker’s Yeast 
 Mechanisms underlying heme uptake in microbes is not completely understood.  
Saccharomyces cerevisiae traditionally are inefficient at importing exogenous heme, but 
the growth of hem1Δ deficient cells can be rescued be heme treatment120. Even so, hem1Δ 
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cells supplemented with exogenous heme are not filled with LH unlike those that are 
allowed to biosynthesize heme by ALA supplementation (Figure 2.11).  
 
Figure 2.11 – Overnight exposure of cells to ALA but not heme decreases heme 
dependent EGFP:mKATE ratio of hem1Δ cells expressing HS1. WT HS1 expressing 
cells are unaffected by ALA or hemin chloride as HS1 is already >95% bound to heme in 
these cells. Heme was supplied from a 10mg/mL DMSO stock of hemin chloride. 
Are hem1Δ cells that are rescued by extracellular heme not able to fill their LH pools 
with extracellular sourced heme? Is exogenous heme handled differently than 
biosynthesized heme? To test if heme deficient cells could incorporate exogenous heme 
into their labile heme pools, we tested if heme deficient hem15Δ cells grown in the 
presence of heme for prolonged periods would adapt and incorporate exogenous heme 
into their LH pools. Indeed, when exposed to heme plates for 9 days, then set up in liquid 
culture with and without hemin, hem15Δ cells are able to incorporate LH into their 
cytosol in the same fashion as hem1Δ cells that were fed ALA (Figure 2.12). 
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Figure 2.12 – Comparison of hem15Δ and hem1Δ LH availability in response to 
prolonged heme exposure with hem15Δ cells vs an overnight culture of hem1Δ with ALA 
HS1-M7A expressing cells. Prolonged exogenous heme exposure to hem15Δ cells on 
solid media followed by overnight culture in YPDE media supplimented with (purple) 
and without (orange) 25 µM heme are compared to hem1Δ cells treated overnight with 
(blue) or without (red) 800µM ALA. hem15Δ cells were exposed to heme for 9 days 
before culturing. 
2.6 Hyper-expression of Cytosolic Heme Sensor Induces a Heme Sink 
While the titration of HS1-M7A heme sensor does not itself perturb heme 
metabolism and is a reliable reporter for LH29, we pursued if hyperexpression of the tight 
binding HS1 sensor could induce a heme sink inside cells. The generation of a tool that 
could perturb heme homeostasis by sequestering cellular LH would be instrumental in 
probing the roles of LH in health and disease models and could also be implemented in 
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high copy suppressor screens to identify new heme regulatory genes and trafficking 
factors.  To this end, given its high promoter strength, we used a 2 micron high copy 
GPD promoter (p425-GPD) (Figure 2.13) to hyper-express HS1 and test its ability to 
sequester LH. 
 
Figure 2.13 – Expression levels of different vectors. Figure was reproduced with 
permission from work done by Funk et al. Gene, 156 (1995) 119-122 ©1995 Elsevier 
Science B.V. All rights reserved. 
To demonstrate that hyperexpression of HS1 induces a heme sink that perturbs cell 
growth,  WT and hem1Δ cells expressing p425-GPD (EV), p425-GDP-HS1 (GPD-HS1), 
or a non-cytochrome containing, non-heme binding p425-GDP-mKATE-EGFP (GPD-
mKATEeGFP) control, were grown in SC media with or without ALA to supply cells 
with heme. On SC plates, all WT strain cells grew fine regardless of expressed vector, 
while hem1Δ cells will only grow in the presence of ALA, which allows them to 
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synthesize heme (Figure 2.14A-D). At the low 5 µg/mL dose of ALA, hem1Δ cells have 
some rescue in their growth relative to WT cells, as seen by their highest seed density 
tier, 104 cells, having colony forming units (Figure 2.14B). In addition to this, the GPD-
HS1 expressing cells, but not the EV or mKATE2-eGFP control, have their growth 
stunted, indicating that HS1 is sequestering enough heme to impact cell growth (Figure 
2.14B). At the intermediate 10 µg/mL dose of ALA, hem1Δ have even more growth 
rescued with almost full rescue at the 104-cell tier for the hem1Δ EV and pGPD-mKATE-
EGFP expressing cells (Figure 2.14C). hem1Δ cells hyper-expressing HS1, on the other 
hand, have stunted growth displaying about 10-fold less cell growth relative to the hem1Δ 
controls at the 103-cell tier (Figure 2.14C). Finally, at the high 50 µg/mL concentration of 
ALA, which typically rescues heme content in cells grown in solid media, the cell growth 
of the non-HS1 expressing hem1Δ cells has been rescued while the HS1 overexpressing 
cells still display impaired growth under this heme replete growth condition. The 
impaired growth can be seen at the 103- to 104-cell tier patches, but is most noticeable at 
the 102 cells patch, where there are only several colonies forming for HS1 expressing 
hem1Δ cells, while the hem1Δ controls grow like WT cells and have many colony 
forming units (Figure 2.14D). 
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Figure 2.14 – Overexpression of HS1, but not empty vector (EV) or a non-heme binding 
EGFP:mKATE control, by p425-GPD expression vectors induces a heme sink in cells 
grown with glucose as a carbon source. WT vs hem1Δ cells were plated in 104, 103, and 
102 in 4 µL patches serially diluted in Sterile MilliQ onto SC 2% glucose plates that were 
supplemented with either (A) 0, (B) 5, (C) 10, or (D) 50 µg/ µL ALA and grown at 30 °C 
for 3 days. 
These results were shown both in media containing glucose, which favors 
fermentation, and media lacking glucose but containing glycerol, a non-fermentative 
carbon source, which requires cells to favor a respiratory mode of metabolism (Figure 
2.15). Cells grown on glycerol containing plates for 3 vs 4 days both show that HS1 
impairs growth of hem1Δ cells grown in the presence of 50 µg/mL ALA, while this dose 




Figure 2.15 – Overexpression of HS1, but not empty vector (EV) or a non-heme binding 
EGFP:mKATE control, by p425-GPD expression vectors induces a heme sink in cells 
grown with glycerol as a carbon source. WT vs hem1Δ cells were plated in 104, 103, and 
102 in 4 µL patches serially diluted in Sterile MilliQ onto SC 3% glycerol plates that 
were supplemented with either (A-B) 0 or (C-D) 50 µg/ µL ALA and grown at 30 °C for 
(A, C) 3 or (B, D) days. 
To my knowledge, these are the first results showing that the overexpression of a 
hemoprotein in cells can induce a heme sink that impairs cell growth. The utilization of a 
heme sink that is targeted to different cellular locales in tandem with our heme sensors 
could shed light on how heme availability and heme dependent processes change when 
LH is sequestered. In addition, this technology could be coupled with a genetic screen to 
identify novel heme related proteins that could rescue the growth defect imparted by this 
heme sink. 
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2.7 Cellular Heme Imaging: Nucleus and Mitochondria 
To probe the subcellular distribution of heme, we targeted HS1 and HS1-M7A to 
the mitochondria and nucleus by appending N-terminal COX4 mitochondrial matrix or 
C-terminal SV40 nuclear localization sequences, respectively118, 121 (Figure 2.16). The 
localization tags do not affect heme binding to the sensors29. 
 
Figure 2.16 – Localization imaging of nuclear and mitochondrial heme sensors. To label 
DNA, hem1Δ cells expressing nuclear or mitochondrial targeted HS1-M7A were stained 
with DAPI. Live cells were imaged as described in Materials and Methods at a 
magnification of 63×. “Merge” is the merged images of DAPI, EGFP, and mKATE2. 
Fluorimetry (Figure 2.17) and fluorescence microscopy (Figure 2.18) indicate that 
nuclear and mitochondrial HS1 exhibit EGFP/mKATE2 fluorescence ratios in WT cells 
that are distinctly lower than in hem1Δ cells, indicative of heme binding. In contrast, 
nuclear and mitochondrial HS1-M7A EGFP/mKATE2 fluorescence ratios are unaltered 
between hem1Δ and WT cells (Figure 2.17, Figure 2.18). To determine the fractional 
saturation of our sensors in these compartments, we developed an in situ sensor 
calibration method analogous to the one described for the cytosol. However, because 
digitonin cannot permeabilize nuclear or mitochondrial membranes111, we first had to 
enzymatically digest the yeast cell wall with zymolyase and then incubate the resulting 
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spheroplasts with 0.1% Triton X-100, 50 μM heme, and 1 mM ascorbate to heme-saturate 
the sensors. As shown in Figure 2.7, this in situ calibration method resulted in limiting 
Rmax values for HS1 and HS1-M7A that are identical within experimental error. 
 
Figure 2.17 - Nuclear and mitochondrial heme monitoring with HS1 and HS1-M7A: 
fluorimetry. Heme-dependent EGFP/mKATE2 fluorescence ratios of nuclear and 
mitochondrial targeted HS1 and HS1-M7A in WT and hem1Δ yeast cells as measured by 
fluorimetry. “Heme-saturated” is the ratio recorded upon Triton X-100 permeabilization 
of yeast spheroplasts and incubation with excess heme as described in the main text for in 




Figure 2.18 - Nuclear and mitochondrial heme monitoring with HS1 and HS1-M7A: 
microscopy. Confocal microscopy of WT and hem1Δ cells expressing nuclear and 
mitochondrial targeted HS1 and HS1-M7A. Fluorimetry data represent the mean ± SD of 
triplicate mid-log-phase cultures grown in SCE-LEU. Microscopy images are 
representative of at least two independent cultures. DIC, differential interference contrast. 
In total, these data indicate that HS1 is ∼100% heme-saturated in the mitochondria 
and nucleus, whereas HS1-M7A is ∼0% heme-saturated in these organelles. Given the 
HS1-M7A Kd
II of 25 nM, we estimate that heme is buffered at an upper limit of 2.5 nM in 
the mitochondria and nucleus. This concentration corresponds to fewer than six 
molecules in the nucleus [Vnuc ∼ 5 fL
122] and ∼0.6 molecules in the mitochondria [Vmito 
∼ 0.5 fL119, 123]. 
2.8 Nitric Oxide Mobilizes Cytosolic and Nuclear Heme 
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Previous work demonstrated that NO could regulate heme transfer between certain 
protein pairs41. Could NO also mobilize LH pools? Using cytosolic, nuclear, and 
mitochondrial targeted HS1-M7A, we found that NO derived from the small molecule 
NOC-7124 rapidly increases cytosolic (Figure 2.19A) and nuclear (Figure 2.19B) LH in 
WT cells, but not in the mitochondria (Figure 2.19C) or in heme-deficient hem1Δ cells 
(Figure 2.20A). In the cytosol, LH increases from 17 nM to 40 nM within 20 min of 
adding 50 μM NOC-7 (t1/2 = 10 min at 22 °C), which corresponds to an increase from 
500 to 1,200 molecules of heme, assuming Vcyt ∼ 50 fL119. This rapid increase is 
followed by the reestablishment of the initial steady-state heme levels over the course of 
∼80 min. In the nucleus, there is an even more pronounced change in the HS1-M7A 
EGFP/mKATE2 ratio upon NOC-7 treatment. NO results in an increase in nuclear LH 
from <2.5 nM to a maximum of 218 nM, corresponding to a change from fewer than six 
to ∼650 heme molecules assuming Vnuc ∼ 5 fL122. NO-mediated heme mobilization is 
dose-dependent (Figure 2.20B), and the observed changes in fluorescence ratios are not 
due to NO interactions within HS1-M7A because incubation of purified heme-bound 
HS1-M7A with NOC-7 does not alter sensor fluorescence29. 
 
Figure 2.19 - NO-dependent mobilization of LH. WT cells expressing cytosolic (A), 
nuclear (B), or mitochondrial (C) HS1-M7A were incubated with 50μM NOC-7, and 
EGFP/mKATE2 fluorescence ratios were monitored by fluorimetry. The data represent 
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the mean ±SD of triplicate mid-log-phase cultures grown in SCE-LEU. The red and black 
lines indicate the fluorescence ratios of HS1-M7A when it is 0% and 100% saturated with 
heme as derived from hem1Δ cells expressing HS1-M7A or WT cells expressing HS1, 
respectively. This approach for determining Rmax is validated by the fact that the 
EGFP/mKATE2 fluorescence ratio of HS1-M7A that is saturated with heme from the in 
situ calibration methods is identical within experimental error to HS1 (Figure 2.7, Figure 
2.17). 
 
Figure 2.20 - Mobilization of cytosolic heme by NO. (A) WT and hem1∆ cells 
expressing HS1-M7A were incubated with 5 µM NOC-7 and EGFP:mKATE2 
fluorescence ratios were monitored. (B) WT cells expressing HS1-M7A were incubated 
with the indicated concentration of NOC-7 and EGFP:mKATE2 fluorescence ratios were 
monitored. (C) WT cells expressing HS1-M7A were incubated with the indicated 
concentration of NOC7 and/or iodoacetamide (IAM) and EGFP:mKATE2 fluorescence 
ratios were monitored. (D) WT cells expressing HS1-M7A were incubated with the 
indicated concentration of NOC-7, diamide, H2O2 or paraquat (PQ) and EGFP:mKATE2 
fluorescence ratios were monitored. Fluorimetry data represent the mean ± SD of 
triplicate cultures. Cells were cultured to mid-exponential phase in SCE-LEU media prior 
to analyses. 
Given that cellular thiols are targets of NO, we sought to determine the effect of a 
thiol-specific alkylating agent [e.g., iodoacetamide (IAM)] on heme mobilization. 
Although IAM does not initiate the mobilization of heme, it does prevent the 
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reestablishment of the steady-state LH pool after NO treatment (Figure 2.20C). This 
observation suggests that IAM blocks the rebinding of heme from sites of mobilization, 
presumably certain thiol-containing factors.  
To differentiate the effects of NO and general oxidative stress on heme 
mobilization, we probed the role of various oxidative insults. Diamide, a thiol-specific 
oxidant; paraquat, a superoxide-generating agent; and H2O2 had no impact on LH pools, 
suggesting that heme mobilization is specific to NO (Figure 2.20D).  
2.9 Discussion 
The mobilization of LH underlies all heme-dependent processes, including heme 
acquisition by client proteins and heme-based signal transduction. However, the 
properties of the LH pool are poorly understood. To address this fundamental gap in 
heme cell biology, we developed genetically encoded ratiometric heme sensors and 
deployed them in Baker’s yeast to probe key characteristics of the LH pool, including its 
concentration, subcellular distribution, buffering factors, and dynamics. In addition, HS1 
was tested for its ability to act as a heme sink when hyper-expressed to be used in the 
design of genetic screens and to probe Cyt b562’s potential as a cite specific chelator of 
labile heme. 
Using our heme sensors we see that cells do not incorporate exogenous heme into 
their LH pools over short exposures (Figure 2.11), even though extracellular heme 
rescues the growth of cells that cannot synthesize their own heme120. However, when 
cells have prolonged exposure to exogenous heme, their ability to incorporate 
extracellular heme into their LH pools are enhanced, where an overnight growth with 
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exogenous heme mirrors the effects of allowing hem1Δ cells to biosynthesis their own 
heme by ALA supplementation (Figure 2.12). What molecular changes facilitated this 
stark change in cells’ heme management, allowing them to integrate extracellular heme 
into their LH pools (Figure 2.11, Figure 2.12)? Designing the proper studies to elucidate 
the proteins that are expressed in response to heme starvation in the presence of 
exogenous heme is warranted and should reveal novel heme trafficking factors that can 
affect cellular heme management. 
Interestingly, hyper-expressed HS1 in the yeast cytosol acts as a heme sink, 
perturbing cell growth, mostly under heme limiting conditions. This growth phenotype 
could be exploited in a genetic screen to find proteins that affect heme availability. For 
example, looking for a high copy suppressor of the heme sink by transforming a high 
copy plasmid library into hyper-expressing HS1 hem1Δ cells grown with limited ALA 
could be used to detect novel heme trafficking factors that that rescue cells from the heme 
sink growth defect125-127. Conducting the screen would be done by plating enough 
transformed cells to get colonies under heme replete conditions that represent the entire 
overexpression library. Next, these colonies that represent the high copy suppressor 
library could be velveted to an ALA limited and an ALA replete plate128. Ultimately, the 
colonies that are able to grow well on both velveted plates represent those that are likely 
overexpressing a protein that rescues the heme sink phenotype seen Figure 2.14. These 
identified proteins would be potential heme trafficking factors and/or be involved in 
heme dependent signaling pathways required for cell viability. 
Our heme sensors reveal that the cytosol has more LH (∼20–40 nM) than the 
nucleus or mitochondria (<2.5 nM). Further, the cell-to-cell heterogeneity in cytosolic 
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heme suggests its availability may be dynamically regulated (Figure 2.4B). Given the 
subcellular distribution of heme, we propose that once heme is biosynthesized in the 
mitochondrial matrix, a fraction of heme transits to the cytosol and acts as a reservoir for 
signaling and/or a heme source for proteins. 
The mitochondria, which have a very high demand for heme and are the site of 
heme biosynthesis, have exceptionally low quantities of LH, less than 2.5 nM or fewer 
than one molecule. By comparison, total ferrous heme in the yeast mitochondria has been 
estimated to be ∼30 μM, or ∼9,000 molecules119. Taken together, this low amount of 
mitochondrial LH suggests that mitochondrial heme is tightly regulated and trafficked in 
a manner that limits its availability. This observation is consistent with the identification 
of mitochondrial heme metabolism complexes that traffic heme via transient protein–
protein interactions, thereby circumventing the LH pool74. 
The nucleus also limits LH to less than 2.5nM or fewer than six molecules. This 
low amount of nuclear LH is not surprising, given the cytotoxicity of heme and proximity 
to genetic material1, 44. However, this observation raises the question of how nuclear 
heme-regulated transcription factors acquire heme, given that the heme-regulatory motifs 
(HRMs) of many heme-dependent transcription factors, including Hap1p in yeast, exhibit 
micromolar affinities for heme31. Factors like Hap1p may acquire heme from transient 
increases in LH due to active signaling processes. Indeed, this concept is supported by 
our demonstration that signaling molecules like NO can result in a >10-fold increase in 
nuclear LH (Figure 2.19B). An alternative possibility is that the heme affinities of many 
HRM-containing proteins are mischaracterized. For instance, a reevaluation of the heme 
dissociation constants of the HRM-containing transcription factor Rev-erbβ found that 
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heme binds 100-fold tighter than previously estimated, with Kd
III and Kd
II of ∼20 nM vs. 
2–6 μM112. 
Our observation that subcellular [LH] is heterogeneous stands in striking contrast to 
a recent report by He and coworkers111 that used a heme chaperone-based FRET sensor 
(CISDY-9) for heme in human cell lines. In that work, cytosolic, mitochondrial, and 
nuclear heme were all reported to be∼25nM. The deviation between our two results 
needs to be clarified but could reflect organismal variation, difficulty in calibrating 
CISDY-9 in organelles, or uncertainties in LH oxidation state. 
Quite surprisingly, we observed that Saccharomyces cerevisiae, which is not 
thought to import exogenous heme but solely rely on endogenously biosynthesized heme, 
can rely on exogenous sources of heme to fill its labile heme pools under extreme 
conditions such has prolonged hemin treatment of heme deficient cells (Figure 2.11, 
Figure 2.12). Studying the genetic differences, such as differences in mRNA transcripts, 
may reveal proteins that are upregulated under heme deficiency in these cells to facilitate 
the upregulation of heme in these cells129-131. And, as Saccharomyces cerevisiae is a 
model eukaryote that is genetically tractable with higher organisms, this may reveal new 
mechanisms by which other cell types respond to cellular stress.  
We demonstrate, for the first time to our knowledge, that LH is dynamic and can be 
mobilized by signaling molecules like NO (Figure 2.19,Figure 2.20). Although previous 
studies have indicated that H2O2 and NO can regulate heme transfer between specific 
protein pairs37, 41, our results suggest that NO can mobilize cell-wide LH pools to regulate 
heme-dependent processes in multiple compartments. The mechanism of NO mediated 
 47 
heme mobilization is unknown, but likely involves S-nitrosation of certain hemoproteins 
and heme dissociation41, 67. 
NO-mediated heme mobilization provides insights into NO physiology, including 
NO-dependent inflammatory responses. Both heme and NO regulate inflammation, but 
through distinct mechanisms99, 132, 133. Our work indicates that NO can promote 
inflammation via heme mobilization. Indeed, previous observations in endothelial cells 
found that NO elevates cellular iron due to enhanced activity of the heme-degrading 
enzyme, HO60. This observation was proposed to occur as a result of NO-induced heme 
release from hemoproteins. Our current studies are the first to our knowledge, to provide 
direct support for this model. 
Since developing and characterizing these heme sensors, they have been deployed 
to both mammalian cells to bacteria to study heme in neurodegeneration and infectious 
disease. In addition, HS1 and HS1-M7A have been used to screen for new heme 
homeostatic factors in genetic screens. Indeed, it was found using the sensors that 
GAPDH was a heme trafficking factor that regulates heme dependent transcription in 
Saccharomyces cerevisiae29, 40. Our findings that NO regulates heme availability and 
mobilization are highly reminiscent of and supported by previous studies demonstrating 
that GAPDH and NO cooperate to control heme insertion into nitric oxide synthase41. As 
such, it is tempting to speculate that Tdh3p is the source of NO-mobilized heme. 
However, NO-dependent heme mobilization is unaffected in tdh3Δ cells29. Altogether, 
the HS1s can be applied across prokaryotes and eukaryotes to probe heme trafficking, 
signaling, and dynamics in various physiological contexts. 
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2.10 Materials and Methods 
2.10.1 Cell Lines, Culturing, and Plasmids 
2.10.1.1 Yeast Strains, Media, and Growth Conditions 
S. cerevisiae strains used in this study were derived from BY4741 (MATa, his3∆1, 
leu2∆0, met15∆0, ura3∆0). tdh1∆::kanMX4, tdh2∆::kanMX4, and tdh3∆::kanMX4 
strains were obtained from the yeast gene deletion collection (Thermo Fisher Scientific). 
A hem1∆::HIS3 strain was generated by deleting HEM1 using the hem1::HIS3 deletion 
plasmid, pDH001. Yeast transformations were performed by the lithium acetate 
procedure134. Strains were maintained at 30 °C on either enriched yeast extract-peptone 
based medium supplemented with 2% glucose (YPD), or synthetic complete medium 
(SC) supplemented with 2% glucose and the appropriate amino acids to maintain 
selection. Culturing of hem1∆ cells required supplementing YPD or SC media with 50 
µg/mL of 5-aminolevulinic acid (5-ALA) or 15 mg/mL of ergosterol and 0.5% Tween-80 
(YPDE or SCE, respectively)114.  
2.10.1.2  E. coli, Media, and Growth Conditions 
For routine cloning, sub-cloning grade chemically competent E. coli cells, strain 
10G E. cloni (Lucigen), were used according to the manufacturer’s specifications. For 
recombinant protein overexpression studies, E. cloni EXPRESS BL21(DE3) chemically 
competent cells (Lucigen) were utilized according the manufacturer’s specifications. 
Unless otherwise stated, all E. coli strains were cultured in Lysogeny broth (LB)135 with 
the appropriate antibiotic selection, either 100 μg/mL ampicillin or kanamycin. 
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2.10.2 Experimental Methods 
2.10.2.1 Instrumentation 
All UV/visible absorbance spectra were recorded on a Cary 60 
spectrophotometer. Fluorescence measurements were collected on a Synergy Mx multi-
modal plate reader. Flow cytometry was performed on a BD FACS Aria Ill Cell Sorter or 
BD LSR II Flow Cytometer, with data analysis accomplished using FlowJo v9.9.3 
software. Confocal laser scanning microscopy was accomplished using a Zeiss ELYRA 
LSM 780 Super-resolution Microscope, with all images processed in ImageJ136. 
Quantifications of metal and heme stock solutions were accomplished by total reflection 
x-ray fluorescence (TXRF) on a Bruker S2 Picofox TXRF. Measurement for cellular 
heme was accomplished by high-pressure liquid chromatography (HPLC) on an Agilent 
1260 Infinity HPLC with a diode array detector. 
2.10.2.2 Characterization of Heme Sensors in Yeast 
For all sensor fluorescence measurements, WT and hem1∆ yeast cells expressing 
the heme sensors were cultured in SCE-LEU media for ~14-16 hours to mid-exponential 
phase (an optical density at 600 nm of OD600 nm ~ 1-2. Unless otherwise noted, all 
cytosolic measurements were accomplished with the indicated sensor proteins expressed 
on the p415-GPD plasmid, a low copy centromeric plasmid with a GPD promoter137. 
Nuclear and mitochondrial matrix targeted sensors were expressed on p415- GPD and 
p415-TEF plasmids, which are low copy centromeric plasmids with GPD and TEF 
promoters, respectively137. After culturing, cells were harvested, washed in water, and 
resuspended in phosphate buffered saline (PBS) solution at concentrations between 3 and 
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5 OD600 nm/mL, or 6 x 10
7 
to 1 x 10
8 
cells/mL. For fluorimetry measurements on a 
population of cells, fluorescence was recorded on a Synergy Mx multi-modal plate reader 
using black Greiner Bio-one flat bottom fluorescence plates. EGFP and mKATE 
fluorescence were recorded using excitation and emission wavelength pairs of 488 nm 
and 510 nm and 588 nm and 620 nm, respectively. Background fluorescence of cells not 
expressing the heme sensors were recorded and subtracted from the EGFP and mKATE2 
fluorescence values.  
The impact of nitric oxide (NO), superoxide (O2
-
), hydrogen peroxide (H2O2), and 
glutathione oxidation on intracellular heme dynamics was determined by incubating 6 x 
10
7 
to 1 x 10
8 
cells/mL of cells expressing the heme sensor in PBS with the indicated 
concentrations of NOC-7 (Enzo Life Sciences), paraquat, H2O2, and diamide, 
respectively. The kinetics of heme mobilization were monitored by measuring the EGFP 
to mKATE2 ratios as described above.  
For quantitative heme monitoring, we developed an in-situ method to calibrate the 
sensor in cells similar to that previously described111. The concentration of [heme] 
accessible to the sensor is governed by the following expression116:  










KD is the heme-heme sensor dissociation constant, Rexpt is the EGFP:mKATE2 
fluorescence ratio under any given condition, Rmin is the EGFP:mKATE2 fluorescence 
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ratio when 0% of the sensor is bound to heme, Rmax is the EGFP:mKATE2 fluorescence 
ratio when 100% of the sensor is bound to heme, Fmin
mKATE2 
is the mKATE2 emission 
intensity when 0% of the sensor is bound to heme, and Fmax
mKATE2 
is the mKATE2 
emission intensity when 100% of the sensor is bound to heme.  
Determination of Rmax and Fmax
mKATE2 
involves recording EGFP and mKATE2 
fluorescence after digitonin permeabilization of cells and incubation with 50 μM heme. 
Briefly, 3 to 5 OD600 nm/mL of cells are resuspended in PBS with 100 μg/mL of digitonin, 
1 mM ascorbate, and 50 μM hemin chloride. After a 30 minute incubation at 30 °C, cells 
were harvested, washed, and resuspended in PBS buffer prior to recording of 
fluorescence by plate reader, flow cytometry, or microscopy.  
Determination of Rmin and Fmin
mKATE2 
involves recording EGFP and mKATE2 
fluorescence after cells are treated with the heme biosynthesis inhibitor 
succinylacetone138 or from hem1∆ cells cultured in parallel.  
Since digitonin cannot permeabilize mitochondrial or nuclear membranes, we 
devised an alternative strategy to determine Rmax and Fmax
mKATE2
. This procedure involved 
digesting the yeast cell wall with Zymolyase, followed by incubating yeast spheroplasts 
with 0.1% Triton-X100, to permeabilize all membranes, as well as 1 mM ascorbate and 
50 μM hemin chloride. Briefly, cells were grown to a density of 1-2 OD600 nm/mL, 
washed in sterile Milli-Q water, and resuspended in “softening buffer” (100 mM Tris-
HCl, pH = 9.4, 10 mM DTT) at a concentration of 10 OD600 nm/mL of cells. Cells were 
incubated at room temperature, with occasional swirling, for 30-60 minutes. Cells were 
then washed and resuspended in a sorbitol buffer containing 50 mM Tris-HCl, pH 7.4, 
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1.2 M Sorbitol. To this cell suspension in sorbitol buffer, 0.5 mg/mL of 100-T Zymolyase 
(MP Biomedicals, VWR) was added, followed by incubated for 45 minutes at 30 °C with 
occasional inversion. Next, cells were washed and resuspended in sorbitol buffer (50 mM 
Tris-HCl, pH 7.4, 1.2 M Sorbitol). 3 to 5 OD600 nm/mL of cells in Sorbitol buffer were 
resuspended in a sorbitol buffer that contained 0.1% Triton X-100, 2 mM Ascorbate, and 
50 μM hemin chloride, and incubated at 30 °C for 30-45 minutes. Cells were then washed 
and resuspended in sorbitol buffer for fluorescence measurements.  
Flow cytometric measurements were performed using a BD FACS Aria Ill Cell 
Sorter or BD LSR II Flow Cytometer, both equipped with an argon laser (ex 488nm) and 
yellow-green laser (ex 561nm). EGFP was excited using the argon laser and was 
measured using a 530/30nm bandpass filter. mKATE2 was excited using the yellow- 
green laser and was measured using a 610/20nm bandpass filter. Data evaluation was 
conducted using FlowJo v9.9.3 software. The number of cells measured per experiment 
was set to 1,000,000 unless otherwise stated. BY4741 empty vector cells were used as a 
negative control for fluorescence. Only mKATE2 positive cells were selected for 
analysis. 
Confocal microscopy was done on a Zeiss ELYRA LSM 780 Super-resolution 
Microscope equipped with a 63x, 1.4 numerical aperture oil objective. EGFP was excited 
with the 488 nm line of an argon ion laser, while mKATE2 was excited using the 594 nm 
of a HeNe laser line. The 494-571nm and 606-686 nm band pass filters were used to filter 
emission for EGFP and mKATE2, respectively. Images were collected using Zeiss 
software and analyzed with ImageJ 1.48v (Rasband, W.S., ImageJ, U. S. National 
Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2007). 
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Ratio images were generated using ImageJ RatioPlus software 
(http://rsb.info.nih.gov/ij/plugins/ratio-plus.html) after background subtraction. To 
confirm mitochondrial or nuclear localization of the sensors, prior to microscopy, 
exponential phase cells were incubated with 2.5 μg/mL 4’,6-diamidino-2-phenylindole 
(DAPI) (Invitrogen) in SCE-LEU media for 30 minutes to stain nuclear and 
mitochondrial DNA. 
2.10.2.3 Immunoblotting 
 Yeast were cultured in 10 mL of SC media for 15 hours to a density of 1 OD600 nm 
/mL. Cells were harvested, washed in ice-cold Milli-Q water, and lysed in two pellet 
volumes of phosphate buffer supplemented with protease inhibitors as described 
previously139, 140. Lysis was achieved at 4 °C using one pellet volume of zirconium oxide 
beads and a bead beater (Bullet Blender, Next Advance) on a setting of 8 for 3 minutes139, 
140. Lysate protein concentrations were determined by the Bradford method (Bio-rad) and 
12% tris-glycine gels (Invitrogen) were employed for SDS-PAGE139, 141. Anti-GFP rabbit 
or anti-GAPDH polyclonal antibodies (Genetex) and a goat anti-rabbit secondary 
antibody conjugated to a 680 nm emitting fluorophore (Biotium) were used to probe for 
HS1 and related variants or GAPDH, respectively. All gels were imaged on a LiCOR 
Odyssey Infrared imager139, 141. 
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CHAPTER 3. HEME BIOAVAILABILITY AND SIGNALING IN 
RESPONSE TO STRESS IN YEAST CELLS 
3.1 Thesis Attribution Statement for Chapter 3. 
 Portions of this chapter are adapted from previously published work: “David A. 
Hanna, Rebecca Hu, Hyojung Kim, Osiris Martinez-Guzman, Matthew P. Torres, and 
Amit R. Reddi. ‘Heme bioavailability and signaling in response to stress in yeast cells. 
Journal of Biological Chemistry. 2018; DOI: 10.1074/jbc.293/32/12378.’” Regarding 
unpublished work investigating heme binding proteins with hemin agarose, sepharose 
beads, and SILAC labeling, Hyojung Kim and the Torres Lab helped set up cultures for 
SILAC labeling and handled these samples post bead elution up to data analysis. 
3.2 Introduction 
 Protoheme (iron protoporphyrin IX or heme b) is an essential cofactor and 
signaling molecule that is also potentially cytotoxic2, 3, 13, 49. The molecules and 
mechanisms cells employ to utilize protoheme, while mitigating its inherent toxicity, are 
complex and poorly understood, especially during stress2, 49. Cells manage protoheme, 
which is hereafter referred to as heme, by controlling both its total concentration and 
bioavailability2, 49. Heme concentration is primarily governed by the relative rates of 
heme synthesis and degradation, which are well understood processes2, 49. Indeed, all the 
enzymes involved in eukaryotic heme synthesis and degradation have been structurally 
characterized to atomic resolution and the mechanisms of action have been largely 
delineated2, 3, 13, 49. On the other hand, the factors that control heme bioavailability are 
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poorly understood2, 49. Bioavailable heme can be operationally defined as a pool of 
chelatable, kinetically labile heme that can readily exchange between biomolecules and is 
accessible for heme-dependent processes. The identity of factors that buffer and traffic 
labile heme (LH) and the mechanisms employed to mobilize it for utilization are largely 
unknown2, 49. In order to mitigate heme toxicity, it is generally thought that heme is made 
on demand, i.e. heme synthesis and utilization are tightly coupled, and heme in excess of 
that required for metabolism is degraded13, 44, 46. As a consequence, it is unclear what role, 
if any, steady-state LH plays in supporting heme dependent functions. Using genetically 
encoded ratiometric fluorescent heme sensors to probe LH and heme homeostatic 
mechanisms, we have previously demonstrated the existence of a highly dynamic steady-
state pool of LH in the cytosol, spanning 20-40 nM, and identified new heme trafficking 
factors, e.g. glyceraldehyde phosphate dehydrogenation (GAPDH), and signaling 
molecules that mobilize LH, e.g. nitric oxide (NO)29. However, the physiological 
importance of LH remained unclear. In the current work, using Saccharomyces cerevisiae 
as a model eukaryote and heme sensors and chelating agents, we establish the functional 
importance of LH in regulating heme signaling, demonstrate that LH is preferentially 
consumed when cells become heme depleted, and discovered that certain xenobiotics, 
e.g. lead ions (Pb2+), can, rather paradoxically, both deplete total cellular heme, primarily 
through its inhibition of heme synthesis, and increase labile bioavailable heme. We 
further find that the proteasome is involved in the regulation of labile heme and its 
response to Pb2+ stress. In total, our results establish a functional role for LH, indicate 
that total and labile heme pools can be decoupled in response to certain stressors, and 
provide evidence for heme-based signaling in response to heavy metal stress. In light of 
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these discoveries under Pb2+ stress, in order to identify heme signaling networks activated 
by Pb2+ we designed a method to identify proteins that bind and release heme in response 
to stress. 
3.3 Sequestering Labile Heme Impacts Heme Signaling 
 We first sought to determine if cytosolic LH serves a functional role in heme 
signaling. Towards this end, we developed an approach to sequester LH and probe its 
effects on the heme-regulated transcription factor Hap130, 142, 143. In order to chelate 
cytosolic LH, we induced the expression of a high affinity hemoprotein, cytochrome b562 
(Cyt b562)
102, 144-147, using a galactose (GAL)-inducible promoter (pGAL)148. Cyt b562 
binds ferric heme at pH 7.0 with a dissociation constant (Kd
Fe(III)
) of 10 nM102. Given the 
reduction potential (EM) of heme-Cyt b562, +200 mV vs. NHE at pH 7.0
149, and the Em of 
free heme, -38 mV vs. NHE 108, 109, one can estimate the ferrous heme dissociation 
constant (Kd
Fe(II)
) to be ~1 pM by completing a thermodynamic cycle109. 
 First, we confirmed that Cyt b562 overexpression could sequester heme by 
measuring changes in LH with the genetically encoded ratiometric fluorescent heme 
sensor, HS1-M7A. HS1 is a tri-domain fusion protein consisting of a heme-binding 
domain, the His/Met coordinating 4-alpha-helical bundle hemoprotein Cyt b562 fused to a 
pair of fluorescent proteins, EGFP and mKATE2, that exhibit heme-sensitive and –
insensitive fluorescence, respectively29 (Figure 3.1A). Heme binding to the Cyt b562 
domain results in the quenching of EGFP fluorescence via resonance energy transfer but 
has little effect on mKATE2 fluorescence29. Thus, the ratio of EGFP fluorescence (ex: 
488 nm, em: 510 nm) to mKATE2 fluorescence (ex: 588 nm, em: 620 nm) provides a 
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readout of cellular heme independently of sensor concentration, with the EGFP/mKATE2 
ratio inversely correlating with heme binding to the sensor29. The high affinity of HS1 for 
ferric and ferrous heme, Kd
III = 10 nM and Kd
II < 1 nM at pH 7.0, renders it fully 
saturated with heme in WT cells29. On the other hand, a variant of HS1, HS1-M7A, in 
which the heme coordinating Met ligand is mutated to Ala, exhibits ferrous and ferric 
affinities of Kd
II = 25 nM and Kd
III = 2 μM at pH 7.0 and is 20-50% bound in the yeast 
cytosol29. The observed sensor EGFP/mKATE2 fluorescence ratio (Rexpt) can be used to 
determine the fractional heme saturation of the sensor and the concentration of LH, 
assuming a 1:1 heme:sensor binding model and previously established sensor calibration 
protocols that involve determining the sensor ratio when the sensor is 100% (Rmax) and 
0% (Rmin) bound to heme (see Chapters 2.10.2.2 and 3.10.5)
29. Notably, heme binding to 
the sensor is reversible and expression of the heme sensor in cells does not itself perturb 
heme homeostasis or otherwise affect viability29. 
 Wild type (WT) cells expressing heme sensor HS1-M7A and GAL-inducible Cyt 
b562 (pGAL-Cyt b562) were cultured in 2% raffinose (RAF) with or without 0.1% GAL for 
16 hours. As demonstrated in Figure 3.1B, induction with GAL results in an increase in 
the EGFP/mKATE2 fluorescence ratio, from 1.90 (.09) to 2.82 (.04), consistent with less 
heme binding to the sensor and diminished LH. By comparison, cells expressing an 
empty pGAL vector (EV) or that are heme depleted with the heme biosynthetic inhibitor, 
succinylacetone (SA)29, 138, 150, are unaffected by induction of Cyt b562. Using the 
aforementioned sensor calibration protocols the induction of Cyt b562 results in a decrease 
in the fractional saturation of the heme sensor from ~60% to ~35% heme bound, which 
corresponds to a change in LH from 35 to 14 nM. 
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 Having established that LH can be sequestered by over-expression of Cyt b562, we 
next sought to determine if this would impact the activity of the heme regulated 
transcription factor Hap130, 142, 143, 151. Heme binding to Hap1 alters its ability to promote 
or repress transcription of a number of target genes, including CYC1, which Hap1 
positively regulates29, 30, 142, 143, 151. In order to probe Hap1 activity, we used a 
transcriptional reporter that employs the promoter of a Hap1 target gene, pCYC1, driving 
the expression of enhanced green fluorescent protein (EGFP)29. As demonstrated in 
Figure 3.1, not only does heme depletion with SA decrease EGFP fluorescence, as 
expected, Cyt b562 induction with GAL also results in a decrease in EGFP fluorescence, 
both of which are consistent with reduced heme binding to Hap1 and diminished 
transcriptional activation of CYC1. Altogether, our results strongly suggest that over-




Figure 3.1 - Overexpression of a high affinity hemoprotein, Cyt b562, attenuates labile 
heme and the activity of heme-regulated transcription factor, Hap1. (A), molecular model 
and design principles of the heme sensor, HS1. Model derived from the X-ray structures 
of mKATE2 (Protein Data Bank code 3BXB) and CG6 (Protein Data Bank code 3U8P). 
(B), cells expressing the heme sensor, HS1-M7A, and an allele of Cyt b562 on a 
galactose (GAL)-inducible promoter (pGAL-Cyt b562) or empty vector (pGAL-EV) 
were cultured in 2% RAF with or without 1.0% GAL or 500 M SA for 16 h in SCE 
medium. After growth, HS1-M7A sensor EGFP (excitation 488 nm, emission 510 nm) 
and mKATE2 (excitation 588 nm, emission 620 nm) fluorescence emission ratios were 
recorded. (C), Hap1 activity was measured in cells expressing pGAL-Cyt b562 or pGAL-
EV and cultured in 2% RAF with or without 1.0% GAL or 500 M SA for 16 h in SC 
medium using a transcriptional reporter consisting of an allele of EGFP driven by the 
CYC1 promoter (pCYC1-EGFP), a Hap1 target gene. All data represent the mean ± S.D. 
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(error bars) of triplicate cultures, and the statistical significance was assessed using a two-
sample t-test. *, p ˂ 0.01; **, p ˂ 0.001. 
3.4 Labile Heme is Preferentially Consumed Relative to Total Heme During Heme 
Depletion 
 We next sought to determine if LH is consumed preferentially relative to total 
heme during conditions of heme deficiency in order to ascertain if LH is mobilized for 
heme dependent functions when cells are confronted with defects in heme synthesis. 
Towards this end, we titrated the heme biosynthetic inhibitor succinylacetone (SA) in 
WT cells expressing the high affinity heme sensor, HS1, or the medium affinity sensor, 
HS1- M7A, and measured total and labile heme (Figure 3.2). Titration of SA over a broad 
concentration range, up to 500 μM, results in the depletion of both total (Figure 3.2C) and 
labile heme (Figure 3.2A,B) as expected. However, most interestingly, LH is more 
sensitive than total heme to SA-mediated heme depletion (Figure 3.2). When total heme 
is only modestly depleted by 25% using a relatively low 25 μM dose of SA (Figure 3.2), 
there is a much larger diminution of LH as measured by HS1- M7A and HS1 (Figure 
3.2A,B); heme loading of the medium affinity sensor, HS1-M7A, shifts from ~26% 
bound to ~ 0% bound, and the high affinity sensor, HS1, shifts in heme loading from 
~100% bound to ~60% bound. In terms of LH concentration, based on the ferrous heme 
dissociation constants of HS1-M7A, Kd
II = 25 nM29, and HS1, assumed to be Kd
II ~ 1 pM 
based on the estimated Kd
II  for Cyt b562, we would estimate LH decreases from ~10 nM 
to < 1 nM (likely ~2 pM based on the predicted Kd
II for HS1) in response to an SA 
concentration that modestly depletes total heme by 25%. Taken together, these data 
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strongly suggest that heme deficiency mobilizes labile heme to non-exchangeable, and 
likely higher affinity and/or buried, heme-binding sites. 
 
Figure 3.2 - LH is more sensitive to heme depletion using the heme biosynthetic 
inhibitor, SA, than total heme. Labile heme was measured in HS1- M7A– expressing (A) 
or HS1-expressing (B) cells cultured in SCE medium for 16 h with the indicated 
concentration of SA before measurement of the eGFP/ mKATE2 fluorescence ratios. (C) 
total heme was measured in the cultures depicted in A or in heme-deficient hem1Δ cells. 
All data represent the mean ± S.D. (error bars) of triplicate cultures, and the statistical 
significance was assessed using a two-sample t-test. Black asterisks, statistical 
significance between the indicated pairwise comparisons of conditions; red asterisks, 
statistical significance relative to 0M SA. *, p ˂ 0.05; **, p ˂ 0.005; ***, p ˂ 0.001; n.s., 
not significant. 
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3.5 Pb2+ Depletes Total Heme but Increases Labile Heme and Heme Mediated 
Signaling 
 A number of xenobiotics and environmental toxins negatively impact heme 
homeostasis152, including N-methylprotoporphyrins153, 154, certain alkylating agents, e.g. 
2-Allyl-2-isopropylacetamide155, tetrachlorodibenzo-p-dioxin and various 
polyhalogenated biphenyls156, 157, and heavy metals158-163. Pb2+, in particular, is a major 
public health concern given the ubiquity of Pb2+-based paints, piping, and munitions163. 
Among other targets, Pb2+ is well known to inhibit heme biosynthetic enzymes 
aminolevulinic acid (ALA) dehydratase (ALAD) and ferrochelatase (FECH), resulting in 
defects in heme synthesis, which in-turn leads to anemia, cognitive decline, and other 
health problems163. Further, Pb2+ and other heavy metals are known to induce HO164, 165, 
which may also contribute to decreased heme levels. However, while much is known 
about the role of Pb2+ in impacting heme synthesis and degradation, virtually nothing is 
known about the effects of Pb2+ on bioavailable labile heme. Given our findings that LH 
is important for maintaining heme signaling to Hap1 and is preferentially consumed 
relative to total heme during heme deficiency, we sought to determine the effects of Pb2+ 
on LH and heme-based signaling. Towards this end, we established a yeast model of Pb2+ 
toxicity and probed the effects of Pb2+ on total heme, LH, and heme signaling. 
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Figure 3.3 - Correlation between yeast cell viability as scored by outgrowth and a dye, 
FUN-1, that is sensitive to metabolic activity. (A) Outgrowth and FUN-1 measured 
viability was plotted as a function of [Pb] without normalization. Cell viability using 
FUN-1 was measured by taking the fraction of cells exhibiting red punctate fluorescence 
of the dye, which is indicative of metabolically active cells, and dividing over the total 
number of fluorescence positive cells that displayed either red punctate fluorescence or 
diffuse green fluorescence, which is indicative of metabolically inactive cells. (B) The 
data in A was normalized to the outgrowth or FUN-1 based viability at 0 µM [Pb]. These 
data are representative of two independent trials. 
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 Due to the insolubility of Pb(NO3)2 in standard yeast growth medias, we 
employed a Pb2+ toxicity model similar to what was previously described in which yeast 
cells are subjected to an acute 3 hour exposure to varying concentrations of Pb2+ in 10 
mM 2-(N-morpholino)ethanesulfonic acid (MES), pH = 6.0 buffer, a media in which 
Pb(NO3)2 is soluble and Pb
2+ is not complexed by the buffer166. Following Pb2+ exposure, 
cells are washed and allowed to recover for 4 hours in an appropriate synthetic complete 
(SC) drop-out media prior to subsequent analyses. Cell viability is measured by diluting 
cells into SC media after the recovery period and monitoring growth for 20 hours. Cell 
viability as measured by outgrowth is virtually identical to viability measurements using 
FUN-1, a fluorescent dye that exhibits red punctate emission in the vacuoles of 
metabolically active live cells and diffuse green cytosolic emission in dead cells (Figure 
3.3A-C)166. As shown in Figure 3.4A, yeast viability decreases with increasing [Pb2+]. 
The concentration of Pb2+ that inhibits growth by 50%, lethal dose-50 (LD50), varied 
between 25 and 500 μM over the course of our studies with different batches of media for 
reasons that are not completely understood. As a consequence, all of our analyses were 
done at the Pb2+ LD50 dose and not necessarily at a constant Pb
2+ concentration.  
 At the Pb2+ LD50 dose, elemental analysis using total reflection X-ray 
fluorescence (TXRF) spectroscopy confirms a significant enrichment of Pb2+ in yeast 
cells (Figure 3.4B). In addition, a host of other bio-elements are impacted as a 
consequence of Pb2+ toxicity; P, S, K, Fe, and Zn are diminished, whereas Ca and Cu are 
increased167. These effects are consistent with prior studies in a number of organisms and 
cell types demonstrating the impact of Pb2+ on various aspects of metal166, 168-172, 
phosphate173, 174, and sulfur homeostasis175-177. 
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Figure 3.4 - Labile heme and heme signaling is increased, but total heme is attenuated in 
response to Pb2+ toxicity. (A) yeast cell viability, as measured by solution turbidity at an 
optical density (O.D.) of 600 nm, is diminished by exposure to Pb2+ in a dose-dependent 
manner. (B) at the LD50 dose of Pb2+ (500 µM), cells hyperaccumulate up to 10 mM 
Pb2+, as measured by TXRF. (C) a dose of 500 M Pb2+ diminishes total heme to levels 
similar to 500M SA, but Pb2+ increases labile heme 2-fold, whereas SA does not. (D) 
Hap1p activity in response to heme depletion by SA or Pb2+ is measured using the 
pCYC1-EGFP Hap1 reporter construct (pCYC1). To control for the Hap1-independent 
effects of Pb2+ on EGFP expression, we measured EGFP fluorescence in response to Pb2+ 
or SA using an allele of EGFP driven by the heme/Hap1-independent promoter, GPD 
(pGPD). The ratio of pCYC1 to pGPD EGFP expression (pCYC1/pGPD) is a measure of 
heme/Hap1-specific activation of CYC1. All data represent the mean  S.D. (error bars) of 
triplicate cultures, and the statistical significance relative to untreated cells was assessed 
using a two-sample t-test. *, P ˂ 0.05; **, P ˂ 0.005; ***, P ˂ 0.001; n.s., not significant. 
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 Interestingly, while total heme is depleted due to Pb2+ exposure, as expected due 
to its known effects on inhibiting heme synthesis163 and up-regulating heme 
degradation164, 165, LH is completely maintained, and in fact, increases by 2- fold (Figure 
3.4C). In striking contrast, a dose of SA that depletes total heme to a similar degree as 
Pb2+ treatment attenuates both LH and total heme (Figure 3.4C). Titration of Pb2+over a 
broad concentration range indicates a dose dependent increase in LH (Figure 3.5A), 
decrease in total heme Figure 3.5B), and decrease in cell viability (Figure 3.5C). The 
Pb2+-dependent depletion of total heme and increase in LH primarily occurs after the 
recovery period in SC media; measurement of total heme and LH after the 3 hour 
Pb2+exposure in MES buffer has minimal effects on LH (Figure 3.5D) and total heme 
(Figure 3.5E) relative to cells allowed to recover in SC media (Figure 3.5A,B). The 
changes in HS1-M7A sensor ratio are not due to artifacts associated with Pb2+-dependent 
changes in sensor expression given that the emission of mKATE2, the heme-insensitive 
fluorophore, is constant over a wide-range of Pb2+doses (Figure 3.6A). Furthermore, a 
variant of HS1 that cannot bind heme, HS1-M7A, H102A, which has the Met and His 
heme coordinating residues mutated to Ala, does not exhibit Pb2+-dependent changes in 
fluorescence ratio (Figure 3.6B). Altogether, these data indicate that the total and labile 
heme pools can be acted upon independently of each other in response to stress and 
metabolically active cells are required for the observed changes in Pb2+-dependent LH 
and total heme. 
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Figure 3.5 - Pb2+ only perturbs total and labile heme after a recovery period following 
exposure to Pb2+. In cells expressing HS1-M7A, Pb2+ increases labile heme (A), 
decreases total heme (B), and diminishes cell viability (C) in a dose-dependent manner if 
cells are allowed to recover for 4 hr in SCE medium following Pb2+ exposure in MES 
buffer. However, labile (D) and total heme (E) in cells expressing HS1-M7A 
immediately after the exposure to Pb2+ in MES buffer are not significantly affected. All 
data represent the mean ± S.D. (error bars) of triplicate cultures, and statistical 
significance was assessed using a two-sample t-test. Black asterisks, statistical 
significance between the indicated pairwise comparisons of conditions; red asterisks, 




Figure 3.6 - The Pb2+-dependent changes in heme sensor fluorescence ratios are not due 
to degradation of sensor and are heme dependent. (A) The EGFP (ex. 488 nm, em. 510 
nm) and mKATE2 (ex. 588 nm, em. 620 nm) fluorescence channels that give rise to the 
HS1-M7A EGFP/mKATE2 ratios depicted in Figure 3.5A. The relatively constant 
mKATE2 fluorescence emission across a wide array of Pb2+ doses indicate that sensor 
expression is stable. (B) A sensor variant that cannot bind heme, HS1-M7A, H102A, 
does not exhibit Pb2+-dependent changes in EGFP/mKATE2 fluorescence ratio relative to 
the heme sensor, HS1- M7A. This suggests that the change in sensor fluorescence 
emission is due to heme and not Pb2+- dependent, heme-independent changes in sensor 
fluorescence. All data represent the mean ± SD of triplicate cultures and statistical 
significance was assessed using a two-sample t-test. These data support Figure 3.5. Black 
asterisks represent the statistical significance between the treated and untreated samples. 
* P < 0.05, ** P < 0.01, n.s. not significant. 
 Given that LH levels are changes so differently between SA and Pb2+ treatment, 
and that SA inhibits ALAD while Pb2+ inhibits both ALAD and FECH, we sought to 
analyze differences in protoporphyrin IX (PPIX) levels between these treatments. 
Correlating a buildup of PPIX in Pb2+ treated cells may indicate a preferential inhibition 
of FECH, and may allow us to derive insight from these results to help understand 
potential causes for heme mismanagement in porphyria. When comparing SA and Pb2+ 
inhibition of heme synthesis, total heme decreases to a similar degree with comparable 
doses of each inhibitor (Figure 3.7A,B); however, PPIX levels change differently in 
response to each inhibitor (Figure 3.7C,D). At low doses of Pb2+ PPIX levels decrease 
only slightly with larger absolute drops in total heme, presumably by inhibiting FECH 
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much more than ALAD (Figure 3.7B,D). At higher doses of Pb2+, however, there appears 
to be more inhibition of ALAD, resulting in the tapering of PPIX levels that was not 
apparent at lower doses of Pb2+ (Figure 3.7B). SA, on the other hand, has a steady dose 
dependent decrease in PPIX, as reflected by its sole inhibition of ALAD (Figure 3.7C). 
 
Figure 3.7 – Relative changes in total heme and total cellular PPIX levels in Pb2+ versus 
SA treated cells. (A) Total heme changes in response to SA. (B) Total heme changes in 
response in response to Pb2+ post recovery. (C) Total protoporphyrin IX (PPIX) changes 
in response to SA. (D) Total PPIX changes in response in response to Pb2+ post recovery. 
 We next addressed if the increase in LH in response to Pb2+ translates to changes 
in heme signaling. Towards this end, we measured Hap1 activity using the pCYC1-EGFP 
transcriptional reporter in cells conditioned with the LD50 dose of Pb
2+. In order to 
account for the effects of Pb2+ on EGFP expression independently of Hap1 activation, we 
also expressed EGFP under control of the GPD promoter (pGPD), which is not a 
transcriptional target of Hap1. As shown in Figure 3.4D, exposure to Pb2+ results in a 
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~33% decrease in the EGFP fluorescence of the Hap1 reporter while SA exposure results 
in a 6-fold decrease, despite a similar depletion in total heme.  
 Given that Pb2+ also affects EGFP fluorescence independently of Hap1, as 
evidenced by a ~60% decrease in fluorescence of parallel cultures harboring the pGPD-
EGFP construct, we normalized the fluorescence from pCYC1 driven expression of 
EGFP to the fluorescence from pGPD driven expression of EGFP, giving a 
pCYC1/pGPD ratio. Exposure to Pb2+ results in a nearly 2-fold increase, from .16 to .26, 
in the pCYC1/pGPD ratio of EGFP fluorescence, an indicator of Hap1/pCYC1 specific 
activation. In striking contrast, cells conditioned with a dose of SA that results in a 
similar concentration of intracellular heme as the LD50 dose of Pb
2+ exhibits a nearly 
~10-fold decrease in the pCYC1/pGPD ratio of EGFP fluorescence, with a nearly 10-fold 
decrease in fluorescence of the pCYC1-EGFP construct and minimal perturbation to 
fluorescence from the pGPD-EGFP construct. 
 Taken together, at minimum, these results suggest that, in response to Pb2+ 
toxicity, Hap1 activity is largely maintained, despite a > 10-fold decrease in total heme. 
At maximum, these results suggest that “heme-specific” Hap1 activity, as recorded from 
the pCYC1/pGPD ratio, actually increases in response to Pb2+ stress. The maintenance of 
or increase in Hap1 activity, depending on the interpretation of the data, is presumably 
due to the Pb2+-induced increase in LH. 




Figure 3.8 - Pb2+-dependent attenuation of total heme is largely dependent on heme 
synthesis. (A) WT cells untreated (left) or treated (right) with 500 µM SA and the 
indicated concentrations of Pb2+-demonstrate that Pb2+ has a larger effect on depleting 
total heme in cells that can properly synthesize heme. (B) and (C) endogenous heme, but 
not exogenous heme, is degraded in a Pb2+-dependent manner. Total (B) and labile heme 
(C) were measured in HS1-expressing WT or hem1Δ cells conditioned with the indicated 
Pb2+ concentration and/or 200 µM ALA or 50 µM hemin chloride during the preculture 
and/or post- Pb2+ recovery period. All data represent the mean ± S.D. (error bars) of 
triplicate cultures, and statistical significance was assessed using a two-sample t-test. In 
A, black asterisks represent the statistical significance between the indicated pairwise 
comparisons of conditions, and red asterisks represent the statistical significance relative 
to 0 µM Pb for each time point. In B, black asterisks represent the statistical significance 
relative to 0 µM Pb foreach test condition. In C, the black asterisks represent the 
statistical significance between the indicated pairwise comparisons of strains. *, P ˂ 0.05; 
**, P ˂ 0.01; ***, P ˂ 0.001; n.s., not significant. 
 72 
 We next sought to determine the mechanism by which intracellular heme is 
depleted in response to Pb2+ toxicity. The intracellular concentration of heme is governed 
by the relative rates of heme synthesis and degradation or export. In order to parse apart 
the effects of Pb2+ on these opposing processes, we tested the effects of Pb2+ on cells that 
had a defect in the ability to synthesize heme. First, we determined that Pb2+-dependent 
heme depletion occurs within the first 1.5 hours of the 4-hour recovery period in SC 
media (Figure 3.8A, 0 μM SA). Second, we found that in cells that had a defect in heme 
synthesis due to conditioning with 500 μM SA, Pb2+ had an attenuated effect on the loss 
of total heme. For instance, after 2.7 hours, cells that could biosynthesize heme (Figure 
3.8A, 0 μM SA) exhibited a 2-fold and 6-fold decrease in total heme when treated with 
125 and 250 μM Pb2+, respectively. On the other hand, in cells with ablated heme 
biosynthesis (Figure 3.8A, 500 μM SA), both 125 and 250 μM Pb2+ resulted in a 
relatively modest ~30% decrease in total heme. The diminished effect of Pb2+ on total 
heme in cells conditioned with the heme biosynthetic inhibitor SA suggested that Pb2+ 
depletes total heme by largely suppressing heme biosynthesis. 
 We next sought to further validate the observation that Pb2+ depletes heme by 
primarily affecting heme synthesis and not heme degradation or export. Towards this end, 
we utilized a hem1∆ strain, which lacks the 1st enzyme in the heme synthesis pathway, 
ALA synthase (ALAS), to test the effects of Pb2+ on the degradation of mitochondrially-
derived de novo synthesized heme or exogenously supplied heme. hem1∆ cells can only 
acquire heme by stimulating mitochondrial heme synthesis via supplementation with 
ALA, the product of ALAS, or by heme uptake via hemin supplementation. We 
supplemented hem1∆ cells with ALA or heme during a 16-hour pre-culture in SCE 
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media, subjected them to Pb2+exposure in MES buffer for 3 hours, followed by a 4-hour 
recovery in SCE media, and then analyzed total heme (Figure 3.8B). WT and hem1∆ 
cells supplemented with ALA in both the pre-culture and during the recovery 
accumulated similar amounts of intracellular heme, experienced a Pb2+-dependent 
depletion of total heme (Figure 3.8B, black and green columns) and exhibited >80% 
heme-loading of the high affinity heme sensor HS1 (Figure 3.8C, black and green 
columns). hem1∆ cells treated with ALA only during the pre-culture, but not during the 
recovery, also exhibited a Pb2+-dependent attenuation in intracellular heme (Figure 3.8B, 
red columns). However, the total amount of heme was ~5-fold lower (Figure 3.8B, red 
columns) and the heme-loading of HS1 was considerably reduced, ~10% bound, 
compared to hem1∆ cells supplemented with ALA in both the pre-culture and the 
recovery media (Figure 3.8C, red columns), presumably due to the fact that ALA was 
limiting since it is not supplied during the recovery phase. In striking contrast to ALA 
supplementation, hem1∆ cells supplemented with exogenous heme during the pre-culture, 
which contributed to a 2-fold increase in intracellular heme relative to ALA 
supplemented hem1∆ cells, did not exhibit the Pb2+-dependent depletion of heme (Figure 
3.8B, yellow columns). Exogenously supplied heme is still available to bind HS1, and in 
fact, its fractional saturation is similar to ALA treated cells after normalizing for the 
change in total intracellular heme concentration (Figure 3.8C, yellow columns). The 
observation that Pb2+ depletes endogenously synthesized heme and not exogenously 
supplied heme strongly suggests that Pb2+ primarily inhibits heme synthesis, with minor 
effects on heme degradation.  
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 Given that heme synthesis is O2-dependent and our results that Pb
2+ largely 
inhibits heme synthesis, we next sought to test our prediction that Pb2+ should have 
minimal impact on total heme in the absence of O2. To test the O2 dependence of Pb
2+-
induced heme depletion, we subjected aerobically grown cells to Pb2+ exposure in MES 
buffer in an anoxic or normoxic environment, followed by recovery in anoxic or 
normoxic culture conditions and measurement of total heme, LH, and Pb2+ toxicity 
(Figure 3.9). Quite strikingly, despite accumulating similar levels of Pb2+ between 
normoxic and anoxic Pb2+-exposures (Figure 3.10), in the absence of O2, cells do not 
exhibit Pb2+-dependent heme depletion (Figure 3.9A). On the other hand, the increase in 
LH in response to Pb2+ is similar between both normoxic and anoxic Pb2+ exposures 
(Figure 3.9B). Notably, Pb2+-mediated cell toxicity is entirely O2-dependent given that 
viability is not affected in anoxic cultures (Figure 3.9C). Taken together, our data suggest 
that Pb2+-induced depletion of total heme only occurs in cells that are synthesizing heme 
de novo, further supporting the notion that Pb2+ largely inhibits heme synthesis. 
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Figure 3.9 – Pb2+-induced depletion of heme is O2-dependent. Cells expressing HS1-
M7A were conditioned with the indicated concentration of Pb2+ and allowed to recover in 
an anoxic, nitrogen-rich (N2) atmosphere or in air (O2), and total heme (A), labile heme 
(B), and viability (C) were measured. All data represent the mean ± S.D. (error bars) of 
triplicate cultures, and statistical significance was assessed using a two-sample t-test. 
Black asterisks, statistical significance between the indicated pairwise comparisons of 
conditions; red asterisks, statistical significance relative to 0 µM Pb.* *, P ˂ 0.05; **, P ˂ 
0.01; ***, P ˂ 0.001; n.s., not significant. 
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Figure 3.10 - Anaerobic and aerobic Pb2+ uptake are virtually identical. Intracellular Pb 
was measured by TXRF after treatment with a bolus of 100 µM or 200 µM Pb(NO3)2 that 
was administered either anaerobically (N2) or aerobically (O2) as described in 3.10.11. 
The data are presented as a ratio of aerobic (O2) to anaerobic (N2) cellular Pb
2+ 
concentrations and represent the mean ± SD of triplicate cultures. The statistical 
significance was assessed using a two-sample t-test. These data support Figure 3.9. n.s. 
not significant. 
 We next sought to determine if a block in heme degradation or export could 
preserve total heme in the face of Pb2+ toxicity and affect labile heme. One established 
mechanism of heme degradation is via heme oxygenase (HO), an enzyme that oxidatively 
degrades heme into bilirubin, carbon monoxide (CO), and ferrous iron (Fe2+)165. In order 
to test the role of HO in Pb2+-dependent heme depletion, we compared WT and hmx1∆ 
cells, which lacks heme oxygenase 1178, 179, for Pb2+-dependent heme depletion. As 
shown in Figure 3.11A, in the absence of Pb2+, hmx1∆ cells exhibit a ~25% increase in 
total heme, consistent with prior studies in yeast and the known role of Hmx1 in heme 
degradation178. However, both WT and hmx1∆ cells exhibit the Pb2+-induced depletion of 
heme to similar degrees, indicating HO does not play a role in the loss of heme during 
Pb2+ toxicity. Both WT and hmx1∆ cells exhibited a Pb2+-dependent increase in LH 
(Figure 3.11B). For reasons that are not entirely clear at this time, hmx1∆ cells appeared 
to be more resistant to Pb2+ toxicity (Figure 3.11C). In contrast, prior work has 
demonstrated that Hmx1p confers resistance to various oxidative insults, including H2O2, 
diamide, and menadione179, presumably due to released CO, bilirubin, and biliverdin. 
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Figure 3.11 - Pb2+-induced depletion of heme does not involve HMX1 or PUG1. (A-C) 
hmx1∆ cells exhibit a Pb2+-dependent (A) decrease in total heme and (B) increase in 
labile heme. (C) hmx1∆ cells are more resistant to Pb2+ toxicity. (D-F) pug1∆ cells 
exhibit a Pb2+-dependent (D) decrease in total heme, (E) increase in labile heme, and (F) 
WT-sensitivity to Pb2+ toxicity. All data represent the mean ± SD of triplicate cultures 
and statistical significance was assessed using a two-sample t-test. Black asterisks 
represent the statistical significance between the indicated pairwise comparisons of 
conditions and red asterisks represent the statistical significance relative to 0 µM [Pb]. * 
P < 0.05, ** P < 0.01, *** P < 0.001, n.s. not significant. 
 An alternative mechanism for cellular heme depletion is heme export. Many 
metazoans express heme exporters, e.g. FLVCR1, to aid in heme detoxification. 
Saccharomyces cerevisiae expresses a porphyrin-heme exchanger, PUG1, which uptakes 
protoporphyrin IX and expels heme120. In order to test the role of heme export via Pug1 
during Pb2+ toxicity, we determined the extent to which heme is depleted in WT and 
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pug1∆ cells exposed to increasing doses of Pb2+. As with hmx1∆ cells, pug1∆ cells 
exhibit a similar degree of Pb2+-induced heme depletion as WT cells (Figure 3.11D), 
indicating Pug1 does not affect the loss of heme during Pb2+ toxicity. Both WT and 
pug1∆ cells exhibit an increase in LH in response to Pb2+ (Figure 3.11E) and similar 
sensitivities to Pb2+ toxicity (Figure 3.11F). 
 Altogether, our data indicate that: a. Pb2+ depletes total heme primarily through its 
ability to inhibit heme synthesis and b. heme degradation and export pathways do not 
affect Pb2+-dependent changes in total and labile heme.  
3.7 Pb2+-dependent Increases in Labile Heme Correlate with Protein Degradation 
 Most heme is associated with non-exchangeable binding sites in high affinity 
hemoproteins. As such, we predicted that the increase in labile heme in response to Pb2+ 
may be associated with the degradation of hemoproteins and the release of heme into the 
labile heme pool. To test this hypothesis, we conducted 1-D PAGE analysis of cells 
conditioned with and without Pb2+ at the LD50 dose immediately after the 3-hour 
exposure to Pb2+ in MES buffer and after the 4-hour recovery phase (Figure 3.12A). We 
found that immediately following exposure to Pb2+, protein expression is unaffected, 
whereas after the 4-hour recovery, a number of proteins are degraded (Figure 3.12A). The 
diminished protein expression during the recovery phase correlates with when we 
observe increased LH, suggesting protein turnover and an increase in LH are linked. 
Notably, using tandem mass spectrometry, we found that GAPDH, a component of the 
LH buffer29, is retained during Pb2+ exposure (Figure 3.12A,B and Table 1). Another 
glycolytic protein, enolase, is also maintained during Pb2+ exposure. On the other hand, 
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Pb2+ has the capacity to degrade high affinity hemoproteins. Ctt1, which is a heme 
containing catalase enzyme, is degraded in a Pb2+-dependent manner (Figure 3.12B). 
Altogether, our data is consistent with a model in which Pb2+ induced degradation of 
hemoproteins releases heme that contributes to the LH pool. 
 In order to test the hypothesis that Pb2+-dependent protein turnover releases heme 
from hemoproteins and increases LH, we assayed Pb2+-dependent changes in LH in yeast 
mutants defective in various protein degradation pathways, including vacuolar, 
autophagic, and proteasomal degradation. We found that a proteasome mutant, rpn10∆180, 
exhibited Pb2+ dependent and independent changes in LH (Figure 3.12C), whereas 
mutants defective in vacuolar, pep4∆181, (Figure 3.12D) or autophagic, atg1∆182, (Figure 
3.12C), pathways did not have altered LH. Under non-stressed conditions, WT cells 
exhibited a LH concentration of ~ 5 nM, corresponding to an HS1-M7A fractional 
saturation of 17%. On the other hand, HS1-M7A was ~ 0% bound to heme when 
expressed in rpn10∆ cells, which corresponds to a LH concentration of < 1 nM. 
However, Pb2+ induced a greater increase in LH (Figure 3.12C) and decrease in total 
heme (Figure 3.12E) in rpn10∆ cells relative to WT. Moreover, the growth of rpn10∆ 
cells were more sensitive to Pb2+ toxicity that WT (Figure 3.12F). In total, these results 
indicate that the proteasome positively regulates LH and loss of proteasomal function 
sensitizes cells to Pb2+-dependent effects on heme homeostasis. 
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Figure 3.12 - Pb2+-dependent changes in heme homeostasis correlate with the 
degradation of a large fraction of the proteome and are affected by the proteasome. (A) 
SDS-PAGE and Coomassie staining of lysates prepared from cells conditioned with or 
without an LD50 dose of Pb2+, 100 µM, that did or did not undergo a post- Pb2+ exposure 
recovery period. Tandem mass spectrometry reveals that the high intensity chromatic 
bands that are retained under Pb2+-stress, indicated by the arrows, are GAPDH and 
enolase (Table 1). (B) The expression and activity of the high affinity hemoprotein Ctt1p, 
a heme-catalase enzyme, is down-regulated in response to Pb2+ conditioning, whereas 
GAPDH expression, a constituent of the labile heme buffer, is maintained. All gels are 
representative of at least three independent cultures. (C and D) The effects of atg1∆ (C), 
rpn10∆ (C), and pep4∆ (D) deletion on Pb2+-dependent changes in labile heme were 
assessed. (E and F) Pb2+-dependent changes in total heme (E) and growth (F) were 
assessed in WT and rpn10∆ cells. All labile and total heme measurements represent the 
mean ± SD of triplicate cultures, whereas the growth data represent the mean ± SD of 
duplicate cultures. Statistical significance was assessed using a two-sample t-test. Black 
asterisks represent the statistical significance between the indicated pairwise comparisons 
of conditions and red asterisks represent the statistical significance relative to 0 µM [Pb]. 
* P < 0.05, ** P < 0.01, *** P < 0.001, n.s. not significant, n.d. not detectable. 
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Table 1 - Mass spectrometry-based protein identification of enolase and GAPDH from 
the SDS-PAGE gel depicted in Figure 3.12 (Hyojung Kim167). 
 
3.8 Investigation of Heme Binding Proteins in Untreated vs. Pb2+-shocked Cells 
Up to this point, using our models of heme inhibition with SA, heme chelation by 
Cyt b562 induction, and Pb
2+ poisoning we have divulged a great deal of details 
underpinning how yeast handle heme under stress. Specifically regarding Pb2+ poisoning, 
we revealed that Pb2+ increases cellular LH but decreases total heme, and tight binding 
hemoproteins like catalase among others, (data not shown), are turned over while labile 
heme buffering protein GAPDH is preserved. Additionally, the LH preserved under Pb2+ 
stress sustains heme signaling (Figure 3.4, Figure 3.12). Further, we have unveiled that 
the proteasome, which is positively regulated by Pb2+, positively regulates LH 
availability and that the loss of proteasomal function by RPN10 deletion sensitizes cells 
to Pb2+ dependent effects on heme homeostasis (Figure 3.12). Given all these details, and 
specifically that heme signaling is maintained while heme and hemoprotein availability 
are drastically altered between non-stressed and Pb2+ stressed cells, we sought to reveal 
what proteins are binding and releasing heme in response to stress to reveal new heme 
signaling networks in yeast. 
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To do so, we optimized the use of hemin agarose beads to affinity purify 
hemoproteins from cellular lysates in hopes of identifying proteins that bind or release 
heme in response to Pb2+ stress. We did this under two assumptions. 1.) These proteins 
that are binding and releasing heme in response to Pb2+ stress, by definition, are part of a 
heme signaling network. 2.) With this approach, proteins that change in their heme 
speciation or fractional saturation upon stress (Pb2+ poisoning) will bind differently to 
hemin agarose (Figure 3.13), and the abundance by which they are affinity purified with 
hemin agarose between two conditions reflects the relative change in fractional saturation 
of that protein with heme. To do this, we optimized hemin agarose chromatography 
methods (See Appendix) coupled to quantitative mass spectrometry (LC MS-MS) to 
assess the heme speciation of proteins eluted from hemin agarose beads to identify new 
heme binding factors involved in heme signaling. 
3.8.1 Validating Approach: Hemin Agarose Binding Apo-hemoprotein 
 To test our approach and functional assumptions of hemin agarose illustrated in 
Figure 3.13, we sought to determine how well the canonical hemoprotein myoglobin 
would stick to hemin agarose in its unbound versus heme loaded state. 1-D PAGE 
analysis of elutions from hemin agarose beads treated with apo-myoglobin with and 
without co-treatment of hemin reveal that only apo-myoglobin sticks to the hemin 
agarose beads (Figure 3.14). These results served as an initial validation of our approach. 
See Appendix for more details regarding optimization of preparing, treating, and eluting 
heme-binding proteins off the beads. 
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Figure 3.13 – Cartoon representation of hemin agarose beads, detailing that heme 
saturated, holo-hemoproteins will not stick to hemin agarose beads, while heme vacant, 
apo-hemoproteins will bind to hemin agarose.  
 
Figure 3.14 – Elution of myoglobin off of hemin agarose beads. Each heme treated 
sample received 30 equivalents of heme to be co-incubated with the hemin agarose beads. 
 From here, we further tested our original hypothesis that hemin agarose would 
preferentially bind with heme binding proteins based on their heme load using cellular 
lysates. To do this, cellular lysates from heme deficient hem1Δ cells and WT cells treated 
with and without a low or high dose of heme biosynthesis inhibitor SA to starve cells of 
heme were treated with hemin agarose to interrogate whether heme availability to these 
cells’ proteins impacts their ability to bind heme (Figure 3.15). The same lysates were 
 84 
treated with sepharose control beads to ensure that any eluted protein stuck to hemin 
agarose because of an interaction specific to the heme of the hemin agarose bead matrix 
(Figure 3.13, Figure 3.15). Fitting to our model, there are at least 8 noticeable protein 
bands visible in both contrast settings displayed in Figure 3.15 that bind hemin agarose 
better when extracted from heme starved cells (WT + 500 µM SA or hem1Δ cells) with 
very little abundance in the sepharose bead elutions. Interestingly, only complete 
depletion of heme availability by 500 µM SA, and not partial depletion by 100 µM SA 
treatment, has these 8 proteins bind hemin agarose more effectively (Figure 3.15). 
 
Figure 3.15 – Hemin agarose versus sepharose treated lysates from WT ± SA and hem1Δ 
cells analyzed by 1-D PAGE. Results are displayed with two different contrast settings. 
Bands that increased in abundance in hemin agarose elutions in heme depleted cells are 
pointed out with black arrows. Protein bands detected in hemin agarose treated lysates far 
outweigh those from sepharose treated lysates. 
3.8.2 SILAC Labelling and Analysis of Heme Binding Proteins by Hemin Agarose 
versus Sepharose Chromatography 
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 Given that our model and hypothesis that proteins would stick to hemin agarose 
preferentially based on their heme load was consistent with both analyses with myoglobin 
experiments and with cellular lysates (Figure 3.14, Figure 3.15), we sought to apply our 
hemin agarose and sepharose bead chromatography methods to study heme speciation of 
proteins between untreated (-Pb) vs Pb2+ poisoned (+Pb) cells. To comprehensively 
distinguish proteins that are binding or releasing heme between -Pb vs +Pb cells we 
devised a means to couple our hemin agarose chromatography (HAC) methods with 
stable isotope labeling by amino acids in cell culture (SILAC) to accurately quantify the 
differences in all affinity purified proteins eluted from the beads. Given the extreme 
differences in protein expression observed by 1-D PAGE and whole proteome (WP) 
analysis (Figure 3.12A, Figure 3.17A), it would be difficult to directly compare the 
protein abundances resulting from hemin agarose treated with -Pb or +Pb cellular lysates 
directly. Instead, we devised a means to use SILAC labeling to characterize the heme-
binding specificity of proteins, operationally defined as the ratio of protein eluted from 
hemin agarose vs sepharose, measured in both -Pb lysates and +Pb lysates independently 
(Figure 3.16, See 3.10.3 for relevant details on our model of Pb2+ toxicity). Utilizing this 
approach, the heme binding specificity of each identified protein was plotted to compare 




Figure 3.16 – Cartoon for SILAC growth of cells coupled to Pb2+ shock protocol and LC 
MS-MS to identify heme binding proteins in Pb2+ (+Pb) shocked versus non-Pb2+ (-Pb) 
treated cells. To identify specific binders of heme in Pb2+ treated cells, a heavy (13C6,
15N2 
lysine) and light (12C6,
14N2) culture of cells, were grown, both subject to Pb
2+ treatment, 
allowed to recover, and lysed. The lysates from the light labeled samples were treated 
with sepharose beads, while the heavy labeled cellular lyates were treated with hemin 
agarose beads. A 1:1 volume ratio of the eluents from the light labeled, sepharose treated 
cells was mixed with with the eluents from the heavy labeled, hemin agarose treated 
cells. This elution was prepped for and analyzed by LC MS-MS and the proteins that 
bound to hemin agarose but not sepharose beads were deemed putatitive heme binding 
proteins. The same procedure was conducted in tandem for the non-Pb2+ treated cells. 
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Figure 3.17 – Proteomics analysis of global protein expression and fractionally saturated 
heme proteins in nontreated (-Pb or PbN) versus to Pb2+ treated (+Pb or PbP) cells. (A) 
Whole proteome (WP) analysis of the relative abundance of proteins between -Pb and 
+Pb treatment conditions on a Log2 scale. Blue circles represent proteins that decreased 
in abundance in response to Pb2+ treatment, and red circles represent proteins with 
increased abundance to Pb2+ treatment. The results indicate that protein expression 
changes dramatically following Pb2+ treatment. The WP analysis helped filter changes in 
protein binding to hemin agarose between -/+ Pb conditions by controlling for loss or 
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gain in protein abundance. (B) Results of SILAC labeled hemin agarose chromatography 
(HAC) proteomics study in both +Pb (y-axis, PbP_HAC) and -Pb (x-axis, PbN_HAC) 
treated cells. The hemin agarose specificity, a measure of protein abundance from hemin 
agarose divided by the protein abundance from sepharose elutions, from +Pb lysates was 
plotted against those from -Pb lysates as a Log2 ratio. Only the proteins detected from 
HAC analysis in both +Pb and -Pb treatment conditions were plotted. The graphed 
proteins fall into 4 main groups identified in the plot. In the legend on the right, the 
changes in general protein abundance measured from the WP are indicated in color, and 
the size of the circles are direct measure of the PSM values from the WP analysis. The 
WP analysis metrics were essential in deciding how much a protein’s change in affinity 
for hemin agarose was a measure of heme specificity or not, and therefore, proteins 
without WP detection, were excluded from analysis in panel B. This data was generated 
with eluents provided to Hyojung Kim and Matthew Torres, who provided this graph. 
 The eluted protein abundances from the heavy labeled hemin agarose were ratioed 
against their light labeled negative control sepharose bead abundances to give them a 
measure of specificity for hemin agarose, which is ideally a direct measure of their heme 
specificity. The resulting heme specificities, or the ratio of hemin agarose to sepharose 
enrichment, for the Pb2+ treated cells (y-axis, HAC_PbP) were plotted against those for 
the untreated cells (x-axis, HAC_PbN) in order to assess how the heme specificity of 
proteins change in response to Pb2+ treatment (Figure 3.17B). Only proteins that were 
detected by WP analysis were included in Figure 3.17B so that the changes in protein 
abundance in the HAC study can be assessed to be from changes in ability to be 
preferentially enriched by hemin agarose rather than from a change in general protein 
abundance between -Pb and +Pb conditions, which is quiet variable (Figure 3.17A). 
 Proteins that were not enriched by sepharose in either -Pb, +Pb, or both conditions 
represent Groups 3, 2, and 1 proteins, respectively (Figure 3.17B). When a protein was 
not detected in the sepharose eluents, its value for sepharose enrichment was set to a 1, 
yielding higher hemin agarose to sepharose enrichment ratios for many proteins in 
Groups 1 through 3. Group 4 proteins, on the other hand, were enriched by both hemin 
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agarose and sepharose with and without Pb2+ treatment. For these reasons, the Groups 1 
to 3 protein lists were deemed more likely to contain heme binding proteins than Group 4 
proteins. Even so, Group 4 proteins should not be ignored as there plenty of proteins with 
heme agarose to sepharose enrichment ratios that are greater than 6 on a Log2 scale, and 
the heme binding chaperone protein GAPDH was identified in this group. 
 All in all, Group 1 proteins bind to hemin agarose specifically under both 
treatment conditions. Group 4 proteins may contain heme binding proteins but were 
enriched by both hemin agarose and negative control sepharose beads. Group 2 proteins 
bind to hemin agarose specifically only under Pb2+ treatment conditions; and therefore, 
Group 2 is hypothesized to contain proteins that have lost their heme in response to Pb2+ 
stress, increasing their capacity to bind to hemin agarose. Conversely, Group 3 proteins 
are those that only bind to hemin agarose without Pb2+ treatment; therefore, Group 3 
proteins are hypothesized to have lost the ability to bind to hemin agarose post Pb2+ 
treatment by acquiring heme in response to Pb2+ stress. In total, Groups 1 to 4 represent a 
putative heme binding proteome in yeast, Groups 1 to 3 are easier to prioritize given their 
lack of enrichment with sepharose beads, and Groups 2 and 3 represent putative heme 
binding proteins whose fractional saturation with heme changes dramatically as a 
function of Pb2+ stress. 
3.8.3 PANTHER Analysis of Group 2 and 3 Putative Heme Binding Proteomes 
 Given the evidence supporting Groups 2 and 3 proteins to heme binding proteins 
involved in heme signaling and/or trafficking in responses to stress we analyzed them by 
PANTER pathway analysis to investigate what types of proteins were identified by 
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molecular function (Figure 3.18, Figure 3.19), biological process (Figure 3.20), and 
protein class (Figure 3.21). 
 
Figure 3.18 - Groups 2 and 3 catalytic proteins analyzed for their molecular function 
using PANTHER. 
 The largest subset of molecular functions ascribed to Group 2 and 3 proteins were 
either the class of having catalytic activity, which are further analyzed in Figure 3.19, or 
binding (Figure 3.18). The major class of binding proteins identified were of the class 
heterocyclic compound binding (77 proteins, GO:1901363), which were all nucleoside 
and nucleotide binding proteins. This is an overrepresented class of proteins involved in 
DNA and RNA binding, including many ribosomal subunits. The second major class of 
binding proteins identified includes proteins that are involved in protein binding (47 
proteins, GO:0005515), including cytoskeleton protein binding (GO:0008092), enzyme 
binding (GO:0019899), unfolded protein binding (GO:0051082), heat shock protein 
binding (GO:0031072), and transcription factor binding (GO:0008134) among several 
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others. In total, the most abundant molecular functions of the identified proteins include 
enzymatic activity, interacting with other proteins, controlling translation and 
transcription, and facilitating transport within the cell (Figure 3.18).  
 
Figure 3.19 - Groups 2 and 3 catalytic proteins analyzed for their molecular function 
using PANTHER. The 161 catalytic proteins identified in Figure 3.18 where analyzed 
here for their specific catalytic function. 
 Of the catalytic proteins identified, the most abundant enzyme activity identified 
was hydrolase activity, oxidoreductase activity, and transferase activity. The proteins 
with transferase activity are those involved in the transfer of phosphorous containing 
groups, acyl groups, and several other organic functional groups (Figure 3.19). 
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Figure 3.20 - Groups 2 and 3 proteins analyzed by biological process. 
 Grouping proteins by their biological process revealed that most identified 
proteins are involved in regulating metabolic and cellular processes (Figure 3.20). A 
breakdown of these processes reveal that the main biological processes regulated by these 
proteins include gene expression (57 proteins, GO:0010467), organelle organization (29 
proteins, GO:0006996), translation (28 proteins, GO:0006412), amino acid biosynthesis 
(19 proteins, GO: 0008652), macromolecule catabolic processes (15 proteins, 
GO:0009057), and cofactor metabolic processes (14 proteins, GO:0051186). 
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Figure 3.21 - Groups 2 and 3 proteins analyzed by Protein Class. 
 Additional organization by protein class further reveals the diversity of the 
identified proteins. Relevant to nutrient trafficking and signaling there were 13 
transporters, 3 transfer/carrier proteins, 30 transferases, 9 membrane trafficking proteins, 
1 storage protein, 10 transcription factors, and 7 proteins with transcription regulatory 
activity (Figure 3.21). 
 Lastly organizing proteins based on pathways using PANTHER’s organization by 
GO:Terms reveals an exhaustive list of 149 pathways affected by these proteins. For 
brevity, the top 7 pathways affected were (1) ubiquitin proteasome pathway, (2) a 
pathway ascribed to Parkinson’s disease, (3) the EGF receptor signaling pathway, (4) 
purine biosynthesis, (5) genes implicated in Huntington’s disease (6) inflammation 
mediated by chemokine and cytokine signaling pathway, and the (7) integrin signaling 
pathway. The most represented pathway, the ubiquitin proteasome pathway included 9 
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subunits of the 26 S proteasome, and the Parkinson’s disease pathway included several 
genes involved in nutrient trafficking, proteasomal proteins, stress response, and 
signaling proteins, including a 14-3-3 protein and a mitogen activated protein kinase. 
3.9 Discussion 
 Heme synthesis and degradation is tightly coordinated so as to minimize the 
accumulation of potentially cytotoxic "free” or labile heme (LH)13, 44, 46. As a 
consequence, the concentration and physiological role of LH in biology has been 
controversial2, 49. While estimates for the concentration of LH across various cell types 
have spanned sub-pM to µM quantities2, 44, 49, 183, 184, the use of genetically encoded heme 
sensors in yeast and various non-erythroid human cells lines have established a consensus 
range for cytosolic LH that spans 10-100 nM, representing up to 10% of the total heme 
concentration29, 111. However, few studies have directly probed the contribution of steady-
state LH as a heme source for hemoproteins and heme signaling. Herein, we established a 
functional role for LH in regulating heme signaling and demonstrated that LH is 
preferentially consumed relative to total heme when cells become heme depleted. 
 We find that modestly depleting total heme by 25% with succinylacetone, an 
inhibitor of the second enzyme in the heme biosynthetic pathway, ALAD, results in a 
much larger perturbation to LH, depleting it more than 10-fold, from 10 nM to < 1 nM, 
possibly as low as ~ 2 pM (Figure 3.2). The sensitivity of the LH pool towards heme 
depletion relative to total heme is an indication that LH is mobilized to support heme-
dependent processes when cells are confronted with diminished heme synthesis. In other 
words, LH re-equilibrates with other high-affinity and/or poorly exchangeable heme 
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binding sites that may become vacant when heme is depleted. These results are consistent 
with prior pulse-chase experiments that utilized radiolabelled ALA and/or heme sources 
to demonstrate that P450 enzymes equilibrate with LH152. Altogether, these observations 
may have significant implications for conceptualizing new heme-based therapies for 
porphyrias, a family of inherited disorders associated with defects in heme biosynthesis. 
For instance, treatment methods designed to increase LH via supplementation with 
appropriate heme complexes may form the basis for alleviating the symptoms of heme 
scarcity185. 
 In order to address the role of LH on heme dependent functions, we induced a 
site-specific heme chelator in the cytosol via the overexpression of Cyt b562 and assessed 
its effect on heme signaling through the yeast heme regulated transcription factor Hap1 
(Figure 3.1). We found that sequestration of LH inhibited Hap1 activity, demonstrating 
that LH can control heme-signaling processes. Importantly, these results indicate that 
increasing heme synthesis, a metabolically demanding process, is not the only means to 
activate heme signaling, as was previously suggested for activation of Hap1143, 186 and 
metabolic cycling in yeast187, 188, as well as heme regulation of the circadian clock 
through the nuclear receptors, Rev-erb-α and Rev-erb-β, in mammals35. 
 In order to understand the relationship between total heme, LH, and heme 
signaling during adaptation to cellular stress, we subjected yeast cells to an 
environmentally-relevant toxicant well known to affect heme homeostasis, Pb2+163. In 
yeast, Pb2+ toxicity suppresses metabolic activity and proliferation through a mechanism 
that requires new protein synthesis166. In addition, mitochondria are a major target of Pb2+ 
toxicity and are the source of Pb2+-induced reactive oxygen species production (ROS)189. 
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Heavy metal sequestration by vacuoles and binding to glutathione and metallothioneins 
are important detoxification pathways for Pb2+190. 
 A number of previously established yeast models for Pb2+ toxicity employ 
exposures spanning 0.1 – 10 mM, which is high relative to the 240 nM [Pb2+] threshold in 
patient blood samples used to initiate public health actions191, the 1 – 5 µM blood [Pb2+] 
associated with inhibition of heme biosynthesis in humans192, 193, or the 0.1 – 250 µM 
[Pb2+] used in mammalian cell culture models of Pb2+ toxicity194, 195. However, it is 
important to note that the biochemical features of Pb2+ toxicity at these high 
concentrations in yeast phenocopy many of the hallmarks of Pb2+ toxicity in mammalian 
cell lines at lower concentrations35, 166, 190, 196-198, including inhibition of heme synthesis 
(current work). The higher Pb2+ exposure concentrations required for yeast may reflect 
differences in Pb2+ uptake, efflux, or intracellular bioavailability. 
 While Pb2+ has the capacity to deplete cellular heme through its ability to inhibit 
two enzymes in the heme biosynthetic pathway, ALAD, also the target of SA, and FECH, 
and upregulate the expression of the heme-degrading enzyme HO163-165, we found that, in 
yeast, Pb2+ significantly attenuates total heme primarily due to the inhibition of heme 
synthesis (Figure 3.8, Figure 3.11). However, rather surprisingly and paradoxically, we 
found that Pb2+ significantly increases LH (Figure 3.4C). When comparing heme 
synthesis inhibition between SA and Pb2+, there is higher PPIX levels in Pb2+ treated cells 
indicating that FECH is inhibited by Pb2+. If the mode of inhibition contributes to 
uncoupling LH from total heme, a potential explanation could be that Pb2+ may be 
affecting the proposed heme transport machinery that may associate with FECH and the 
heme synthesis metabolon71. Otherwise, given our previous findings that thiol-specific 
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alkylating agents impact the NO-mediated mobilization of LH29 and the well documented 
interactions between Pb2+ and cysteine residues199, we propose that Pb2+ may liberate 
heme in cells from certain thiol containing heme binding sites. Alternatively, since Pb2+-
induces the degradation of a large fraction of the proteome, the increase in LH could 
simply be a result of heme that is released from hemoproteins that are being turned-over. 
Consistent with this model, we found that a mutant that has a defect in proteasomal 
function, rpn10∆, has less LH than WT cells (Figure 3.12C). However, it is unclear why 
rpn10∆ cells exhibit a greater magnitude increase in LH (Figure 3.12C) and decrease in 
total heme (Figure 3.12E) in response to Pb2+ stress. One explanation that could account 
for the former is that Pb2+ is directly or indirectly inducing the release of heme from a 
hemoprotein target that is stabilized due to the attenuation in proteasome function in 
rpn10∆ cells. Given that previous studies have demonstrated that Pb2+ positively 
regulates the proteasome200 and heme and ALAD act as negative regulators of the 
proteasome201, 202, there is a complex mosaic of competing effects that might account for 
the Pb2+-dependent changes in heme homeostasis in WT and rpn10∆ cells. We are 
currently elucidating the molecular mechanisms underlying heme regulation of LH and 
the proteasome. 
 The Pb2+-induced increase in LH seems to impact heme signaling via Hap1 
(Figure 3.4D). Indeed, despite the attenuation in total heme concentration due to Pb2+ 
toxicity (Figure 3.4C), we still observe a level of Hap1 activity that is much greater 
relative to SA-mediated heme depletion (Figure 3.4D), which attenuates both LH and 
total heme (Figure 3.4C). 
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 The observation of an increased LH pool in response to Pb2+ may have 
implications for the pathology of Pb2+ toxicity. For instance, the increase in LH in 
response to Pb2+ may contribute to a cytotoxic heme pool44, 46 that leads to the oxidative 
stress associated with Pb2+ toxicity203, 204. Alternatively, given that there are a number of 
heme regulated transcription factors, kinases, and ion channels2, 49, the increase in LH in 
response to Pb2+ may be required to activate heme-based signaling pathways important 
for adaptation to heavy metal stress. The specific physiological consequences of 
increased LH in response to Pb2+ stress remains to be fleshed out. 
 Interestingly, when optimizing and validating our methods to interrogate what 
proteins bind and release heme in response to stress, we found that a number of proteins 
preferentially stick to hemin agarose only when completely depleted of their cellular 
stores of heme by 500 µM SA treatment, but not with partial depletion with 100 µM SA 
treatment. The increased protein abundance detected between 100 and 500 µM SA 
treated cells may result from there still being approximately 30% total cellular heme and 
have LH buffered to less than 1 pM in the 100 µM SA cells, while the 500 µM SA cells 
are completely depleted of both total heme and LH (Figure 3.2). This suggests that the 8 
protein bands that increase in affinity for hemin agarose under heme starvation, hold onto 
heme when cells are moderately heme starved and only release their heme when heme 
pools are completely depleted (Figure 3.15). Therefore, the identification of these 
proteins by our methods may only be possible under extreme heme depletion by SA or 
using hem1Δ cells, and their identities should be pursued as they may represent 
previously undisclosed, tight-binding heme trafficking factors or shed light on cellular 
processes for heme that are maintained even under heme limiting conditions. 
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 To determine the specific roles and potential signaling networks employed by LH 
in response to Pb2+ stress, we sought to discover all of heme’s specific heme binding 
partners in untreated versus LD50 Pb
2+ poisoned cells by coupling SILAC with hemin 
agarose (heavy label) and sepharose bead (light label) chromatography (Figure 3.16). 
Identifying the differences in a protein’s ability to stick specifically to hemin agarose 
between any two conditions that elicit dynamic responses in heme homeostasis, like 
untreated versus either NO (Ch. 2.7)29 or Pb2+ poisoning, ideally represents a dynamic 
change in a protein’s fractional saturation with heme in response to the induced signal 
(i.e. Pb2+). Furthermore, the proteins identified to have any dynamic change in their 
fractional saturation with heme, by definition, are those that are involved in a heme 
signaling network by binding or releasing heme in response to that signal. Hence, our 
hemoprotein discover approach here was to identify any putative heme binding proteins 
that are changing in their heme fractional saturation in response to Pb2+ stress by 
identifying stark differences in protein heme binding capacity between the treated and 
untreated conditions. Ultimately, as identified in Figure 3.17B, when plotting the heme 
binding specificities of proteins in +Pb versus -Pb treated cells, we were able to identify 
differences in heme binding capacity of proteins. Indeed, we believe to have identified 
many putative hemoproteins in Group 2 that lost heme in response to Pb2+ stress, and 
therefore, stick to hemin agarose specifically only in Pb2+ treated cells (Figure 3.17B). 
And, conversely,  in the smaller Group 3 list of proteins to have identified potential 
hemoproteins that gained heme in response to Pb2+ stress as indicated by their binding to 
hemin agarose under basal conditions but not in Pb2+ treated cells (Figure 3.17B). The 
proteins identified in Groups 1 and 4 should not be ignored, but Groups 2 and 3 proteins 
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were prioritized as they had the most adverse changes in their enrichment by hemin 
agarose relative to negative control beads in response to Pb2+ stress. Most 
prioritized proteins for screening fell into Group 2, which are hypothesized to have lost 
heme in response to stress. The fact that most proteins that stuck to hemin agarose seem 
to have lost heme in response to stress fits with our model that heme binding proteins 
should only be enriched by hemin agarose if their heme binding site is vacant (Figure 
3.13). Additionally, this observation is consistent with the fact that most cellular heme is 
depleted in cells treated with this dose of Pb2+ and several canonical hemoproteins have 
their expression depleted in Pb2+ treated cells as indicated by our whole proteome 
analysis (data not shown). Pertaining to Group 3 proteins, consistent with the idea that 
these proteins gained heme in response to Pb2+, is the fact that of 9 proteins that made our 
final list (Figure 3.17B), there was an isoform of the heme trafficking factor GAPDH, an 
iron regulated protein, and a negative regulatory of coenzyme A biosynthesis, which is 
required for the formation of ALA. The result regarding negative regulation of ALA 
synthesis is notable, because heme is known to repress ALA synthesis205. 
 In support of proteins that were starkly enriched by heme agarose relative to 
negative control sepharose beads, within Groups 1 to 3 there were 16 heat shock proteins 
that stick to hemin agarose specifically in the dataset, which are of interest as there are 
several heat shock proteins that have implicated roles in heme trafficking206-212. Other 
promising proteins identified that may be bona fide heme binding proteins include 
proteins with enzymatic functions and sequence similarities to proteins identified in other 
species to be heme binding, including serine proteases213-215 and alcohol dehydrogenases, 
which were shown to bind heme within crystal structures or at least have heme or 
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protoporphyrin modulated activity216-219. Lastly, a large subset of the proteins identified 
in these groups are involved in the proteasome, which heme has been shown to regulate 
by unknown mechanisms201, 202. Finally, there were a number of enzymes with reported 
oxidoreductase activity, which at minimum contain iron to carry out their activity and 
often have heme as a cofactor. Collectively, there is ample support from previous reports 
regarding many of our identified proteins being actual heme binding proteins. Given that 
the identified proteins from Groups 2 and 3 fall into classes involved in controlling gene 
expression, stress response, and transcription, or are transferases, transfer/carrier proteins, 
chaperones, and storage proteins helps solidify the notion that there may be proteins 
involved in direct roles in heme signaling and heme transport (Figure 3.18,Figure 3.20, 
Figure 3.21). 
 Altogether our design to interrogate the heme binding proteins that exist in 
untreated vs. Pb2+ treated cells resulted in the identification of two novel putative heme 
binding proteome lists. The first list, represented a list of heme specific proteins from 
non-stress conditions (x-axis, Figure 3.17) and the second list represented the putative 
heme binding proteome of cells that are recovering from an LD50 dose of Pb(NO3)2 (y-
axis, Figure 3.17). Comparing these two heme binding proteomes resulted in the 
determination of Groups 2 and 3 in Figure 3.17, which represent the proteins that lost or 
gained heme in response to Pb2+, respectively. In total, Group 2 and 3 proteins represent 
many candidate proteins that have the potential to be part of a heme signaling network 
required for cells to adapt to stress. Given the number of identified proteins and their 
diverse set of functions, future work entails screening prioritized proteins from each list 
via the development of heme binding assays and heme dependent enzymatic assays. 
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These screens are warranted given that some of the proteins identified having changes in 
heme specificity may solely be from Pb2+-dependent, heme-independent reasons. One 
such reason would be Pb2+-induced protein misfolding or protein hyper-oxidation that 
could allow these proteins to interact more favorably with hemin agarose independently 
of heme189, 220. Even so, confirming several promising protein hits as bona fide heme 
binding proteins would validate this approach to be used to identify heme signaling 
networks activated between any number of conditions that are known to mobilize heme, 
i.e. heme starvation (Figure 3.2), exogenous nitric oxide supplementation,29 or in between 
two genetic backgrounds that have altered heme homeostasis, for example tdh3Δ vs WT 
cells29. 
 Altogether, our studies demonstrate the functional importance of LH in heme 
utilization, especially during stress associated with heme depletion and Pb2+ toxicity. Our 
future work will involve probing the specific mechanisms by which LH can be coupled to 
heme utilization, as well as the mechanisms underlying the Pb2+ mediated increase in LH 
and the physiological consequences of this action. Furthermore, future work related to the 
putative heme signaling proteins identified in our screen entails using HS1 to elucidate 
the identified putative hemoproteins’ effects on LH availability, design enzyme screens to 
screen many of the identified enzymatic proteins for heme dependent activity (Figure 
3.19), and to canvas the role for the proteasome in regulating heme availability and 
signaling. 
3.10 Materials and Methods 
3.10.1 Yeast Strains, Transformations, and Growth Conditions 
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 S. cerevisiae strains used in this study were derived from BY4741 (MATa, 
his3Δ1, leu2Δ0, met15Δ0, ura3Δ0). pug1::KANMX4, hmx1::KANMX4, 
cta1::KANMX4, and ctt1::KANMX4 strains were obtained from the yeast gene deletion 
collection (Thermo Fisher Scientific) and the hem1::HIS3 strain was described 
previously29. Yeast transformations were performed by the lithium acetate procedure134. 
Strains were maintained at 30 °C on either enriched yeast extract (1%)-peptone (2%) 
based medium supplemented with 2% glucose (YPD), or synthetic complete medium 
(SC) supplemented with 2% glucose and the appropriate amino acids to maintain 
selection29. Cells cultured on solid media plates were done so with YPD or SC media 
supplemented with 2% agar29. Selection for yeast strains containing the KanMX4 marker 
was done with YPD agar plates supplemented with G418 (200 μg/mL)29. WT cells 
treated with the heme synthesis inhibitor, succinylacetone (SA), and hem1Δ cells were 
cultured in YPD or SC media supplemented with 50 μg/mL of 5- aminolevulinic acid 
(ALA) or 15 mg/mL of ergosterol and 0.5% Tween-80 (YPDE or SCE, respectively)29, 
114. 
 For the proteomics studies, an auxotrophic yeast strain lacking lys1, 
lys1D::kanMX4 from the deletion library. This strain was provided by the Torres lab 
following verification that this was lys1D by playing on YPD vs. SD-Lys and found no 
growth on SD-Lys plates. See Appendix for growth conditions for SILAC labeling and 
the Pb2+ treatment using this strain. 
3.10.2 Labile Heme and Total Heme Depletion 
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 In order to sequester labile heme in the cytosol, we generated a WT yeast strain 
expressing an episomal plasmid (p316-GAL) containing an allele of the high affinity 
hemoprotein Cytochrome b562 (Cyt b562) driven by the galactose-inducible promoter 
(pGAL); the plasmid is referred to as pGAL-Cyt b562. A control strain expressing the 
empty vector (EV), (pGAL-EV), was also generated. For labile heme measurements, the 
strains expressing pGAL-Cyt b562 or pGAL-EV also co-expressed the previously 
described heme sensor, HS1-M7A, using an episomal plasmid (pRS415) that drives 
sensor expression with the GPD promoter29. For Hap1 activity measurements, the strains 
expressing pGAL-Cyt b562 or pGAL-EV also co-expressed the previously described 
pCYC1-EGFP Hap1 reporter, which is an episomal plasmid (pRS415) that drives EGFP 
expression using the CYC1 promoter, a transcriptional target of Hap129. In order to 
induce Cyt b562 expression, cells were cultured in SC-URA-LEU media to maintain 
selection of both Cyt b562 and the heme sensor, HS1-M7A, or pCYC1-EGFP. Instead of 
using 2% glucose, which will repress the expression of the GAL-inducible promoter, we 
cultured cells in 2% raffinose and either 0.1% galactose (inducing conditions) or vehicle 
(sterile water, non-inducing conditions). Parallel control cultures were treated with 500 
μM succinylacetone (SA) in order to deplete intracellular heme. All cultures were seeded 
at an initial optical density of OD600 nm = 0.005 and cultured until cells reached a final 
density of OD600 nm ~ 1.0, which typically took 14-16 hours. Following growth, cells were 
harvested, washed, and resuspended in phosphate-buffered saline (PBS) and sensor or 
EGFP fluorescence was measured as described in 3.10.5, “Labile heme quantification” 
and 3.10.7,  “Hap1 activity”.  
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 In order to deplete total heme, cells were cultured with the indicated 
concentrations of the heme biosynthetic inhibitor, succinylacetone (SA), in an appropriate 
SCE drop-out media. All cultures were seeded at an initial optical density of OD600 nm = 
0.005 and cultured until cells reached a final density of OD600 nm ~ 1.0, which typically 
took 14- 16 hours. Following growth, cells were harvested, washed, and processed for 
determination of labile or total heme as described in 3.10.5, “Labile heme quantification” 
and 3.10.6, “Total heme quantification.” 
3.10.3 Yeast Model of Pb2+ Toxicity 
 Due to the insolubility of Pb(NO3)2 in yeast media, we subjected exponential 
phase yeast cells to varying doses of Pb2+ in MES buffer for 3 hours, a media in which 
Pb(NO3)2 is soluble. Cells were pre-cultured in an appropriate SC drop-out media to a 
final density of OD600 nm ~ 1.0. Following washing with sterile water, cells were 
resuspended in 10 mM MES buffer containing varying concentrations of Pb(NO3)2 at a 
density of 1 OD/mL, and mixed every 15 minutes at 25 °C for 3 hours. Following 
exposure to Pb2+ in MES buffer, cells were thoroughly washed with sterile water, 
resuspended in an appropriate SC drop-out mixture to a final density of OD600 nm ~ 1.0 
and allowed to recover for 4 hours, while shaking at 220 RPM at 30 °C. Cell viability 
was measured by diluting the cells to an initial density of OD600 nm = 0.01 in an 
appropriate SC drop-out media after the recovery phase and solution turbidity was 
recorded by measuring OD600 nm after 20 hours of growth shaking at 220 RPM and 30 °C.  
 In order to assess the effects of Pb2+ toxicity in an anaerobic environment, the 
Pb2+ toxicity model described above was modified as follows: the Pb2+ exposure in MES 
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buffer was accomplished in de-gassed MES buffer with varying concentrations of Pb2+ in 
a COY anaerobic chamber maintained with an inert atmosphere of 95% N2 and 5% H2. 
Following Pb2+ exposure, cells were washed with sterile de-gassed water and allowed to 
recover in de-gassed SC media, all anaerobically in the COY anaerobic chamber. Cell 
viability was measured by diluting the anaerobic cultures into in an appropriate SC drop-
out media after the recovery phase and solution turbidity was recorded by measuring 
OD600 nm after 16 hours of growth shaking at 220 RPM and 30° C in air.  
 All analytical analyses, including for labile or total heme, was conducted 
immediately after the 3 hour Pb2+ exposure in MES buffer (pre- recovery) or after the 4 
hour recovery in SC media (post-recovery).  
3.10.4 Viability Measurements Using FUN-1 
 Cells were grown as indicated in 3.10.3, “Yeast model of Pb2+ toxicity”. After 
conditioning cells in MES buffer with or without Pb2+, 1 OD of cells were pelleted, 
washed once with 1 mL sterile Milli-Q water, and once with 500 μL of 10 mM HEPES 
(pH 7.2) with 2% Glucose (w/v) (HG Buffer). Cells were pelleted again then resuspended 
in 300 μL of HG buffer, then treated with 24.5 μL of 200 μM FUN-1 (Thermo-Fisher) to 
a final concentration of 15 μM. The 200 μM FUN-1 working stock solution was prepared 
by diluting a 10 mM DMSO FUN-1 stock solution into HG buffer. Cells were allowed to 
incubate in the dark at 30 °C for 30 minutes and then washed three times in HG buffer. 
Cells were imaged on glass slides with cover slips using the Cytation 3 imaging plate 
reader (Biotek) with GFP and TexasRed Filter Cubes. In stained cells, the observation of 
red puncta was used to score viable cells and the observation of diffuse green 
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fluorescence was used to score dead cells. On average, ~100 cells were analyzed per 
sample.  
3.10.5 Labile Heme Quantification 
 Measurements of labile heme were accomplished as previously described 
(Chapter 2.11.3.3)29. For all heme sensor fluorescence measurements, following cell 
growth, cells were washed in water and resuspended in phosphate-buffered saline (PBS) 
at a density between 3 and 5 OD600 nm /mL, or 6 x 10
7 to 1 x 108 cells/mL. Fluorescence 
was recorded on a Synergy Mx multi-modal plate reader using black Greiner Bio-one flat 
bottom fluorescence plates. EGFP and mKATE2 fluorescence was recorded using 
excitation and emission wavelength pairs of 488 nm and 510 nm and 588 nm and 620 
nm, respectively. Background fluorescence of cells not expressing the heme sensors were 
recorded and subtracted from the EGFP and mKATE2 fluorescence values. The sensor 
EGFP/mKATE2 fluorescence ratio (Rexpt) is a qualitative indicator of labile or 
bioavailable heme, with a low ratio indicating a high concentration of labile heme and a 
high ratio indicating a low concentration of labile heme.  
 For quantitative labile heme monitoring, we can convert Rexpt values to the 
fractional heme saturation of the sensor (% Heme Bound) (Equation 5) or, if the sensor 
heme dissociation constant is known (Kd), the concentration of labile heme (Equation 2). 
Both metrics require that the EGFP/mKATE2 sensor fluorescence ratio is known when 
the sensor is 100% bound (Rmax) or 0% bound (Rmin)
29. Based on a 1:1 heme-binding 
model, the fractional saturation, % Bound, of the sensor can be calculated according to 
Equation 329:  
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[%𝐵𝑜𝑢𝑛𝑑] = ([𝑅 − 𝑅𝑚𝑖𝑛]/[𝑅𝑚𝑎𝑥 − 𝑅𝑚𝑖𝑛]) ∗ 100 
 
(3) 










 The labile heme concentration can be calculated according to Equation 229, 116:  
 Rexpt is the EGFP/mKATE2 fluorescence ratio under any given experimental 
condition, Rmin is the EGFP/mKATE2 fluorescence ratio when 0% of the sensor is bound 
to heme, Rmax is the EGFP/mKATE2 fluorescence ratio when 100% of the sensor is 
bound to heme, FmKATE2min is the mKATE2 emission intensity when 0% of the sensor is 
bound to heme, and FmKATE2max is the mKATE2 emission intensity when 100% of the 
sensor is bound to heme. The FmKATE2min / F
mKATE2
max ratio is typically taken to be 1 given 
that mKATE2 fluorescence emission is not significantly perturbed upon heme binding to 
the sensor29. Determination of Rmax and F
mKATE2
max involves recording EGFP and 
mKATE2 fluorescence after digitonin permeabilization of cells and incubation with 50 
μM heme. Briefly, 3 to 5 OD600 nm/mL of cells are resuspended in PBS with 100 μg/mL 
of digitonin, 1 mM ascorbate, and 50 μM hemin chloride. After a 30 minute incubation at 
30°C, cells are harvested, washed, and resuspended in PBS buffer prior to recording of 
fluorescence. Given that the high affinity heme sensor, HS1, is quantitatively saturated 
with heme and its fluorescence properties are virtually identical to HS1-M7A, we can 
also determine Rmax and F
mKATE2
max from parallel WT cultures expressing HS1
29. 
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Determination of Rmin and F
mKATE2
min involves recording EGFP and mKATE2 
fluorescence after cells are treated with the heme biosynthesis inhibitor succinylacetone 
(SA)138 or from hem1Δ cells cultured in parallel29.  
3.10.6 Total Heme Quantification 
 For more detailed methods with technical instructions, see Appendix. 
 Measurements of total heme were accomplished using a fluorometric assay 
designed to measure the fluorescence of protoporphyrin IX upon the release of iron from 
heme as described previously221. For all total heme measurements, following cell growth, 
2 × 108 cells were harvested, washed in sterile water, and resuspended in 500 μl of 20 
mM oxalic acid and stored in a closed box at 4 °C overnight (16–18 h). Next, an equal 
volume (500 μl) of 2 M oxalic acid was added to the cell suspensions in 20 mM oxalic 
acid. The samples were split, with half the cell suspension transferred to a heat block set 
at 95 °C and heated for 30 min and the other half of the cell suspension kept at room 
temperature (∼25 °C) for 30 min. All suspensions were centrifuged for 2 min on a table-
top microcentrifuge at 21,000 × g, and the porphyrin fluorescence (excitation 400 nm, 
emission 620 nm) of 200 μl of each sample was recorded on a Synergy Mx multimodal 
plate reader using black Greiner Bio-one flat-bottom fluorescence plates. Heme 
concentrations were calculated from a standard curve prepared by diluting 500–1500 μM 
hemin chloride stock solutions in 0.1 M NaOH into MilliQ water, which was then added 
back to extra cell samples as prepared above. To calculate heme concentrations, the 
fluorescence of the unboiled sample (taken to be the background level of protoporphyrin 
IX) is subtracted from the fluorescence of the boiled sample (taken to be the free base 
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porphyrin generated upon the release of heme iron). The cellular concentration of heme is 
determined by dividing the moles of heme determined in this fluorescence assay and 
dividing by the number of cells analyzed, giving moles of heme per cell, and then 
converting to a cellular concentration by dividing by the volume of a yeast cell, taken to 
be 50 fL29. This fluorescence assay gives similar qualitative trends between samples as an 
HPLC assay for heme we employed previously29, but the absolute concentrations tend to 
be consistently 3–5-fold higher (data not shown). 
3.10.7 Hap1 Activity 
 After growth, cells expressing p415- CYC1-EGFP, or EGFP driven by the Hap1 
regulated CYC1 promoter, were washed in sterile water and resuspended in PBS to a 
concentration of 1 x 108 cells/mL and 100 uL was used to measure EGFP fluorescence 
(ex. 488 nm, em. 510 nm). Background auto-fluorescence of cells not expressing EGFP 
was recorded and subtracted from the p415-CYC1-EGFP expressing strains. In order to 
account for heme/Hap1 independent changes in EGFP expression/fluorescence, we also 
cultured cells expressing p415-GPD-EGFP, a plasmid expressing EGFP under control of 
the heme/Hap1 independent GPD promoter.  
3.10.8 Immunoblotting 
 After culturing, cells were harvested, washed in ice-cold Milli-Q water, and lysed 
in two pellet volumes of phosphate buffer supplemented with protease inhibitors as 
described previously29, 139. Lysis was achieved at 4 °C using one pellet volume of 
zirconium oxide beads and a bead beater (Bullet Blender, Next Advance) on a setting of 8 
for 3 minutes29. Lysate protein concentrations were determined by the Bradford method 
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(Bio-rad) and 14% tris-glycine gels (Invitrogen) were employed for SDS-PAGE29. α- 
GAPDH rabbit polyclonal antibodies (Genetex, GTX100118) and a goat α-rabbit 
secondary antibody conjugated to a 680 nm emitting fluorophore (Biotium) were used to 
probe for GAPDH. Yeast cytosolic catalase, Cttp1, was probed using a custom antibody 
generated by Genscript’s custom antibody service (Poly Express Premium Service, 
SC1676). An α-Ctt1p antibody was raised in rabbit against a 1-320 amino acid fragment 
of Ctt1p. The α-Ctt1p antibody was validated in yeast by comparing immunoreactivity 
between WT, ctt1∆, and cta1∆ cells, the latter being a deletion mutant of a 
peroxisomal/mitochondrial catalase, Cta1p, unrelated to Ctt1p167. All gels were imaged 
on a LiCOR Odyssey Infrared imager29, 139. 
3.10.9 Catalase Activity 
 After culturing, cells were harvested and lysed in phosphate buffer and 10 μg of 
protein lysate were subjected to native PAGE on a 10% tris-glycine gel (Invitrogen). 
After electrophoresis, an in-gel activity stain was utilized to measure catalase activity26, 
29. Briefly, a catalase staining solution containing 1 part Dopamine (20mg/mL) in pH 8 
0.2 M KPi buffer, 1 part para- phenylenediamine (3.5mg/mL) in pH 8 0.2M KPi, 1 part 
15% H2O2, and 2 parts DMSO were mixed in the order listed. The staining solution was 
added directly to the gel and allowed to stain for 2 minutes, followed by rinsing in Milli-
Q water and imaging. 
3.10.10 Plasmids 
 All yeast expression plasmids used in this study are listed in Table 2 and were 
previously described, except for pDH039, the plasmid expressing Cytochrome b562 (Cyt 
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b562) driven by a galactose (GAL)-inducible promoter, pGAL-Cyt b562. This plasmid was 
constructed by amplifying the coding sequence of Cyt b562 from the HS1 sensor
29. The 





 Following amplification and digestion with BamHI and XbaI, the Cyt b562 coding 
sequence was ligated into BamHI and XbaI digested p316-GAL1148. The amino acid 





Table 2 – List of plasmids used in Chapter 3 studies. See Appendix for more details 
regarding construction of previously reported pDH plasmids, else see 29 for details 
regarding the construction of the pJA, pRH, and pOM plasmids. 
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3.10.11 Total Reflection X-ray Fluorescence (TXRF) Spectroscopy 
 Elemental analysis of cells, and in particular metal analysis of Pb, 1st row 
transition elements, P, and S, were accomplished by total reflection x-ray fluorescence 
(TXRF) on a Bruker S2 Picofox TXRF as described previously29. Briefly, following 
growth, cells were washed sequentially in ice-cold Tris-EDTA (TE), pH 8.0 buffer and 
Milli-Q water, and then finally resuspended in Milli-Q water to a density of 2 x 109 
cells/mL. 2 μL of a cell suspension, spiked with 1 ppm of a Ga internal standard, were 
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spotted onto a quartz sample disc, and atomic fluorescence emission spectra were 
collected according to the manufacturer’s recommendations29. The cellular metal 
concentrations were determined by assuming a yeast cell volume of 50 fL and that a 





CHAPTER 4. INTERROGATING COMPARTMENT SPECIFIC 
HEME AVAILABILITY AND TRAFFICKING DYNAMICS WITH 
GENETICALLY ENCODED HEME SENSORS IN MAMMALIAN 
CELLS 
4.1 Introduction 
 Heme, an essential iron containing metallo-nutrient located in every subcellular 
compartment, has long been thought of as a static protein cofactor buried in the core of 
hemoproteins. However, genetic and biochemical evidence have indicated that heme may 
act as a dynamic signaling molecule that regulates cell metabolism and physiology2, 27, 29. 
Since heme is tightly regulated and buffered to low levels due to its toxicity, heme 
acquisition by client hemoproteins that regulate heme dependent functions and signaling 
are reliant on the ability to safely mobilize heme. This tightly buffered and controlled 
pool of bioavailable heme is often referred to as labile heme (LH), defined as a pool of 
heme chelatable, kinetically labile heme that can readily exchange between biomolecules 
and is accessible for heme-dependent processes167. The emergence and continued 
development of several LH sensing technologies is opening the means to characterize and 
understand the nature and dynamics of LH, aiding investigations for factors that control 
its availability, which are largely unknown29, 111, 167, 222-224. The use of these heme sensors 
has demonstrated that LH has a functional role in regulating heme signaling and can act 
independently of heme synthesis for regulatory purposes167. Truly, the development of 
new heme sensing technologies has aided in identifying several heme trafficking factors 
and insights into the importance of LH. 
 116 
 In this work, we find that our heme sensor associates with a pool of LH that is 
buffered to either low pM levels of ferrous heme or low nM levels of ferric heme in the 
mitochondrial, nuclear, and cytosolic fractions of HEK293 cells. These reports are in 
staggering contrast to the previously assessed levels demonstrated with activity based 
heme reporters that report ferric LH levels on the order of 100s of nM in HEK293 
cells222. We demonstrate that cytosolic, nuclear, and mitochondrial LH availability can be 
replenished to varying degrees by synthesis alone, but when cells are supplied with 
excess heme synthesis intermediate, the heme sensor becomes saturated with heme in 
each compartment. Additionally, the cytosol and nucleus equilibrate with extracellularly 
supplied heme to a higher degree than mitochondrial LH pools. Finally, given that 
previous reports ascribed cytoprotective roles to heme oxygenase 2 (HO2) independent of 
its catalytic function, we sought to probe HO2’s effects on LH availability using our 
sensors. Our investigation revealed novel LH heme sequestering and buffering roles for 
HO2 that have no effect on total heme availability and are completely independent of its 
catalytic function, but solely relies on HO2’s ability to bind heme in its catalytic heme 
binding pocket. Our work demonstrates the functionality of our sensor to quantitate 
compartment specific LH levels and its use in characterizing new heme trafficking 
factors, like the unexpected role for HO2 as a heme buffering factor. 
4.2 Cellular Heme Imaging: Cytosol. 
 To assess LH availability in HEK293 cells, we first began by testing how human 
codon optimized HS1 (hHS1) sensors responded to heme depletion and heme 
supplementation. Briefly, as mentioned in previous chapters, HS1 employs a tri-domain 
architecture consisting of a fusion of heme binding protein cytochrome b562, plus two 
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proteins that exhibit fluorescence that is quenched (eGFP) or unaffected (mKATE2) by 
heme. Thus, heme binding to HS1 results in a decrease in the eGFP to mKATE2 
fluorescence emission ratio, allowing for ratiometric [heme] measurements. In these 
studies, heme replete media refers to basal growth media or regular media with heme 
containing serum, while the heme depleted (HD) media contains heme depleted serum 
and a heme biosynthesis inhibitor, succinyl acetone (SA). 
 The high affinity hHS1 sensor, Kd
III = 3nM, Kd
II ~10 pM, is quite sensitive to 
heme availability in HEK293 (Figure 4.1A), while the weaker affinity variant, HS1-
M7A, Kd
III = ~1 µM, Kd
II 25 nM, is much less responsive to heme in HEK293 cells29 
(Figure 4.1B). Cells expressing hHS1 have large differences in heme-dependent 
fluorescence in heme-depleted (HD + SA, eGFP:mKATE2 mode ~ 9) vs regular media 
(eGFP:mKATE2 mode ~ 4), and become saturated with heme in response to prolonged 
heme treatment (10, 25, or 50µM heme) or from upregulation of heme synthesis by 
supplementation with a bolus of heme synthesis intermediate δ-aminolevulinic  acid 
(ALA) (modes ~ 1) (Figure 4.1A). The difference in modes between each treatment 
conditions exhibits the hHS1’s sensitivity of heme and its ability to sense both increases 
and decreases of LH availability. Cells expressing hHS1-M7A, on the other hand, do not 
respond as well to heme depletion by HD + SA cell growth (mode ~ 6.5) compared to 
regular media growth (mode ~ 5). Additionally, there is no difference in the HS1-M7A 
ratios in regular media cell growth with and without 10 µM heme treatment or ALA 
supplementation, which are conditions that drastically effected hHS1 heme binding 
(Figure 4.1A,B). However, these cells do seem to respond to larger doses of exogenous 
heme treatment, indicated by the regular media mode ratio lowering from ~ 5 to a ratios 
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of ~2.6 with higher doses of heme (Figure 4.1B). Even though the modes do change, the 
overall distribution of the hHS1-M7A ratio histograms between conditions that effect its 
eGFP:mKATE2 mode are much broader than with hHS1  (Figure 4.1A,B). Taken 
together, hHS1 is very heme responsive and can sense both increases in heme availability 
in HEK293 cells, while hHS1-M7A is much less useful. 
 To further assess the heme responsiveness of the more useful sensor variant, cells 
expressing hHS1 were titrated with smaller doses of exogenous heme in regular versus 
HD + SA media. Regular media cells have a characteristically lower ratio (mode ~5.5) 
than HD + SA media cells (mode ~11), and the heme deficient cells have a broad range 
of eGFP:mKATE2 ratios, indicative of heterogeneity in the ability to heme starve cells 
(Figure 4.2). Both heme-starved and regular media cells have dose-dependent responses 
to 0.2, 0.5, and 1 µM exogenous heme treatment (Figure 4.2).  HD + SA media have a 
mode of ~11, that decreases to 8.5 with 0.2 µM heme treatment, 4.5 with 0.5 µM heme, 
and sit at a mode of ~3.0 with 1 µM heme treatment. Regular media cells have a mode of 
~ 5.5, and then decrease to ~4.2 with 0.2 µM, ~2.8 with 0.5 µM, and ~2.1 with 1 µM 
heme treatment. When comparing regular media to HD +SA grown cells at any given 
heme dose, the sensor fluorescence ratio is always lower in the regular media cells. 
However, gap between the ratios in regular vs HD + SA grown cells is much smaller at 
the 1 µM exogenous heme treatment dose (Figure 4.2). Based off the binding affinities of 
hHS1, these dose dependent responses from these low µM supplements of exogenous 
heme correspond to much smaller changes in intracellular labile heme (Figure 4.2). 
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Figure 4.1 – Heme-dependent responses in heme sensor fluorescence in HEK293 cells. 
Flow cytometric analysis of HEK293 cells transiently transfected with (A) hHS1 or (B) 
hHS1-M7A sensors and cultured in heme-deficient (HD) succinylacetone (SA) treated 
media (HD + SA) or in regular media (heme replete) media exhibit differential responses 
to heme. In each panel heme replete cells were treated with 0, 10, 25, or 50 µM heme or 
with 350 µM δ-aminolevulinic acid (ALA), a heme synthesis intermediate, for 24 hours. 
In B dotted lines were drawn to depict a heme-dependent change in the HD + SA 




Figure 4.2 - Cytosolic expressed hHS1 heme sensor responds to low µM doses of 
exogenous heme. Histograms of the heme sensor of cells grown in regular media (shaded 
histograms) and heme depleted media HD + SA media (unshaded histograms) are plotted. 
Both regular and HD + SA media cells were grown in the presence of 0 (red), 0.2 
(orange), 0.5 (blue), or 1 µM (purple) hemin chloride. 
 For quantitative measuring of labile heme availability in these cells, an in situ 
calibration method was developed, where the [heme] accessible to the sensor is governed 
by Equation 4116: 
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[ℎ𝑒𝑚𝑒] = 𝐾𝑑  ×  
𝑅𝑒𝑥𝑝𝑡 − 𝑅𝑚𝑖𝑛
𝑅𝑚𝑎𝑥 − 𝑅𝑒𝑥𝑝𝑡
  (4) 
In Equation 4, Kd is the heme-sensor dissociation constant, Rexpt is the eGFP/mKATE2 
fluorescence ratio under any given condition, Rmin is the eGFP/mKATE2 fluorescence 
ratio when 0% of the sensor is bound to heme, assumed to be the histogram 
eGFP:mkATE ratio mode of HD + SA media grown cells, and Rmax is the histogram 
mode eGFP/mKATE2 fluorescence ratio when 100% of the sensor is bound to heme. To 
acquire Rmax, digitonin permeabilized cells were treated with excess heme in the presence 
of ascorbate. Given the broad ratio distributions in the histograms from flow cytometric 
analysis, the ratio for each condition is derived from the mode of each histogram.  See 
Appendix for more details regarding in situ calibration. Sensor fractional saturation can 
be calculated using Equation 5. 
 
𝑆𝑒𝑛𝑠𝑜𝑟 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑏𝑜𝑢𝑛𝑑 =  
𝑅𝑒𝑥𝑝𝑡 − 𝑅𝑚𝑖𝑛
𝑅𝑚𝑎𝑥 − 𝑅𝑚𝑖𝑛
  (5) 
 
 The developed calibration method was applied to the hHS1 sensor, the weaker-
affinity hHS1-M7A sensor, and a heme-insensitive mutant, hHS1-M7A, H102A (Figure 
4.3). Only the hHS1 sensor has heme-dependent changes between HD + SA and regular 
media and is the only sensor that responds to the in situ saturation protocol (Figure 4.3). 
The results demonstrate the efficacy of this procedure for calibrating the hHS1 sensor, 
and indicate that both hHS1-M7A and hHS1-M7A, H102A are unbound to heme and do 
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not respond well to heme in these cells (Figure 4.3). Further, when comparing the mode 
of each relevant histogram to acquire Rexpt (~2), Rmin (~5), and Rmax (~1) values for use in 
Equation 4, the mode hHS1 ratio represents 75% bound heme sensor (Figure 4.3), 
indicating that LH is buffered to as low as 7.5 pM ferrous heme or 2.2 nM ferric heme. 
Using Equation 4, and reported volumes for the HEK293 cytoplasm of 0.8 pL225, we 
calculate that there are a < 4 molecules assuming all LH is reduced or a maximum of 
~1350 ferric cytoplasmic LH molecules assuming all LH is oxidized225. Moving forward, 
given that the weaker affinity sensors do not respond well to heme and hHS1 is easily 
calibrated, all further studies focused on the use of hHS1. 
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Figure 4.3 – In situ calibration of hHS1 heme sensor. (A) Tight binding hHS1 sensor, but 
not weaker affinity sensor (B) hHS1-M7A or heme insensitive mutant (C) hHS1-M7A, 
H102A, is heme responsive and can be saturated with heme when digitonin 
permeabilized and treated with excess hemin and ascorbate. Cells from 6-well plates 
were harvested in media by pipetting, treated with calibration reagents for 30 minutes at 
30 °C, pelleted, washed in PBS, then prepped for flow cytometric analysis. Heme 
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depleted HD+SA represent cells that center a ratio representing 0% bound sensor (red 
histograms). The in situ saturation treatment, treating cells treated with digitonin, 
ascorbate, and 100 µM hemin (black histograms), represents 100% bound sensor in these 
cells. 
 Having determined the efficacy of using hHS1 in these cells, we sought to 
monitor the kinetics of LH replenishment after heme starving cells. Additionally, 
comparing LH versus total heme replenishment may yield information regarding how 
much total heme must build up before LH pools may be replenished. Understanding these 
factors may designate the rate at which new heme dependent processes may be activated 
from endogenously synthesized heme. Hence to test the dynamics of heme replenishment 
and cytosolic heme acquisition, total and LH heme were monitored over 24 hours in cells 
grown in HD or regular media after depleting their cellular heme by HD + SA growth 
(Figure 4.4). Surprisingly, total heme pools are replenished within the first 2 hours of 
recovery in each media (Figure 4.4B), but LH stores replenish much more slowly (Figure 
4.4A). Additionally, there is more heme loading in cells replenished with HD media 
compared to regular media, but there was no difference in total heme between the media 
conditions (Figure 4.4A,B). Cells replenished in HD media have a mode eGFP:mKATE2 
ratio of ~5.2 at time 0, ~4.7 at 2 hours, ~4.2 at 6 hours, ~4.0 at 8 hours, and ~3.2 at 24 
hours. Similarly, cells replenished in regular media, have a mode eGFP:mKATE2 ratio of 
~5.2 at time 0, ~5 at 2 hours, ~4.5 at 4 hours, ~4.0 at 6 hours, ~3.8 at 8 hours, and ~3.8 at 
24 hours (Figure 4.4). The differences between cytosolic LH and total heme (measured 
by the porphyrin fluorescence assay) replenishing kinetics between HD and regular 
media seem to be negligible. 
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Figure 4.4 – Heme repletion kinetics of cytosolic LH and intracellular total heme. (A) 
Heme repletion kinetics of cells starved of heme for 48 hours in HD+SA media, switched 
to either heme deficient media (histograms on the left) to allow cells to synthesis 
endogenous heme, or regular media (histograms on the right) to allow cells to both 
synthesis and uptake any exogenous heme from the serum. The dotted red line in each 
histogram represents the mode of heme starved HD+SA, 0 hr replenished cells, while the 
dotted black line represents the mode ratio post 24 hours of heme replenishment. (B) 
Total heme repletion kinetics of biological duplicates utilized for labile heme 
measurements. 
4.3 Cellular Heme Imaging: Cytosol, Nucleus, and Mitochondria 
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 Heme monitoring with hHS1 and hHS1-M7A was extended to mitochondria and 
the nucleus, and the subcellular targeting of each sensor was validated by microscopy 
(Figure 4.5). To confirm heme-dependent changes in mitochondrial and nuclear localized 
sensors, the in situ calibration protocol developed for the cytosolically expressed sensor 
was applied to cells expressing cytosolic, mitochondrial, and nuclear localized hHS1 
(Figure 4.6A-C). hHS1 is well poised to sense labile heme in each of these compartments 
as basal conditions exhibit ratios in between heme starved and the heme treated cells 
(Figure 4.6A-C); however, the in situ saturation protocol did not seem to saturate 
mitochondrially localized hHS1 (Figure 4.6A-C). Given this small decrease in the 
mitochondrial hHS1 eGFP:mKATE2 ratio and since digitonin treatment only 
permeabilizes the outer membrane of the cell, it was assumed the mitochondrial sensor 
was not saturated with heme. 
 
Figure 4.5 -  Localization of targeted hHS1. HEK293 cells were transfected with WT and 
M7A sensor constructs made for targeting to the cytosol, nucleus, and mitochondria. 
Cells imaged 42 hours post-transfection using a Leica DM IRE2 fluorescence microscope 
under 63x oil immersion objective. Scale bar = 10 µm. Images were taken and provided 
by Xiaojing Yuan. 
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Figure 4.6 – In situ saturation protocol optimized for cytosolic hHS1 applied to cells 
expressing sensor in (A) cytosol,  (B) nucleus, and in the (C) mitochrondria. Regular 
media cells (blue) are compared to heme starved HD + SA cells (red) and cells treated 
with digitonin, ascorbate, heme to saturate the sensors (black). 
 Since the cell permeabilizing saturation protocol does not work for mitochondrial 
hHS1 sensor (Figure 4.6C), a new protocol was adapted and compared to the previous 
method to in situ saturate hHS1. Simply, cells were treated with a large overnight dose of 
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heme biosynthetic intermediate ALA, which drastically increases the endogenous 
synthesis of heme inside HEK293 cells. This method of upregulating heme synthesis 
supplied each compartment with enough heme to saturate the sensor to equal degrees as 
the in situ saturation protocol in the cytosol and nucleus (Figure 4.7A,B), or more 
efficiently in the case of mitochondrial hHS1 (Figure 4.7C). The saturation of the heme 
sensor in each compartment reveals that regular media treated cells are ~78% bound in 
the cytosol (Rexpt (~1.7), Rmin (~2.8), and Rmax (~0.4)), ~53% bound in the nucleus (Rexpt 
(~1.4), Rmin (~2.6), and Rmax (~0.25)), and ~71% bound in mitochondria (Rexpt (~0.7), Rmin 
(~1.8), and Rmax (~0.25)). Using Equation 4 and reported HEK293 cytoplasmic volume of 
0.80 pL225, nuclear volume of 1.00 pL225, and that mitochondrial volumes are 
approximately 10% of the total cellular volume, 0.2 pL226, we can calculate the 
concentration of LH in each compartment. If each compartment’s heme is assumed to be 
completely reduced, cytosolic LH would be ~7.8 pM or <4 molecules of free heme, the 
nuclear LH would be ~5.3 pM or ~3 molecules of heme, and the mitochondrial LH would 
be ~7.1 pM or ~1 molecule of heme. If all LH is assumed to be completely ferric, which 
would only be the case if LH’s redox status was determined independently of the 
glutathione redox system, we calculate that cytosolic LH would be ~2.3 nM or ~ 1100 
molecules of heme, nuclear LH would be ~1.6 nM or < 960 molecules of heme, and the 
mitochondrial LH would be ~2.1 nM or ~ 250 molecules of heme. The contribution of 
ferrous and ferric heme in each compartment is not discernable with the hHS1 heme 
sensor without knowing what dictates heme’s oxidation state within the cell. If heme is 





Figure 4.7 – In situ saturation of (A) cytosolic, (B) nuclear, and (C) mitochondrial hHS1 
by prolonged exposure to δ-aminolevulinic  acid (ALA). Permeabilizing cells with 
digitonin in the presence of heme and reducing agent ascorbate (black histograms) is 
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compared to a 20 hour supplementation of growth media with 300 µM (δ-
aminolevulinic  acid) ALA, which saturates hHS1 in each compartment (blue 
histograms). 
 Armed with the tools and methods to quantitate LH in these compartments, we 
sought to characterize the contributions from extracellular by derived heme vs 
biosynthesized heme on LH availability in each compartment. We started by 
investigating if endogenous heme synthesis is sufficient for cells to produce LH by 
interrogating the amount of LH in cells grown in HD versus regular media. The results 
demonstrate that heme synthesis in HD media cells is indeed sufficient to fill LH to some 
degree in each compartment, but there was additional LH availability in the cytosol and 
nucleus when grown in regular media (Figure 4.8). We next sought to address if cells that 
could not utilize heme synthesis to fill their LH pools, could fill their LH with 
extracellular heme sourced from the serum in regular media cells. To test this, we 
interrogated compartment specific LH availability in cells grown in regular media + SA 
media and compared the fraction bound of hHS1 to cells grown in other relevant growth 
conditions (Figure 4.8). The results show that cytosolic LH is completely depleted by 
inhibition of synthesis alone as the mode ratio between regular media + SA is nearly 
identical to that in HD + SA treated cells (Figure 4.8A). Mitochondrial and nuclear LH 
pools, on the other hand, are not completely depleted in regular media + SA,  and contain 
hHS1 that is ~20% bound with heme, indicating that inhibiting synthesis does not deplete 




Figure 4.8 – Measuring differences in (A) cytosolic, (B) mitochondrial, and (C) nuclear 
labile heme sensed by hHS1 in response to heme starvation. Data is displayed in two 
different ways, with overlaid histograms in the left column, and half offset histograms in 
the right column. 
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 To further parse out the details underlying compartment specific LH management 
from exogenous versus endogenous heme sources, changes in total and LH availabilities 
were analyzed for their response to treatment with different sources of exogenous and 
endogenous heme. Specifically, cells grown in regular or HD media treated with ALA, 
SA, and/or hemin were compared for their relative changes in fractional saturation of 
hHS1 from these treatments in each compartment (Figure 4.9B) and compared to total 
cellular heme (Figure 4.9A). The results reveal that total heme and the amount of LH 
accessible to each compartment generally correlate with one another, but there are 
differences in labile heme availability in each compartment that is specific to source of 
heme made accessible to the cells (Figure 4.9A,B). As shown previously in Figure 4.8, 
cytosolically expressed hHS1 in regular media + SA (~4 % bound) detects less heme than 
mitochondrial or nuclear hHS1 in regular media + SA treated cells (both ~20 % bound) 
(Figure 4.8, Figure 4.9B). Under conditions that increase heme availability via treatment 
with large amounts of exogenous heme or ALA, each compartment increases in LH 
availability, but mitochondrial hHS1 is less sensitive to exogenous heme treatment than 
the cytosolic and nuclear heme sensors. See Figure 4.9B; mitochondrial hHS1 is closer to 
80 % bound, while nuclear and cytosolic hHS1 are closer to 90 % bound from excess 
exogenous heme treatment. Moreover, mitochondrial hHS1 is more saturated with heme 
under conditions that facilitate heme synthesis and is not impacted by heme from serum 
in the media. To this point: in HD media hHS1 is ~25% bound in the cytosol and ~40% 
bound for nucleus, while the mitochondrial hHS1 is ~65 % bound. Additionally, the 
cytosolic and nuclear hHS1 sensors acquire more heme when grown in regular media vs 
HD media than mitochondria do. When comparing the fraction bound of sensor in HD 
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versus regular media, there is an 11 % change in cytosolic hHS1, a 15% change in 
nuclear hHS1, and only a < 5% change in mitochondrial hHS1 heme loading (Figure 
4.9B). In total, mitochondria are much more responsive to endogenously supplied heme 
while the cytosol and nucleus have the potential to acquire more extracellular heme than 
mitochondria while synthesis is not inhibited by SA (Figure 4.9). 
 
 
Figure 4.9 – Heme dependent changes in total cellular heme and LH sensed by cytosolic, 
mitochondrial, and nuclear hHS1. (A) Total heme values for each media condition were 
taken in triplicates. Regular media grown cells were supplemented with or without 500 
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µM SA, 5 µM hemin, 100 µM or 300 µM ALA, and HD media grown cells were grown 
with or without 500 µM SA ± 5 µM hemin. (B) The corresponding cells for the total 
heme measurements were used to take analyze the fraction of hHS1 bound with heme in 
the cytosol (orange), mitochondria (blue), and nucleus (purple), which are indicative of 
the LH availability sensed by hHS1 targeted to these locals. These % hHS1 fraction 
bound was calculated using eGFP:mKATE2 histograms generated by flow cytometric 
analysis of sensor expressing cells. 
4.4 Heme Oxygenase 2 (HO-2) Sequesters Cellular Labile Heme Independent of 
Catalytic Activity and without Impacting Total Heme Availability 
 Previous studies found that heme oxygenase 2 (HO2) imparts cytoprotective 
effects to cells under oxidative stress even if catalytically inactive227. This suggested that 
part of the protection afforded by HO2 was independent of heme degradation. Given that 
soluble HO2 has heme binding sites with nM affinities for ferric heme, we tested if HO2 
and its catalytically inactive mutants were able to perturb and/or sequester LH113. We first 
tested the effects of HO2 levels on hHS1 and its heme insensitive variants in regular 
versus HD + SA media (Figure 4.10). The results clearly show that WT HO2 
overexpression depletes LH accessible to hHS1 (Figure 4.10A), and the effects are 
visibly heme-dependent as there are no HO2 dependent changes in sensor fluorescence 
ratio in HD + SA media or in the ratios of heme irresponsive mutants, hHS1-M7A and 
hHS1-M7A,H102A (Figure 4.10B,C). 
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Figure 4.10 - Overexpression of HO2 lowers labile heme availability. Overlaid 
histograms and half offset histograms of (A) hHS1, (B) hHS1-M7A, and (C) hHS1-M7A, 
H102A sensor expressing cells with and without HO2 overexpression in regular media 
versus HD + SA medias. (A) Overexpression of HO2 in regular media lowers labile heme 
to the same degree as heme depleted media (HD + SA). There is no effect in seen by HO-
2 in HD + SA media, indicating that the change in ratio in regular media is heme 
dependent. (B-C) There is no change in sensor fluorescence ratio in the heme insensitive 
sensors, indicating that HO-2 changes in sensor fluorescence ratio seen with hHS1 (A) 
are not heme independent changes to the sensor. 
 Having discovered that WT HO2 lowers LH availability, we tested the roles the 
catalytically inactive mutant, H45A, and HO2’s heme regulatory motif (HRM) mutants, 
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C265A and C282A, for their role in LH depletion. None of these mutants effected the 
lowering of labile heme (Figure 4.11A) and there were no heme-independent 
perturbations in sensor fluorescence when any of these mutants were expressed in HD + 
SA media (Figure 4.11B). Given these results, we tested if the lowering of LH by HO2 
required heme binding at the catalytical site by testing mutants that include the H45W 
and G159W point mutations, which completely block HO2’s ability to bind heme at its 
catalytic core. In addition to the heme binding mutant, we examined a more expansive list 
of catalytic and HRM mutants to probe any potential catalytic or HRM dependence of 
this LH phenotype. In regular media, the heme binding mutants containing the H45W, 
G159W mutations do not affect labile heme at all. Additionally, every other tested mutant 
lowers LH to the same degree as WT HO2 in regular media (Figure 4.12B). All mutants 
were expressed well in regular media (Figure 4.12F), and these changes were heme 
dependent as there was no change in the eGFP:mKATE2 ratio of cells due to HO2 
overexpression in HD+SA grown cells (Figure 4.12A). To definitely rule out the roles of 
the HRM and catalytic mutants in sequestering LH, we tested their effects on LH under 
high heme conditions with either 5 µM exogenous heme or 300 µM ALA 
supplementation (Figure 4.12C,D). Each mutant was able to reduce LH under these high 
heme conditions but not quite as much as in regular media (Figure 4.12B-D). 
Additionally, under excess heme availability the catalytically incompetent mutants with 
H45A mutations seem to have a very modest defect in its ability to lower LH relative to 
the other mutants, but this result was only reproducible in 2 of 4 trials (Figure 4.12C,D, 





Figure 4.11 – Overexpression of HO2 lowers labile heme availability regardless of 
catalytic function or either of its HRMs. (A) Overexpression of WT HO2 compared to 
H45A catalytic mutant, and two HRM mutants, C265A and C282A are identical in 
regular media. Cells expressing hHS1 in regular media, regular media + 300 µM ALA 
(saturated), and heme depleted HD + SA were analyzed as controls. See legend on the 
left for the identity of each histogram.  (B) Overexpression of WT HO2, catalytic mutant, 
45A, and the two HRM mutants C265A and C282A do not affect sensor fluorescence 
when compared in HD + SA media. See legend on the right for the identity of each 
histogram. 
 Given that exogenous heme treatment resulted in the same depletion of LH 
regardless of most HO2 mutations, we next sought to test if the inducible heme 
oxygenase 1 isoform (HO-1) was compensating for any loss of function within these 
mutants, masking any contribution they play in effecting LH availability (Figure 4.12E). 
Indeed, exogenous heme treatment induces expression of HO-1, but the results indicate 
that HO-1 is not expressed higher in any of the mutants than in hHS1 only or WT HO2 
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expressing cells (Figure 4.12E). In fact, there appears to be lower HO-1 expression in 
cells expressing HO2 mutants (Figure 4.12E). 
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Figure 4.12 – Overexpression of a panel of HO2 mutants for their ability to effect LH 
availability in (A) HD + SA, (B) regular, (C) HD + SA + 5 µM heme, and (D) Regular + 
300  µM ALA media, with corresponding western blots for HO2 and HO-1 in HD + SA ± 
heme with a GAPDH loading control (E) and a western blot confirming HO2 
overexpression in regular media (F). 
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 To further solidify that HO2 is truly acting on LH by sequestering it, we checked 
that HO2 was not lowering LH via decreasing total heme stores. The results confirm that 
WT HO2, catalytical deficient H45A, and heme binding HO2 mutant have no impact on 
total heme availability when overexpressed (Figure 4.13). 
. 
 
Figure 4.13 – Total heme availability in response to HO2 overexpression in HEK293 
cells. Total heme per cell was measured using the porphyrin fluorescence assay to 
quantify total cellular heme (n = 6)167.  
 Lastly, we sought to test if the sequestering of LH by HO2 was unique to the 
cytosol or if it also affected mitochondrial and nuclear stores of LH. Additionally, we 
wished to interrogate if any HO2 sequestration of LH depended on origin of the heme, 
either from heme biosynthesis or from an extracellular source. To these ends, we 
interrogated HO2 specific changes in LH in each compartment under regular media 
conditions containing excess endogenous or exogenously supplied heme and under HD + 
SA media growth with and without excess exogenous heme (Figure 4.14A-C). The 
results indicate that the overexpression of HO2 affects the nuclear and cytosolic LH heme 
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pools equally (Figure 4.14A,C); however, the mitochondrial pool of heme is mostly 
unaffected (Figure 4.14B). Mitochondrial LH under regular media conditions with and 
without ALA supplementation are completely unaltered by HO2, but heme starved HD + 
SA cells overexpressing HO2 fed exogenous hemin are completely depleted relative the 
non-overexpressing HO2 cells in this condition (Figure 4.14B, black histograms). 
 
Figure 4.14 – Subcellular LH monitoring in cells with and without the overexpression of 
HO2. (A) Cytosolic, (B) mitochondrial, and (C) nuclear hHS1 expressing cells were 
grown in the regular vs HD + SA media with ALA or heme supplementation to determine 
the effects of HO2 in sequestering exogenous vs endogenously produced heme in each 
compartment. 
4.5 Discussion 
 Until recently, there was no precise way to quantify or interrogate the nature of 
LH. The development of novel heme sensors like HS1 have provided concentrations of 
LH that may be dependent on the probes’ ability to access particular heme pools. 
Additionally, the amount of LH available between cell types is quite variable2, 28, 111, 222, 
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224, 228-230. Therefore, in order to understand the factors that control LH, it is instrumental 
to develop several different heme sensing technologies that can together more 
comprehensively assess the nature of LH of which so little is known. Indeed, the factors 
that affect LH dynamics, oxidation state, speciation, heme availability, and the 
differences in these factors amongst different organisms warrants investigation. The 
knowledge of these factors is imperative to understanding the basis for how new heme 
dependent processes and signaling are activated as well as understanding how cells must 
properly manage LH to avoid the deleterious effects of misregulated heme. To these 
points, in this study, we characterized the use of genetically encoded hHS1 in HEK293 
cells to interrogate how they manage LH and to reveal a novel role for the constitutive 
heme degradation enzyme HO2 in sequestering LH independent of its catalytic function. 
 Our first results indicate that HEK293 cells tightly regulate their heme pools and 
will not hyperaccumulate LH as sensed by hHS1 and hHS1-M7A (Figure 4.1). Given the 
binding affinities of our sensors, we cannot distinguish between ferrous or ferric heme 
pools in these cells: hHS1 has a dynamic range for ferrous heme spanning between ~1 
and ~100 pM and a dynamic range for ferric heme spanning between ~0.3 and 30 nM, 
while hHS1-M7A sensor has a dynamic range for ferrous heme spanning between ~2.5 
and ~250 nM and a dynamic range for ferric heme spanning 0.1 to 100 nM at pH 728. 
Given the binding affinity of hHS1, the data in Figure 4.1 entails that the hHS1 heme 
dependent fluorescence changes in cells treated excess 10-50 µM exogenous heme for 24 
hours results in pM ferrous or very low nM ferric changes in the buffered concentration 
of LH. On the other hand, hHS1-M7A cells are unaffected by 10 µM exogenous heme 
treatment, but this sensor does respond to 25 and 50 µM exogenous heme treatment. The 
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responses from hHS1-M7A at these high doses suggests that there is either more than 2.5 
nM ferrous heme or more than 100 nM ferric heme at these pathophysiological doses of 
heme treatment, either of which would saturate hHS1. However, the fact that 10 µM 
exogenous heme saturates hHS1 but leaves hHS1-M7A at 0% bound, may suggest that 
some amount of the LH pool exists in a ferric state. The details regarding the oxidation 
state of heme remain unclear. Even so, one might predict that LH is largely ferrous if it 
were to equilibrate with the cellular redox buffer, glutathione, which poises the Em
Cytosol ~ 
-320 mV vs. NHE118. If free heme, which has redox potentials that can span Em = -50 mV 
to -220mV vs NHE, reacts with the glutathione redox buffer (Em = -250 mV vs NHE), 
ferric heme should only constitute 0.003 % (using -50 mV vs NHE) to 2.05 % (using -
220 mV vs NHE) of LH at equilibrium. Even so, the speciation and redox potentials of 
buffered LH as well as the degree to which LH assessible to hHS1 equilibrates with the 
glutathione redox buffer are unknown.  
 Even so, a considerable fraction of buffered LH may be ferric as previous 
reporters with activity-based heme reporters report ferric heme on the order of 100s of 
nM in HEK293 cells. Perhaps these previous values with subcellular localized reporters 
may be largely ferric due heme oxidation that may result from cell lysis implored with 
this heme detection method. Even so, the regulatory heme pool is typically thought to 
comprise of 10% of the total heme quota, which equates to 1-2 µM heme in these cells 
(Figure 4.4). If cells truly buffer LH to pM levels, which equates to almost no free heme, 
what can buffer heme to these low levels and be used to regulate heme dependent 
processes? To better address the specific concentrations and oxidation states of LH and 
its buffer depth more sensors with different dynamic ranges for ferric and ferrous 
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affinities need to be utilized, and the degree to which heme equilibrates with the 
glutathione redox buffer warrants investigation. 
 Interestingly, the conditions under which hHS1-M7A detects LH were also found 
to induce the increased formation of heme granules in HEK293 cells as detected by the 
label-free transient absorption microscopy technique by Chen et al224. Perhaps, hHS1-
M7A interacts with heme that may accumulate in these enlarged extra-mitochondrial 
heme granules that abundantly increase under heme stress conditions224. This explanation 
is consistent with the fact that hHS1-M7A cells do not respond to a dose of ALA that 
saturates hHS1 but do respond to excess exogenous heme treatment (Figure 4.1). The 
nature of these heme granules and their involvement in controlling LH availability merits 
further investigation. 
 All considered, the data in Figure 4.1 clearly demonstrated that hHS1 was much 
better suited for sensing due to its heme responsiveness, so all further studies were 
addressed using this sensor. To further assess the sensitivity of hHS1, we subjected 
heme-starved HD + SA vs regular media cells to low µM doses of exogenous heme. 
These results indicate that prolonged treatment with 0.2 µM heme are sufficient to 
considerably alter LH availability in both heme starved and regular media grown cells  
(Figure 4.2). Additionally, excess of 1 µM exogenous heme treatment is required to make 
up for the gap between LH availability between HD + SA and regular media cells. This 
observation between heme starved and regular media cells fed exogenous heme primed 
us to later investigate what component of LH exists in regular media cells from the 
import of extracellular heme versus endogenously synthesized heme.  
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 Having optimized the use of cytosolic hHS1, we next investigated the repletion 
kinetics of cytosolic LH versus total heme. Surprisingly, total heme pools were refilled 
within two hours, while cytosolic LH was replenished slowly over 24 hours post heme 
starvation (Figure 4.4). Other studies in yeast looking at LH versus total heme repletion 
kinetics have indicated that LH is restored concurrently with TH, but this is not the case 
here in HEK293 cells231. The nature of how this total heme and hemoproteins are 
replenished in HEK293 cells while bypassing the side-by-side refilling of cytosolic LH 
seen in yeast is of interest. When cells are replenishing LH through synthesis, is there not 
a pool of LH that is responsible for refilling hemoproteins, or is this heme pool buffered 
to undetectable levels until other heme proteins are filled? These results might indicate 
that heme transport to client hemoproteins from the site of synthesis in the mitochondria 
may rely on some uncharacterized method that may utilize direct protein-protein heme 
transfer mechanisms circumventing the use of a regulatory LH pool until these proteins 
acquire heme. The evidence for a heme metabolon with structural components that may 
facilitate its coordination with different organelles that may integrate scaffolds with 
signaling proteins71, in addition to mitochondrial dynamics affecting heme delivery rates 
to subcellular locals231, and our data in HEK293 cells, are all consistent with the potential 
for a novel mechanism of heme delivery that can bypass the LH pool. Complimentary to 
this theory is the potential for the newly synthesized heme to first be portioned to the ER 
by translocation through mitochondrial associated membranes (MAMs). Indeed, several 
factors key in the regulation of heme homeostasis, including coproporphyrinogen III 
oxidase, ferrochelatase, HBP-1, and HO2, have been found to associate with MAMs232. 
Even so, these results still warrant the question, what is the role of cytosolic LH in 
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HEK293 cells? And, is there a pool of LH being used under these heme repletion 
conditions but is either inaccessible or below the detection limit of hHS1? 
 Regarding the importance of developing several different heme sensors, previous 
reports of labile heme in cancer cell lines report subcellular labile heme levels of between 
20-40 nM in cytosolic, nuclear, mitochondrial, and ER subcellular compartments, 
indicating roughly equal distribution of LH throughout these cells. Contrary to this, our 
previous results in Saccharomyces cerevisiae indicate that these cells have much lower 
LH availability in their nuclear and mitochondrial fractions (<2.5 nM), but between 20-40 
nM labile heme in the cytosol. The differences in these LH measurements could reflect 
organism to organism differences but may also arise from the potential of each heme 
sensor to have differential capacities to equilibrate with proteins that buffer LH. Towards 
this point, in the current work in HEK293 cells we report pM ferrous or nM ferric 
cytosolic, nuclear, and mitochondrial LH under basal conditions (Figure 4.7), while 
previous work with activity-based reporters indicate that LH in HEK293 is buffered to 
100s of nM ferric heme. Taken together, there may be several different factors that buffer 
LH inside these cells, which may serve as regulatory reservoirs for different heme 
dependent processes. Ultimately these results highlight the importance of the continued 
development of heme sensors with a variety of binding affinities and heme binding 
scaffolds to better understand the nature of LH. 
 Utilizing our calibration methods to assess hHS1 fractional saturation in cells, we 
were able to give estimates for the maximum amount of ferrous and ferric heme in each 
compartment, assuming only one oxidation state of heme existed in each compartment 
(Figure 4.7). When reporting molecules of heme per each compartment, the number of 
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molecules changed of less than 5 molecules of ferrous heme in each compartment to 
~250 -1,100 molecules of ferric heme depending on the particular organelle and the 
oxidation state of heme being sensed, demonstrating the importance of developing more 
oxidation state specific sensors for heme. 
 Interestingly, our results interrogating the compartment specific response to 
endogenous versus exogenous heme sources indicate that nuclear and mitochondrial LH 
is affected differently than cytosolic LH under heme starvation (Figure 4.8). Indeed, 
heme starvation by inhibiting synthesis in heme replete media almost completely depletes 
cytosolic LH (<5 % hHS1 loading) while mitochondrial and nuclear hHS1 sensors are 
around 20% bound with heme (Figure 4.9). These results indicate that cells undergoing 
heme starvation by inhibition of synthesis either hold on to LH in these compartments, or 
the cell recognizes a need for heme, and uptake it from the extracellular media (Figure 
4.9). This same study clearly indicates that mitochondrial LH pools are more sensitive to 
endogenous heme supply than the cytosolic and nuclear compartments. As seen in Figure 
4.9B, mitochondrial LH is almost completely replenished by synthesis alone, where there 
is very marginal impact on mitochondrial LH in cells being grown in HD versus regular 
media. Cytosolic and nuclear heme on the other hand, seem to equilibrate more with 
extracellular heme than the mitochondrial LH pool does, indicated by the increase in their 
LH availability in response to growth in HD versus regular media. Further, under high 
heme conditions, the fraction of hHS1 bound to heme in mitochondria indicate that the 
mitochondria equilibrate with extracellular heme less than cytosol and nucleus in 
HEK293 cells. Given that total heme is roughly the same between the compared 
conditions (i.e. regular media vs HD vs regular + SA media, and regular media + heme vs 
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+ ALA), the changes in fraction bound in each compartment are from compartment 
specific preferences for heme source more so than from changes in total heme availability 
(Figure 4.9A,B). 
 Our observations that HO2 lowers LH independent of its catalytic function, but 
solely by its potential to bind heme in its catalytic core were quite surprising (Figure 
4.11). Further evincing this heme sequestering role of HO2 is the fact that HO2 does not 
impact total heme stores when overexpressed (Figure 4.13) and acts independently of 
HO-1 induction (Figure 4.12E). Given that mitochondrial LH is unaffected by HO2 in 
regular media ± ALA, mitochondria seem to maintain a LH pool that is not impacted by 
overexpressed HO2, unlike the cytosolic and nuclear LH pools (Figure 4.14A-C). 
Additionally, as mitochondria are only affected when cells have been heme starved and 
then fed exogenous heme, overexpressed HO2 likely prevents the translocation of 
exogenous heme to the mitochondria (Figure 4.14B). HO2 is canonically thought of as a 
heme degrading enzyme, and not necessarily a heme buffering or trafficking factor as 
these results mandate. How HO2 functions and its physiological roles for binding LH 
without degrading it are still unknown, but this newly identified heme buffering role may 
explain why the catalytic mutant of HO2 benefits cryoprotection to cells confronted with 
oxidative stress in previous reports227. Although we were not able to ascribe a role to the 
HRMs, which have been thought to tune the affinity of HO2 for heme depending on their 
redox state113, 233, we hypothesize that these HRMs modulate the activity of HO2 to 
switch from heme buffering to heme catabolic roles. The identification of conditions that 
may satisfy this switch may explain more of the HO2’s other implicated roles in 
cryoprotection in inflammatory and neurogenerative disorders. Indeed, as HO2 seems 
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have some preference for exogenously supplied heme (Figure 4.14B) it may act to 
sequester this heme under conditions like hemolytic stress to prevent the deleterious 
effects of excess free or mishandled heme. 
 Altogether we have demonstrated the utility of hHS1 in heme sensing in 
mammalian cells and have employed this sensor in HEK293 cells to both interrogate 
compartment specific preferences for heme and to identify a new LH sequestering role 
for HO2. The continued development of sensors with differently tuned affinities for heme 
are required to establish the specific quantities of LH in these cells, but for now, hHS1 is 
a sensitive tool that can be utilized in detecting compartment specific fluxes in LH 
availability and should be used to interrogate the nature of LH in other more relevant 
mammalian cell lines. 
4.6 Materials and Methods 
4.6.1 Human Embryonic Kidney (HEK293) cells, Media, and Growth Conditions 
HEK293 cells were plated and transfected in 60 mm X 15 mm polystyrenecoated 
sterile dishes (Corning) for flow cytometry. The cells were plated on day 0 in basal 
growth medium (Dulbecco’s modified eagle medium (DMEM) containing 10% fetal 
bovine serum. On day 1 or 2, cells were transfected with heme sensor plasmids 
pcDNA3.1-HS1, pcDNA3.1-HS1-M7A, pcDNA3.1-HS1-M7A, H102A or pEF52α-hHS1 
or hHS1-M7A expression constructs for cytosolic, nuclear, or mitochondrial targeting of 
heme sensor. For HO2 overexpression studies, HO2 expressed by the CMV promoter of 
pcDNA3.1 were cotransfected into cells with hHS1 using Lipofectamine LTX. If cells 
were transfected for longer than 60 hours, media was changed 24 hours before 
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harvesting. See Appendix for details concerning each plasmid and each of the several 
transfection protocols utilized in this study. 
4.6.2 Characterization of Heme Sensors in Human Embryonic Kidney (HEK293) cells 
Flow cytometric measurements were performed using a BD FACS Aria Ill Cell 
Sorter, BD LSR II Flow Cytometer, or BD Fortessa Flow Cytometers, both equipped 
with an argon laser (ex 488 nm) and yellow-green laser (ex 561 nm). EGFP was excited 
using the argon laser and was measured using a 530/30 nm bandpass filter. mKATE2 was 
excited using the yellow- green laser and was measured using a 610/20 nm bandpass 
filter. Data evaluation was conducted using FlowJo v10.4.2 software. The number of cells 
measured per experiment was set on an experiment by experiment basis, but a set number 
of medium fluorescence mKATE2 positive cells, gated on dot plots while analyzing cells, 
were selected and counted for analysis. The typical range was between 2000-25,000 of 
these mKATE2 positive cells. 
4.6.3 Total heme Quantification 
 Measurements of total heme were accomplished using a fluorometric assay 
designed to measure the fluorescence of protoporphyrin IX upon the release of iron from 
heme as previously described221. For most total heme measurements, following harvest, 
HEK293 cell counts were assessed using automated TC20 cell counter (BioRad). Cells 
pellets were resuspended in 20 mM oxalic acid overnight at 4°C protected from light. 
Following the overnight, cell suspensions were treated an equal volume of warm oxalic 
acid to give a final [oxalic acid] of ~ 1M.  This suspensions of samples were split, with 
half the cell suspension transferred to a heat block set at 100 °C and heated for 30 
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minutes and the other half of the cell suspension kept at room temperature (~25 °C) for 
30 minutes. All suspensions were centrifuged for 2 minutes on a table-top microfuge at 
21000 x g and the porphyrin fluorescence (ex: 400 nm, em: 620 nm) of 200 µL of each 
sample was recorded on a Synergy Mx multi-modal plate reader using black Greiner Bio-
one flat bottom fluorescence plates. Heme concentrations were calculated from a standard 
curve prepared by diluting 500-1500 µM hemin chloride stock solutions in 0.1 M NaOH 
into blank oxalic acid stocks prepared the same way as for the cell samples. In order to 
calculate heme concentrations, the fluorescence of the unboiled sample (taken to be the 
background level of protoporphyrin IX) is subtracted from the fluorescence of the boiled 
sample (taken to be the free base porphyrin generated upon the release of heme iron). The 
cellular concentration of heme is determined by dividing the moles of heme determined 
in this fluorescence assay and dividing by the number of cells analyzed, giving moles of 
heme per cell, and then converting to a cellular concentration by dividing by the volume 
of a HEK293 cells approximated to be 1.23 pL226. 
4.6.4 Immunoblotting 
 Cells were harvested in the same way as described for flow cytometry as outlined 
in the Appendix. Briefly, cells grown in 6-well plates were aspirated of their media, 
rinsed with 1 mL DPBS, then harvested by pipetting in 1 mL DPBS. Cells were harvested 
into microcentrifuge tubes for freeze thaw lysis or in hefty tubes for lysis by bullet 
blending. To pellet, cells were centrifuged at 400 x g for 4 minutes at 4 °C, aspirated, 
then resuspended in lysis buffer for 3x freeze thaws or had lysis buffer added for bullet 
blending. For freeze thawing, cells were frozen twice at 80 °C for at least 1 hour, then 
thawed in a 37 °C water bath, then frozen a third time then thawed at room temperature. 
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For bullet blending, lysis was achieved at 4 °C using one pellet volume of zirconium 
oxide beads and a bead beater (Bullet Blender, Next Advance) on a setting of 8 for 3 
minutes139, 140. Post lysis with either method, lysates were centrifuged at max speed for 30 
minutes to separate cellular debris from the supernatants. Lysate protein concentrations 
were determined by the Bradford method (Bio-rad) and 14% tris-glycine gels 
(Invitrogen) were employed for SDS-PAGE139, 141. Anti-GAPDH polyclonal antibody 
(ProScience) and a goat anti-rabbit secondary antibody conjugated to a 790 nm emitting 
fluorophore (Invitrogen) were used to probe GAPDH. Anti-HO2 (Abcam) and anti-HO-1 
(Enzo Life Sciences) polyclonal antibodies were used in sequence to probe HO2 and HO-
1 and were both used in conjunction with a goat anti-rabbit secondary antibody 
conjugated to a 680 nm emitting fluorophore (Biotium). GAPDH was probed with 
primary anti-GAPDH at room temperature for 1 hour. Primary antibodies for anti-HO2 
and anti-HO-1 were each individually applied to membranes overnight treatments at 4 








CHAPTER 5. CONCLUSION 
 The means to elucidate the mechanisms underlying heme trafficking and transport 
as well as the tools to quantitate the amount of labile heme inside cells has been a long 
sought-after goal as more roles for this multifaceted cofactor and signaling molecule are 
unveiled. Uncovering these molecular details regarding how cells manage heme, is not 
only important to understand its potential uses in the cell, but are moreover highlighted 
by the deleterious effects of mishandled heme and the association of aberrant heme 
trafficking in many disease states, including hemolytic diseases, cardiovascular disease, 
neurodegenerative diseases, infectious diseases, and porphyria. 
 To increase the capacity to address the multitude of unknowns pertaining to the 
nature and dynamics of labile heme, including its concentration, oxidation state, 
speciation, distribution and dynamics, we generated genetically encoded sensors for 
heme. Using these sensors in both microbial and mammalian cells, we have divulged 
methods to quantitate changes in subcellular LH availability, ascribed a functional role 
for LH in regulating metabolism, and uncovered novel roles for proteins involved in 
regulating LH availability, including previous suggested factors like the proteasome and 
the signaling molecule nitric oxide. Further, we distinguished a condition under which 
LH is uncoupled due to stress imparted by Pb2+ poisoning, where ironically, total cellular 
heme is depleted while labile heme has been preserved for signaling. 
 Having identified several conditions that effected labile heme availability, we 
sought to develop a method for the quantitation of proteins that bind or release heme in 
response to stress. The application of this approach to Pb2+ poisoned cells should reveal 
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novel heme signaling networks employed by cells to manage stress and may have 
implications in understanding the pathogenesis of heavy metal toxicity, which has 
become a real concern in certain communities. Validating the application of our approach 
to identifying heme signaling networks may poise its use to investigate what proteins are 
involved in signaling and in several other identified conditions that alter protein heme 
speciation in response to either chemical or genetic stresses imparted to cells. 
 With the continued use of the developed heme sensors in ongoing genetic screens 
and investigations for heme’s role in Alzheimer’s disease and infectious diseases that 
require heme for virulence, others are uncovering more factors that are involved in 
regulating heme availability and are ascribing functional roles for LH in the pathogenesis 
of these diseases. With the continued development and use of more heme sensors along 
with cleverly devised biochemical and genetic strategies, who knows, someone may even 









APPENDIX A. SUPPLEMENTARY LIST OF METHODS, 
OPTIMIZATIONS, ANNECODTAL RESULTS SUPPLEMENTARY 
TO THE DISSERTATION, AND CATALOGUE OF HEME SENSOR 
REAGENTS AND STRAIN GENERATION 
A.1 Introduction 
 This appendix is to serve as a supplementary section that includes more detailed 
methods and explanations of the technical details behind each procedure and the 
optimization of protocols utilized in the main body of work. Additionally, this appendix 
is a source for any unpublished data that did not fit with Chapters 2-4. Finally, herein is a 
catalogue of how I generated all of the yeast strains and plasmids that were relevant to 
this work. 
A.2 Chapter 2 Supplementary Methods 
A.2.1 Cellular Heme Imaging Methods: Cytosol – Optimization of the In Situ 
Calibration of HS1-M7A by Flow Cytometry 
Optimization of these calibration procedures with hem1Δ cells expressing HS1-M7A by 
flow cytometry demonstrates that in situ calibration reagents added in parts or without 
heme have negligible effects on the heme sensor fluorescence ratio (Error! Reference s
ource not found.). Additionally, the EGFP:mKATE ratio of cells treated with heme are 
only lowered significantly when cotreated with digitonin (Figure A. 1). When testing the 
effects of two different reductants, ascorbate and DTT, ascorbate was found better suited 
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in equipping ferrous binding HS1-M7A with enough reduced heme to saturate its 
EGFP:mKATE ratio (Error! Reference source not found.). Finally, when testing the u
se of both DTT and ascorbate consequently, there appear to be heme independent effects 
on the HS1-M7A sensor ratio (Figure A. 1). 
 
Figure A. 1 - Flow cytometric analysis of the optimization of heme sensor in situ 
calibration protocol. The effects of the in situ calibration reagents with and without heme 
and with two different reducing agents were tested. Following the same protocol as in 
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Figure 2.7, cells were treated with and without 50 µM heme, 200 µg/mL digitonin, 1mM 
ascorbate, and/or 1mM DTT. The untreated cells, “WT HS1-M7A untreated” and 
“hem1Δ HS1-M7A untreated” were analyzed while all the cells used for the in situ 
calibration optimization were in PBS undergoing different treatment conditions for 30 
minutes at 30 °C (Figure 2.7). 
A.2.1.2 Cellular Heme Imaging Methods: Cytosol —Flow Cytometry Gating 
Yeast Dot Plots to Generate Ratio Histograms 
Single cell analysis of EGFP:mKATE2 expressing gives the power to see 
heterogeneity in cell populations, evincing the tri-modal distribution in labile heme 
availability in yeast (Figure 2.8) and to see secondary cell populations that arise by 
treated with excess reductants but are only a subpopulation of cells. (Figure A. 1). To 
properly analyze these samples, steps must be taken to remove populations that are too 
much like untransfected or EV fluorescence levels and ro remove events that have heme 
independent changes in fluorescence ratio. Herein, are the steps to properly gate yeast 
cell populations expressing HS1-M7A sensor (See Figure A. 2): 
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Figure A. 2 - Steps to follow to gate yeast cells expressing HS1-M7A for flow 
cytometric analyses of heme dependent changes in sensor fluorescence ratio. The steps 
will ensure that the removal of cells that have heme independent changes in sensor 
fluorescence ratio and the removal of low fluorescing cells that are influenced too much 
by EV autofluorescence (Step 5). 
1. Use EV cells to create a gate to apply to all cells populations to only accept cells 
with fluorescence levels above EV autofluorescence (Figure A. 2Figure A. 2 - 
Steps to follow to gate yeast cells expressing HS1-M7A for flow cytometric 
analyses of heme dependent changes in sensor fluorescence ratio. The steps will 
ensure that the removal of cells that have heme independent changes in sensor 
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fluorescence ratio and the removal of low fluorescing cells that are influenced too 
much by EV autofluorescence (Step 5)., Step 1 dot plot). 
2.  To the subpopulations of cells formed using Step 1, apply a gate that keeps the 
most abundant cell population. Do this by creating a gate that selects for the most 
abundant cell population in a dot plot of Forward vs. Side Scatter. See Figure A. 
2, Step 2 dot plot. 
3. The next gate to apply is to subpopulation 2 and removes any remaining cells with 
low or exceedingly high EGFP autofluorescence using a forward scatter vs EGFP 
dot plot. Often, but not always, some cells with very low (those that survived Step 
1) or very high EGFP fluorescence exist (sometimes from cellular clumping that 
can arise with some treatments, i.e. excess heme) that need to be removed. Form 
the gate using a cell sample with high EGFP fluorescing cells like hem1Δ cells 
expressing heme sensor. This gate should not be applied to remove low 
fluorescing EGFP cells from heme saturated samples, as the EGFP fluorescence 
in these heme saturated cells resembles near autofluorescence levels of EGFP. See 
Error! Reference source not found., Step 3 dot plot. 
4.  Make a mKATE2 vs EGFP:mKATE2 dot plot on cells that are in subpopulation 
3, which shows the heme sensor ratio’s dependence on expression. The highest 
expressing cells have a lower ratio and the lowest fluorescing cells have a very 
wide distribution, likely because of autofluorescence variability in cells that will 
affect how much “GFP” fluorescence there is independently of [heme]. These 
high and low expression populations should be gated out. See Figure A. 2, Step 4 
dot plot. 
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5. In WT cells expressing HS1-M7A, check to see if how the bottom fluorescing cell 
population looks like relative to hem1Δ cells by overlaying their EGFP:mKATE2 
histograms. If this dot plot contains a populations population has a very high ratio, 
which can be higher than the mode hem1Δ ratio, (dark red histogram in Figure 
A.3Error! Reference source not found.), then it should be removed. To gate out 
this population, make a mKATE2 vs EGFP:mKATE2 ratio dot plot on cells that 
are in subpopulation 4, and create a gate to remove the lowest expression 
population See Figure A. 2, Step 5 dot plot. This population of low fluorescing 
EGFP:mKATE2 cells may have EGFP values too close to EV EGFP 
autofluorescence if your laser settings for FITC-A are set too low. The 
fluorescence contributed by a cells autofluorescence in low fluorescing cells may 
give an artificially high “EGFP” fluorescence value relative to mKATE2 
expression, giving an uncharacteristically high EGFP:mKATE ratio. This is one 
disadvantage of flow cytometry over fluorimetry unless you take the time to 
export all of the data out of FlowJO and into a software like Excel and determine 
a good way to subtract out EGFP EV autofluorescence from every cell in your 
analysis. However, as the EV autofluorescence between cell varies, it is difficult 
to decide on the best value to subtract from each cell. 
6. Finally, to your subpopulation made in the last mKATE2 vs EGFP:mKATE2 
Ratio dot plot or an EGFP vs mKATE2 dot blot, remove any outlier or low 
abundance populations on the fringe of your most highest cell populations on the 
dot plot countor map (red dots represent the highest abundant cell type on the dot 
plot, while the blue dots on the fringe are the lowest represented cell type). This is 
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not a necessary step but cleans your data up a little bit. See Figure A. 2, Step 6 dot 
plot. 
The cells used in creating this methods primer, Steps 1-6, are the cells plotted in the 
EGFP:mKATE2 histograms in Figure A.3Error! Reference source not found.. F
ollowing Steps 1-6 exactly will gate cells to optimally demonstrate the in vivo heme 
dependent changes in HS1-M7A sensor fluorescence. 
 
Figure A.3 – Resulting histograms from gating WT and hem1Δ cells expressing HS1-
M7A that were treated with a heme depleting dose of SA and heme replenishing dose of 
ALA for hem1Δ cells. Following the gating steps outlined in Error! Reference source n
ot found. yields a trimodal distribution in cells that are heme replete and express HS1-
M7A and yields monomodal distributions of any SA treated cell population (WT or 
hem1Δ) that is marginally lower in ratio than untreated hem1Δ cells expressing HS1-
M7A. 
 Lastly, Figure A.4 and Figure A.5 show all gates applied from Steps 1-6 to hem1Δ  
and WT cells expressing HS1-M7A in FlowJO and are displayed using the “backgating” 
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function option for each EGFP:mKATE ratio histogram. Each gate that was used to 
generate the final figures (red histogram for hem1Δ and blue histogram for WT) are 
shown in grey dot plots shown to the right of each coloured histogram. The red dots in 
each dot blot represent the cells that met the criteria of every gate and are cells that fill 
the population of the final histograms shown in Figure A.4 and Figure A.5. 
 hem1Δ cells in Figure A.4 follow Steps 1-4, and 6 for their gating, which ensures 
that most cells that display heme independent changes in EGFP:mKATE ratio are 
removed from the analysis. Further gating or a tighter threshold could be applied to Step 
4 to remove more of the lower fluorescing cells; however, doing so would only affect the 
tails of each side of the histogram, without affecting the mode or mean of the distribution 
significantly. Keeping some of the lower fluorescing cell population in the Step 4 gate, 
ensures that the tails do not drop off too suddenly, keeping the data from looking too 
artificial (Figure A.4). 
 163 
 
Figure A.4 - Backgating of hem1Δ HS1-M7A expressing cells that underwent all of the 
gates prescribed by Steps 1-4 and 6 as outlined in Figure A. 1. Step 5 does not apply to 
hem1Δ HS1-M7A and is skipped for these cells. 
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Figure A.5 - Backgating of WT HS1-M7A expressing cells that underwent all of the 
gates prescribed by Steps 1-6 outlined in Figure A. 2. 
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 Unlike with the hem1Δ HS1-M7A cells, the analysis for WT HS1-M7A 
expressing cells undergoes all steps outlined in Figure A. 2. to include Step 5. Step 5 is 
necessary in this case as there is a low expressing sensor population that has an 
artificially high EGFP:mKATE ratio due to EGFP autofluorescence contributions that 
affects lower fluorescing cells. Acquiring the data with a lower FITC-A laser setting 
often mandates that the lowest expression population of HS1-M7A cells be removed. See 
Figure A.6, which shows this importance of gating out these low fluorescing cells. A 
higher FITC-A channel laser setting used to analyze the EGFP fluorescence of these cells 
might put the EGFP fluorescence high enough above background to not be give these 
cells an artificially higher ratio from the EGFP contributing autofluorescence that comes 
from a lack of EV autofluorescence subtraction for cells in our analyses. However, the 
FITC-A channel laser cannot be increased too much as the EGFP fluorescence is already 
nearing the dynamic range capacity of the flow cytometer’s detector in this example 
(Figure A. 2, Step 3 dot plot, x-axis). 
 
Figure A.6 – Importance of gating lowest fluorescing cell population from WT HS1-
M7A expressing cells as outlined in Figure A. 2. Light blue EGFP:mKATE ratio 
histogram represent the population of cells that went through Steps 1-5 of gating, while 
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the dark blue histogram are those cells that only went through Steps 1-4 of gating. The 
dot plot on the right represents cells that passed the criteria of Gates 1-4, and contains 
gate 5, which removes most of the lowest expressing cell population. 
A.2.1.3 Cellular Heme Imaging Methods:Flow Cytometry Gating HEK293 Cell 
Dot Plots to Generate Ratio Histograms 
 
Figure A.7 - Steps to follow to gate transiently transfected HEK293 cells expressing 
hHS1 sensors. Following each step will select for the events that are cells expressing 
sensor that have heme dependent changes in their sensor fluorescence ratio by removing 
debris, untransfected cells, and cells that have heme independent changes in sensor 
fluorescence ratio. At high expression, hHS1 has heme independent changes in sensor 
fluorescence ratio, and the lowest expressing cells are influenced too much by EV 
autofluorescence and should be removed (Step 3). 
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1. Apply a gate that keeps the most abundant cell population that is not the smallest 
population using a side scatter (SSC-A) versus forward scatter (FSC-A) dot plot. 
The medium sized population represents your cells and are referred to as 
subpopulation 1 of your specimen. See Figure A.7, Step 1. 
2. Use analyzed untransfected cells create a gate to apply to all subpopulation 1 cells 
that will only accept cells with fluorescence levels above the untransfected cells’ 
autofluorescence (Figure A.7, Step 2 dot plot.). The left panel of Step 2 represent 
the created gate using untransfected cells. The right panel of Step 2 is this gate 
applied to transfected cells, which removes any remaining untransfected cells and 
debris. Step 2 generates subpopulation 2. 
3. Next, make two dot plots, an mKATE2 vs eGFP:mKATE2 dot plot and an 
mKATE2 vs eGFP dot plot on cells that are in subpopulation 2. Analyze these dot 
plots to see where the expression level of sensor begins to cause heme 
independent changes in ratio, which occurs at both high expression and very low 
expression of sensor. (See Step 3 dot plots, Figure A.7). Draw a gate around 
medium mKATE2 expression population on the mKATE2 vs eGFP:mKATE2 dot 
plot to select for these cells and remove any cells with expression dependent 
changes in sensor fluorescence ratio. Apply this gate to subpopulation 2 to make 
subpopulation 3. 
4. Finally, to each subpopulation 3 for all your samples, using an eGFP:mKATE2 
dot plot , apply a gate that removes any outlier or low abundance populations on 
the fringe of your highest cell populations. This is not a necessary step but cleans 
your data up a little bit. See Figure A.7, Step 4. 
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The cells used in creating this methods primer, Steps 1-4, are the cells plotted in the 
eGFP:mKATE2 histograms in Figure A.8. Following Steps 1-4 exactly will gate cells to 
optimally demonstrate the in vivo heme dependent changes in hHS1 sensor fluorescence. 
To see these gates applied to one population of cells, see Figure A.9. 
 
Figure A.8 - Resulting histograms from gating heme depleted (HD +SA media) cells 
versus cells grown in media with sensor saturating amount of heme or ALA for 24 hours. 
These histograms contain cells gated exactly as prescribed in Steps 1-4. 
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Figure A.9 - FlowJO’s backgating function applied to heme deficient HD + SA grown 
cells to visualize the effects of each gate on cells that make it to the final population 
analyzed. Each gate applied to the cells that are in the red histogram are shown on the 
right in gates made following Steps 1 through 4. The top right box represents Step 1 and 
progresses through the steps ending with Step 4 at the bottom. The gray dots that are 
shown in each dot plot did not make it to the final histogram. The red dots of each dot 
plot represent the cells that survived each gate outlined in Steps 1-4 and are the cells 
plotted in red EGFP:mKATE2 ratio plot. 
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A.3 Chapter 3 Supplementary Methods and Optimization Procedures 
A.3.1 Total Heme Quantification 
 Measurements of total heme were accomplished using a fluorimetric assay 
designed to measure the fluorescence of protoporphyrin IX upon the release of iron from 
heme as previously described221. For most total heme measurements, following cell 
growth, 2 x 108 cells were harvested, washed in sterile water, and resuspended in 500 μL 
of 20 mM oxalic acid and stored in a closed box at 4 °C overnight (16-18 hours). The 
total heme assay can work with less than 2 x 108, with the lowest number attempted being 
1 x 107 cells. When using cell numbers this low, instead of resuspended cells in 500 μL 
20mM oxalic acid, cells should be resuspended in 250 μL to concentrate the cells 
slightly. After the 4 °C overnight, a 500mL premade stock of 2 M oxalic acid in a 1 L 
glass media bottle was warmed on a hot plate, with the lid open, in a fume hood. Once 
the oxalic acid is mostly dissolved, overnight treated cells are moved to room 
temperature. Next, 50mL of the warmed 2 M oxalic acid was poured into a 100mL glass 
beaker and from here an equal volume (500 μL in most cases) of 2 M oxalic acid was 
added to the cell suspensions that were moved to room temperature to give a final [oxalic 
acid] of ~1M. The samples were moved to room temperature from 4 °C to warm up since 
concentrate oxalic acid is not soluble at low temperatures. The samples were split, with 
half the cell suspension transferred to a heat block set at 100 °C and heated for 30-35 
minutes and the other half of the cell suspension kept at room temperature (~25 °C) for 
28-33 minutes. The room temperature suspensions are centrifuged first followed by the 
boiled suspensions for 2 minutes on a table-top microfuge at 21000 x g and the porphyrin 
fluorescence (ex: 400 nm, em: 604 nm) of 200 μL of each sample was recorded on a 
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Synergy Mx multi-modal plate reader using black Greiner Bio-one flat bottom 
fluorescence plates. Taking a porphyrin fluorescence spectrum for each sample of each 
independent experiment showed that 604 em was consistently a good wavelength to use 
for collection. Heme concentrations were calculated from a standard curve prepared by 
diluting a 500-1500 μM hemin chloride stock solutions in 0.1 M NaOH into Milli-Q 
water to make a 10 μM hemin chloride working solution, (the first dilution of the heme 
stock is always to 100 μM followed by a dilution 10 μM hemin chloride). The 10 μM 
hemin chloride stock is then added back to extra untreated cell pellets harvested in 
tandem with the treated cells from the experiment to create a heme standard curve to be 
analyzed with the cells whose heme are being quantified. In order to calculate heme 
concentrations, the fluorescence of the unboiled sample (taken to be the background level 
of protoporphyrin IX) is subtracted from the fluorescence of the boiled sample (taken to 
be the free base porphyrin generated upon the release of heme iron). The cellular 
concentration of heme is determined by dividing the moles of heme determined in this 
fluorescence assay using the heme standard curve to relate the porphyrin fluorescence to 
moles of heme, and then dividing by the number of cells analyzed, giving moles of heme 
per cell. After calculating heme per cell to a molarity of hemin by diving the heme per 
cell by the volume per yeast cell, which is ~50 fL29. This fluorescence assay gives similar 
qualitative trends between samples as an HPLC assay for heme we previously 
employed29, but the absolute concentrations tend to be consistently 3-5 fold higher (data 
not shown). 
A.3.2 Preparation and Use of Hemin Agarose and Sepharose Beads to Affinity 
Purify Proteins from Cellular Lysates and Apo-myoglobin 
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 Pipet desired volume of bead slurry, typically 100uL slurry per compact reaction 
column (CRC), in a CRC. Pellet at 700 x g in a microcentrifuge for 5 minutes. Discard 
the collected solvent and conduct 3x1mL 5 minute washes in sodium phosphate lysis 
buffer (0.1% Triton X-100, 10 mM NaPi, 50 mM NaCl, 5mM EDTA, pH 7.4, 1 mM 
PMSF, 1X ProteaseArrest™), double check notebook rotating at 20 rpm. Distribute the 
washed beads in lysis buffer to aliquot 100 uL of washed slurry per CRC, of which there 
should be 1 CRC per reaction condition. Per 100 uL of pelleted slurry (~50 uL volume of 
beads) add 250 uL of cellular lysate at a concentration of a least 1ug/uL achieved by 
lysing several 25-50 OD cellular pellets using one pellet volume of zirconium oxide 
beads and a bead beater (Bullet Blender, Next Advance) on a setting of 8 for 3 minutes29. 
The amount of cells depends on the amount of protein required for the analysis, where at 
least 200 uL of 2 ug/ uL is required for ample detection of eluted proteins from hemin 
agarose beads treated with cellular lysates (Figure A.12). When affinity purifying 
purified proteins with hemin agarose or sepharose, prepare 50 uL of bead bed volume per 
CRC and add at least 2-5ug myoglobin in 200 uL of lysis buffer in lysis buffer. 
 Following preparation of beads and addition of cellular lysate or myoglobin to the 
beads, allow the lysate/protein to incubate with the beads for 60-70 minutes at room 
temperature rotating at 20rpm in the compact reaction columns. After treating cells with 
lysate/protein, collect flow through by pelleting CRCs at 700 x g for 5 minutes. If the 
columns still contain much of the flow through spin for multiple 1 minute spins, making 
sure not to completely dry out the beads but centrifuging until most of the flow through 
was collected. If collecting most of the flow through is not required for the experiment, 
instead, remove most of the rest of the volume by aspirating the rest from the bottom of 
 173 
the CRC with a 1mL pipet tip connected to a hose and vacuum line. After collecting the 
flow through, conduct 3x10 minutes washes in lysis buffer, rotating at 20 rpm at room 
temperature. Collect and/or discard the washes in the same manner as the flow throughs. 
Finally, elute the proteins from the beads with a 15 minute wash in 50-100 uL 1M 
imidazole in lysis buffer followed by a 2 minute pellet at max speed. 
A.3.2.1 Preparation of Apo-myoglobin 
 Adapted protocol from Ascoli et al with slight modifications234. Weighed out 100 
mg of horse heart myoglobin (Sigma-Aldrich). In 1 L beaker on thin layer of ice on a 
magnetic stir plate, precipitated out protein from heme in acid-acetone (2 M HCl, made 
by addition of concentrated HCl into acetone), by slowly adding 200 mL of acid-acetone 
to the myoglobin spinning by magnetic stir bar. The precipitate is white, and the acid-
acetone should contain all of the heme. Pelleted the 200 mL volume in several 50 mL 
conical tubes at -19 °C. Decanted acid acetone supernatant from the pelleted protein and 
washed each pellet in each conical tube with and addition 50 mL of acid-acetone twice, 
repelleting at 4 °C at 4000 rpm. Allow the resulting mass of pelleted proteins to 
solubilize in 4 mL MilliQ water at 4 °C for 1-2 days. Next, conduct two rounds of 
dialysis overnight of the soluble fraction of the pellets against lysis 150 mL of lysis 
buffer at 4 °C rotating slowly by magnetic stir bar. 
Dialyzed half of the soluble fraction of the pellets against each lysis buffer (0.1% Triton 
X-100, 20 mM Tris, 100 mM NaCl, pH 7.4) using 2 rounds of dialysis with 100-150mL 
of each buffer against half the soluble protein. 
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Next, quantify the dialyzed protein by Bradford Reagent assay using known 
concentrations of BSA to make a standard curve and by UV-VIS spectroscopy235. Finally, 
make dilutions apo-myoglobin with and without a half of a molar equivalent of heme 
added and measure the UV spectra relative the spectra of just heme to ensure proper 
binding of heme to myoglobin from the purified, reconstituted protein. 
A.3.2.2 Optimization of Elution Conditions for Hemin Agarose using Apo-
myoglobin 
 An elution condition that would remove heme-binding proteins but would not be 
too harsh to elute non-specific interactors of hemin agarose was required. To optimize 
such an elution condition, 1 M imidazole, which has a strong affinity for heme and can 
compete for heme binding versus the heme matrix of the hemin agarose beads was tested 
for its efficacy versus heat and SDS, which in combination should elute any protein that 
sticks to hemin agarose via heme-binding or non-heme specific interactions. Finally, 
testing imidazole with both SDS and heat should determine any difference in the ability 
of imidazole to elute proteins versus just SDS and heat. Conveniently, there was no 
difference in elution efficacy between 1 M imidazole alone compared to the plus heat and 
SDS conditions, indicating that imidazole alone is enough to elute the myoglobin from 
the beads (Figure A.10). 
 
Figure A.10 - Testing apo-myoglobin elution conidtions with 1 M imidazole, 1x SDS 
loading dye, and heat. Hemin agarose beads were treated with 8 µg of apo-myoglobin at 
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4°C for 50 minutes. After 3x10 minute 1 mL washes in lysis buffer, the beads were split 
into 3 equal volumes then eluted with either 1 M imidazole, 1 M imidazole with 1x SDS 
loading dye, and boiled for 5 minutes, or with 1x SDS loading dye and boiled for 5 
minutes. There is no significant difference between the elution conditons indicating the 1 
M imidazole alone is sufficent to elute heme-binding proteins off of hemin agarose. This 
gel is representative of 2 independent trials. 
 To further validate our elution conditions off of the hemin agarose beads, several 
other candidate elution conditions were tested against 1 M imidazole, including 8 M urea, 
lysis buffer alone, 1 % SDS, 100 µM hemin, and heat alone (5 minute boiling of the 
beads in lysis buffer). To do so, a 200 µL bead bed volume of hemin agarose was 
prepped and resuspended in 1.2 mL of lysis buffer containing 20 µg of apo-myoglobin. 
This bead-myoglobin suspension was split into 6 equal parts into 6 compact reaction 
columns (CRCs) and allowed to incubate at room temperature for an hour. Post treatment 
and after 3x10 minute washes in lysis buffer, the beads were eluted and analyzed by 1-D 
PAGE (Figure A.11). 1 M imidazole, 1% SDS, and 100 µM hemin treatment were both 
the top 3 and the only elution conditions that eluted myoglobin off the beads (Figure 
A.11). From here, all elutions were conducted using 1 M imidazole in lysis buffer, since 
1% SDS is not heme specific, and 100 µM heme may be harder to remove from the 
eluents if the eluents were to be prepared for MS-MS analysis. 
 
Figure A.11 - Apo-myoglobin eluted off hemin agarose beads by 1 M imidazole versus 
other candidate elution conditions, including 8 M urea, lysis buffer, 1 % SDS, 100 µM 
hemin, and heat alone analyzed by 1-D PAGE. 1µg input was completely untreated. 
Hemin agarose protein treatment was conducted at room temperature, 20 rpm. Each lane 
was loaded with 70% of its 50 µL elution, giving a theoretical yield of ~2.3 µg per 
sample. Hence, either not all the myoglobin was eluted off the beads, some myoglobin 
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never stuck to the beads, or some myoglobin came off during the extensive wash steps 
(not tested). 
 After optimizing the elution to remove a canonical heme binding protein from 
hemin agarose beads, and after having validated that a protein’s heme saturation will 
affect how well the heme-binding protein will bind hemin agarose with the myoglobin 
studies, we pursued treating hemin agarose with cellular lysates. Previous models and 
uses of hemin agarose have had success identifying and/or confirming novel heme-
binding roles for proteins using hemin agarose 57, 236-239; however, to date, there has not 
been a published, comprehensive comparison of a hemin agarose binding proteome 
analysis between two conditions that are known impact heme signalling or alter cellular 
protein heme speciation. Specifically, no one for example, no one has devised nor 
pursued the proper methods to investigate what proteins bind or release heme in response 
to stress (i.e. heme starvation or Pb2+ poisoning) but instead only investigated one or two 
candidate proteins.  
 So, to move forward, our next step in establishing such a method with hemin 
agarose in our yeast models began by optimizing the amount of hemin agarose beads to 
use in tandem with how much protein lysate to load the beads with for an hour treatment 
(Figure A.12). The lowest bead bed volume was too low to affinity purify enough protein 
to be visible by coomassie blue staining (Figure A.12, 12.5 µL column). As there is little 
difference between 2.5 µg/µL and 5 µg/µL protein lysate loaded, it is possible that the 
beads have become saturated with proteins at this concentration of protein. Higher 
amounts of eluted protein resulted from using the highest bead bed volume, but there was 
not a large difference between this 100 µL and the 50 µL bead bed volume sample 
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(Figure A.12). Moving forward, all cellular lysates were treated with at least 50 µL bead 
bed volumes of hemin agarose, with cellular lysate volumes between 200-300 µL with 
target protein lysate concentrations of ~2 µg/µL. 
 
Figure A.12 – Optimization of bead bed volume of hemin agarose versus concentration 
of protein to load in 250 µL protein lysate for 1-hour room temperature hemin agarose 
treatments. The results indicate that to optimize the amount of proteins pulled out with 
hemin agarose, at least a 50 µL bead bed volume (~100 µL of slurry) and ~2 µg/µL but 
less than 5 µg/µL protein should be used. 
A.3.2.3 Attempting by 1-D PAGE with Coomassie Staining and SyproRuby 
Staining 
 At this point, our model and hypothesis that proteins will stick to hemin agarose 
preferentially based on whether they are heme bound or not seems accurate with both 
pure hemoproteins, like myoglobin, and proteins extracted from differentially heme 
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starved cellular lysates. Furthermore, the protein interactions are quite heme specific 
when comparing their relative abundances to the proteins resulting from sepharose bead 
treatment as analyzed by 1-D PAGE (Figure 3.15). Herein, having established this, we 
next examined what proteins bind or release heme in response to Pb2+ poisoning in yeast 
by comparing analyzing the relative protein abundances of proteins that stick to hemin 
agarose versus sepharose in Pb2+ poisoned versus non-stressed cells. Any large 
differences in proteins detected between these two conditions are likely, based off our 
well supported hypothesis, to be binding and releasing heme in response to Pb2+ 
treatment. 
 Since the total protein in Pb2+ treated cells is much lower than non-stressed cells, 
analyzing the resulting proteins that stick to hemin agarose from Pb2+ and untreated cells 
was difficult to detect by 1D-PAGE analysis with Coomassie staining, which has a 
detection limit for protein stained bands of ~10 ng. Even though the cells treated Pb2+ 
were protein limiting, coomassie staining of a 1D-Page gel of the eluted proteins from 
hemin agarose and sepharose displays that there are many different proteins that stick to 
hemin agarose versus sepharose in Pb2+ stressed versus non-Pb2+ treated cells (Figure A. 
13). Many faint proteins bands are detected from the hemin agarose elutions of untreated, 
“-Pb lysates,” that do not show up from the treated, “+Pb lysates.” Additionally, there are 
3 distinct bands that are enhanced in the +Pb hemin agarose treated lysates. (See the -Pb 
and +Pb “Brightness/Contrast Enhanced Hemin Agarose Lanes” in Figure A. 13). 
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Figure A. 13 –Probing for differential binding to hemin agarose in lysates from 
nontreated “-Pb” Pb2+ treated “+ Pb” cells.  1-D PAGE displaying the input, flow-
through, and the resulting hemin agarose and sepharose elutions. The brightness and 
contrast enhanced lanes for the -Pb and +Pb hemin agarose elutions reveals several 
differential binders of heme between these two treatment conditions. Protein expression 
is highly varied between -Pb and +Pb treated cells as seen by the input lanes. This data is 
representative of two independent trials with at least 2.8 mg of protein lysate loaded per 




Figure A. 14 - 1-D PAGE and SyproRuby staining of eluents from SILAC labeled 
eluents that were sent for LC MS-MS analysis (Figure 3.16). Unlike with coomassie 
staining, many proteins are detected from both -Pb and + Pb hemin agarose elutions with 
many distinctive bands between the two samples. 
 From the SILAC labeleing experiment, approximately 10% of the elutent volume 
from each condition from outlined in Figure 3.16 was saved to conduct an 1-D PAGE 
analysis with SyproRuby staining while the remaining eluent was sent for LC MS-MS 
analysis. The SyproRuby stained 1-D PAGE shows numerous protein bands that run with 
differing intensities between the -Pb and +Pb treatments with some bands that only 
appear in one of the two treatment conditions (Figure A. 14). The results of the hemin 
agarose versus sepharose proteomics study are depicted in Figure 3.17B. To help 
interpret the results of the proteomics data, some SILAC labeled cells from the 
experiment outlined in Figure 3.16 were set aside to analyze whole proteome abundance 
changes resulting from Pb2+ poisoning (Figure 3.17A). 
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A.3.2 SILAC Media Preparation and MES Treatment with and without Pb2+ to 
Acquire Light and Heavy Labelled Cells for Sepharose versus Hemin Agarose 
Enrichment Studies 
Step 1: Streaked Ly1D cells from a freezer stock onto YPD plates for 2 days. 
Step 2: Prepped 4 L of SD-Lys media. Media was from stock of SD-Lys Powder prepped 
for 15 L that was made by adding each component of the media and then mixing by 
magnetic stir bar. Media was made prepped in 4 L beakers with Sterile MilliQ and stirred 
for 90 minutes with a magnetic stir bar. Afterwards, media was sterilized using the 
autoclave in 2 x 2 L media bottles. Filter sterilized 20% glucose was added to the media 
after it cooled. Light or heavy lysine (50 mg/mL) was added to the media after 
inoculating with cells. 
Step 3: Scraped cells to make a 10 OD/mL (A600) cell stock in Sterile MilliQ. 
Step 4: Inoculated 1.6 L of SD-Lys media at a density of 0.00075, swirled to mix, then 
split into 2 x 800 mL cultures in 2 L flasks. To one flask containing 2 L SD-Lys, added 
50 mg/mL light lysine. To the other flask, added 50 mg/mL heavy lysine. Split the 800 
mL cultures into 2 x 400 mL cultures in 2 L flasks. End result equals, 2 x 400 mL heavy 
lysine and 2 x 400 mL light lysine cultures with Lys1D cells at 0.00075 OD/mL in 2 L 
flasks. Conditions are as follows: “– Pb light lysine for sepharose beads, -Pb heavy lysine 
for hemin agarose beads, + Pb light lysine for sepharose beads, and + Pb heavy lysine for 
hemin agarose beads. 
Step 5: Cells were grown overnight at 30°C at 250 rpm. 
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Step 6: After 14 hours of growth, checked the density. 
Cells will need to grow between 15 and 16 hours and it is vital to read the density at 14 
hours to be able to catch the cells before the go over a density of 1.0- read the densities 
and 14 hours, 15 hours, then every 15 minutes after that by taking out 0.5 to 1 mL media 
into a microcentrifuge tube to use to read the OD. 
Step 7: Cells were grown to final densities between 0.8 and 1.0 (between 10 and 11 
doublings), then were vacuum filtered to harvest the cells.  
Step 8: Cells were then washed twice with 45 mL Sterile MilliQ. 
Step 9: Each pellet was resuspended in 20-30 mL of 10mM pH 6.0 MES then added to 
new 4-liter flask with total volume of 1 L MES post addition of cells. 
Step 10: Add 1 mL sterile MilliQ or 1 mL Pb(NO3)2 to add IC50 dose (85 µM) of Pb2+ 
to cells. 
Step 11: Keep cells in MES buffer for 3 hours, rotating cultures by hand every 15 
minutes to ensure cells do not settle to the bottom of the flask. 
Step 12: After 3 hours of Pb Shock, take out 1mL aliquots of each culture and pellet in 
prelabelled 1.5mL microcentrifuge tubes. Pellet and re-suspend in 1mL Sterile MilliQ. 
Inoculate 100 µL of each washed culture in 10mL of SD-Lys + Light Lys for 20-hour 
growth to assess toxicity of Pb Shock. 
Step 13: Filter the remaining culture to harvest cells. Two flasks were filtered at once. 
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Step 14: 1 x 90 mL wash to collect all cells off each filter. Cells harvested in 2 x 50 mL 
conical tubes. 
Step 15: Resuspend cells in 25mL of appropriate media (light or heavy lysine added to 
SD-Lys), and transfer each resuspended cell pellet into appropriately labeled flasks. 
Step 16: Add back appropriate media to flask so that total volume is 400 mL SD-Lys + 
heavy or light lysine 
Step 17: Let recover for 4 hours at 30 C, 250 rpm 
Step 18: Harvest cells just like in Step 14, but make 3 sets of pellets for each type of 
pellet in prelabeled tubes: 
 3 sets: 
i. 5 OD pellets for double-checking coomassie banding toxicity phenotype 
ii. 50-60 OD pellets for whole proteome analysis 
iii. Remainder of cells in 4 x ~50 OD pellets for each condition for sepharose versus 
hemin agarose bead enrichment 
4 types of pellets 
i. - Pb light lysine 
ii. - Pb heavy lysine 
iii. + Pb light lysine 
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iv. + Pb heavy lysine 
A.4 Chapter 4 Supplementary Methods 
A.4.1 Transfection of hHS1 Sensor Plasmids into HEK293 Cells for Flow 
Cytometric Analysis 
 The protocols described below are for HEK293 cells cultured in 6-well plates. 
However, the same protocols work for cells transfected in similarly sized wells for 
microscopy. 
A.4.1.1 Transfecting Cells with jetPRIME or PolyJet for Flow Cytometric 
Analysis 
Protocol reproduced from Xiaojing Yuan, Hamza Lab 
Day 1: HEK293 cells are seeded at ~40% confluence (0.4 x 10^6 cells / well for 6-well 
plate). For imaging, you may seed at lower confluence. 
Day 2: 30 minutes to 1 hour before transfection, change the medium to fresh medium 
(basal, HD, SA or HD+SA, or HD + SA + heme). In one Eppendorf tube, add 1ug DNA 
to 50 µL DPBS. In another Eppendorf tube, add 4 µL PolyJet to 50 µL DPBS. Then add 
the Polyjet/DPBS solution to DNA/DPBS solution, pipet to mix, wait for 10-15 minutes 
at RT, and then add to cells. 
Day 3: 24 hours post transfection, change to fresh medium (basal, basal + ALA, HD, SA 
or HD + SA, or HD + SA + heme now). 
Day 4: Harvest cells for analysis. 
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Alternatively, for PolyJet Transfections, you could follow this approach to avoid cell 
counting:  
Day 1 – Split ¼ of T75’s cells in a 6 well plate and grow cells for ~40 hours before 
transfecting, or 1/6 of T75’s cells in a 6 well plate and wait 48-60 hours before 
transfecting 
30min to 1h before transfection, change the medium to fresh medium (basal, HD, SA or 
HD + SA, if plan to do HD + SA + heme, change to HD + SA today). In one Eppendorf 
tube, add 1-2μg DNA/well that you are transfected to 50μL DPBS/well you are 
transfecting. In another Eppendorf tube, add (4-8μL PolyJet x n) to (50μL DPBS x n) 
where “n” = the amount of wells you are transfecting. Then add the PolyJet/DPBS 
solution to DNA/DPBS solution, pipet to mix, wait for 10-15min at RT, and then add to 
cells. 
The amount of PolyJet:DNA should always be at a ratio of at least 4:1 
Example: transfecting a 6 well plate with 5 of 6 wells transfected with 1.5 µg hHS1 
Add 250 µL DPBS to two Eppendorf tubes, 1 for to receive DNA, the other to receive a 
PolyJet. 
Add 7.5 µg DNA to the 1st tube, and add 30 uL PolyJet to the 2nd tube 
Add the tubes together and mix by pipetting to get 500+ uL DPBS-DNA-PolyJet 
Incubate at RT 10-15 minutes 
Add to 100 µL to each well 
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UT would be 50 μL DPBS w/o DNA added and 50 μL DPBS + 6 μL of PolyJet 
24hrs post transfection, change to fresh medium (basal, HD, SA or HD+SA, if plan to do 
HD + SA + heme, change to HD + SA + heme now). 
After an overnight, up to 48 hours later, harvest cells for analysis. 
A.4.1.2 Transfecting Cells with Lipofectamine LTX 
Step 1: HEK293 cells are typically seeded into a 6-well plate with ¼ the cells resulting 
from splitting a confluent T75 flask. For larger experiments with cells to be from the 
same parent flask, cells can be split at a lower density to expand the experiment into 
multiple plates.  
Step 2: Once cells are around 50% confluent, 1-2 days after seeding, change the media 30 
minutes to 1 hours before transfection. In one Eppendorf tube, add 100 µL room 
temperature OptiMEM per well that you are transfecting, up to 600 µL OptiMEM per 
tube.  Add 1-2 µg of  hHS1 DNA per well to be transfected. Next, add a volume of 
Lipofectamine Plus Reagent equal in µL to the µg amount of hHS1 DNA added. Then, 
add the Lipofectamine LTX transfection reagent at a volume that is double the volume of 
Plus Reagent. Flick tubes or pipet up and down to mix. Incubate at RT for 5 minutes, then 
add 100 μL of the resulting OptiMEM-DNA-Plus-LTX cocktail to each well. If 
cotransfecting hHS1 with pCMV-HO2 plasmid, then follow same procedure, adding 
pCMV-HO2 DNA with the hHS1 plasmid, and add the appropriate amount of additional 
Plus and LTX reagents in the follow steps. 
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Step 3: Cells can be harvested within 40 hours post transfection to analyze by flow 
cytometry. However, if you need to treat cells with a toxicant or growth supplement to 
investigate the resulting changes on labile heme, wait on harvesting. Instead, around 40 
hours post transfection, change media and include the relevant toxicant (i.e. H2O2 or 
Pb2+) or growth supplement (i.e. heme or ALA). Harvest cells post treatment, typically 
around 20-24 hours for heme or ALA treatment. 
A.4.1.3 Transfecting Cells with Lipofectamine 2000 
Step 1: HEK293 cells are typically seeded into a 6-well plate with ¼ the cells resulting 
from splitting a confluent T75 flask. For larger experiments with cells to be from the 
same parent flask, cells can be split at a lower density to expand the experiment into 
multiple plates. 
Step 2: Transfect cells when they are about 50% confluent. If there are less than 50% 
confluent, transfect for slightly shorter time, or use less Lipofectamine 2000 per well. 
Slightly higher than 50% confluency works well, too. Change media to HD + SA or 
regular media at least 30 minutes before transfection. Aliquot 480 μL OptiMEM to a 
microcentrifuge tube and around 500 μL OptiMEM to a second microcentrifuge tube. To 
the first tube, add 20 μL of Lipofectamine 2000, and to the second tube, add an amount of 
HS1 DNA that gives you ~1 μg of DNA per well. If you added 5 μL of hHS1 DNA to 
this second tube, then you would have added 5 μL DNA to 495 μL OptiMEM. Incubate 
these tubes at room temperature for 5 minutes after flicking the tubes to mix. Then, add 
the contents of each tube together to incubate at room temperature for an additional 25-30 
minutes. Next, add 150 μL of the resulting mixture to each well to be transfected with the 
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heme sensor. If cells were lower than 40% confluent at the time of transfection, add ~140 
μL of this cocktail per well. If cells are higher than 50% confluency, add ~155-165 μL 
per well. 
Step 3: Change media around 20 hours post transfection. 
Step 4: Harvest cells and analyze 16-40 hours post changing media. 
A.4.2 In situ saturation protocols 
 These methods were optimized to in situ saturate hHS1 in HEK293 cells analyzed 
by flow cytometry. The digitonin permeabilization was tried by microscopy and analyzed 
by point scanning confocal microscopy. The cells would not stay attached (data not 
shown). For others attempting this in the future, it should be possible using the Cyation 3 
imaging plate reader, which is less phototoxic. On the other hand, the ALA treatment 
methods to in situ saturate cells should be easily measured by microscopy. 
A.4.2.1 In situ saturation of hHS1 by digitonin permeabilization 
 Transfect cells with hHS1 for 48 hours using any of the above protocols. If cells 
are not over 50% confluent, change media and harvest the next day. Before harvesting, 
pre-warm water baths to 30 °C and 37 °C. Heat regular media to 37 °C. Make 15mM 
hemin chloride stock (10mg/mL in DMSO), 100mM ascorbate stock (17.6mg/mL in 
PBS), and 814μM digitonin stock (1mg/mL in PBS). Acquire cells from CO2 incubator 
and bring to 3D. Aspirate old media. Replace media with 1mL prewarmed 37 °C media. 
Add 49.2 μL digitonin stock = 40 μM digitonin, add 6.5 μL hemin chloride stock = 100 
μM heme, swish cells around to disperse digitonin and heme, then add 10 μL of ascorbate 
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stock = 1 mM ascorbate. Swish around again. Next, pipet cells up and down to detach 
them from dish using 1 mL blue pipet set to 700-800 μL and stick cells in prelabelled 
Eppendorf tubes. Once all cells to be in situ calibrated are harvested, put them in 30 °C 
water bath for 30 minutes. Then pellet at 400 x g (0.4 x 1000g) for 4 minutes at 4 °C. 
Aspirate heme saturating media. 1mL PBS wash, then pellet again but at RT. Aspirate. 
Resuspend in 500μL PBS 1mM ascorbate. Then pass through BD Falcon tube and 
analyze by flow cytometry after running all other harvested samples. 
 This protocol only saturates the cytosolic and nuclear hHS1 but not mitochondrial 
hHS1. 
A.4.2.2 In situ saturation of hHS1 by digitonin permeabilization 
 Transfect cells with hHS1 for 40-48 hours using any of the above protocols. Next, 
change media to include a well that has 300 to 350 µM ALA in each well that you want 
to in situ saturate with heme. Treat with this media for anytime between 20-24 hours. 
Harvest and analyze by flow cytometry.  
A.5 Catalase Activity Assay – Unpublished 
 Any alternative method for investigating cellular heme availability is by 
interrogating heme dependent activity in the cell. If the design and characterization of the 
heme sensors did not work, we were going to conduct genetic screens to look at proteins 
that affect heme accessible to catalase, whose activity can be easily monitored in either 
in-gel or in-solution assays. I developed the in-solution assay to be used on a 96 well 
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plate scale to screen the yeast gene knockout collection for genes that alter catalase heme 
acquisition, which should lead to some proteins that affect heme trafficking. 
A.5.1 Cytosolic catalase acquires heme posttranslationally 
 Applying the in-gel activity assay to ctt1Δ, hem1Δ expressing either EV or a 
constitutively expressed Ctt1 reveals that catalase acquires its heme post translationally. 
Cells treated with cycloheximide, which arrests new protein synthesis, has about 45 % 
less catalase activity than the untreated sample, indicating that there may be a fraction 
of catalase that acquires its heme cotranslationally (Figure A. 15). 
 
Figure A. 15 – Posttranslational and cotranslational heme acquisition by cytosolic 
catalase. Heme deficient ctt1Δ, hem1Δ cells with and without constitutive expression of 
cytosolic catalase protein, ctt1p, by the TEF promoter (prTEF) reveals that heme can be 
acquired by catalase post translationally. Cells were grown in 10mL cultures of SCE-
LEU media to an OD of 1.0, washed in Sterile MilliQ, resuspended in fresh media to an 
OD of 0.65, and then treated with and without 10 µg/mL cycloheximide for 60 minutes to 
arrest new protein synthesis. The cycloheximide treatment was followed by a 60 minute ± 
38 µM hemin treatment from a 10 mg/mL hemin chloride DMSO stock of hemin to 
facilitate heme acquisition in these heme deficient cells. Cells were harvested and washed 
3 times in MilliQ water, lysed, and ran on a native gel and stained for catalase activity. 
The results indicate strong catalase activity in heme treated cells that express the 
constitutively expressed ctt1p, and there is 1.8-fold more catalase activity in cells 
untreated with cycloheximide, suggesting that some component of catalase heme 
acquisition may happen cotranslationally, assuming there is no change in catalase 
expression between the two samples. 
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A.5.2 Catalase activity assay developed for en masse screen of the yeast knockout 
collection 
 To conduct the stain to cells in solution, cells resuspended in 100 µL MilliQ have 
35 µL of a catalase staining solution added to them. The catalase staining solution 
contains 1 part Dopamine (20mg/mL) in pH 8 0.2 M KPi buffer, 1 part para-
phenylenediamine (3.5mg/mL) in pH 8 0.2M KPi, 1 part 15% H2O2, and 2 parts DMSO 
were mixed in the order listed. The cells’ response is measured in a kinetics run 
measuring absorbance at 530 nm. At the point that the activity levels off, deemed the 
endpoint, the A530 of each well was taken to be its catalase activity. 
 To be quantitative in a 96 well format, the procedure was optimized to ensure 
differences in cell growth could be accounted for between each well. 
 First, grow cells in 96-well plate(s), pellet the plate(s) at 4000 rpm, decant, and 
resuspend in MilliQ. From here, the A600 is taken to assess growth, and the A530, the 
wavelength that catalase activity is measured, is taken to get a background measurement 
to be subtracted from each well’s final A530. The A600 can be used to normalize each well 
to account for growth as there is a strong linear relationship of A600 and catalase activity 
measured for cells with an A600 between 0.1 and 1.5 measured in the 96-well plate in the 
BioTEK Synergy Mx multi-modal plate reader (Figure A. 16). The A530 is subtracted 
from each well’s catalase activity measured post adding reagent. 
 These methods were successful used to quantitate differences in catalase activity 
between mutants in the yeast gene knockout collection but was only applied manually to 
a few plates. The whole knockout collection should be screened thoroughly for genes that 
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contribute to differences in catalase activity in tandem with screens that affect HS1 or 
HS1-M7A sensor loading. 
 
Figure A. 16 – Linear relationship between catalase activity versus activity. (A) Plot 
showing linear relation between catalase activity measured at 530nm at the endpoint of a 
kinetic run monitoring the change in catalase activity versus the amount of cells 
measured by at 600 nm. (B) Normalizing the activity at 530 nm by dividing by growth 
measured at 600 nm results in a flat line. 
A.6 Plasmid Constructions and Heme Sensor Gene Sequences 
A.6.1 Plasmids 
Heme Sensor (HS1) Expression Plasmids. The synthetic gene for Heme sensor 1, 
HS1, was obtained from GENSCRIPT as codon optimized constructs for expression in 
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yeast/E. coli or human cell lines. HS1 was generated by fusing mKATE2240, 241 and 
CG6107.  












Red = mKATE2 Black = Linkers Green = EGFP Blue = Cyt b562  
Bold = Heme Iron Coordinating Residues  
For yeast and E. coli expression, CG6 and mKATE2 were ordered as two 
separate gene constructs from GENSCRIPT. The CG6 gene was flanked by 5’/3’ 
BamHI/HindIII sites and subcloned into plasmid pUC57.  






































For expression in human cell lines, HS1 was ordered as a codon-optimized single 




































For yeast expression, HS1 was generated by sub-cloning the 5’ XbaI/3’ BamHI 
mKATE2 fragment and the 5’ BamHI/3’ HindIII CG6 fragment into p415-ADH1, p415-
TEF, and p415-GPD yeast centromeric plasmids137. The BamHI site between the 
mKATE2 and CG6 gene sequences create a GlySer linker between the mKATE2 and 
CG6 domains.  
For E. coli expression, HS1 was sub-cloned into a variant of pET30a(+) (EMD 
Millipore), pAR1008. pAR1008 is derived from pET30(+), but has a Tobacco Etch Virus 
(TEV) protease site (ENLFYQS) flanked by a 3’ BamHI site in place of the original 
thrombin protease site. Sub-cloning of a 5’/3’ BamHI/BamHI fragment of mKATE2 and 
a 5’/3’ BamHI/HindIII CG6 fragment, both generated by PCR, results in an expression 
plasmid that has a His6 tag, followed by a TEV protease site linked to HS1 via a GlySer 
linker.  
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For expression in human cell lines, the human codon optimized HS1 gene was 
sub- cloned into the 5’ BamHI and 3’ XhoI site of pcDNA3-EGFP (Addgene). This 
plasmid drives protein expression using a CMV promoter.  
Heme Sensor Variants. PCR based mutagenesis was used to generate variants of 
HS1 with an additional Gly Ser linker between mKATE2 and CG6, or with mKATE2 at 
the C-terminus of CG6. For the latter, one or two (Gly Ser) linkers between CG6 and 
mKATE2 were introduced. In addition, a stop codon was introduced into mKATE2 using 
Quick Change mutagenesis (Agilent Technologies). These constructs are highlighted in 
Figure 2.6 and are driven by the GPD promoter in p415-GPD. Using similar PCR based 
approaches, an mKATE2-EGFP fusion construct lacking Cytochrome b562 was generated 
and sub-cloned into appropriate expression yeast, E. coli, or mammalian cell expression 
plasmids.  
For mitochondrial matrix or nuclear targeting in yeast, heme sensors were fused 
to N-terminal COX4118 or C-terminal SV40121 localization sequences, respectively. For 
mitochondrial matrix targeting, a COX4 matrix-targeting pre-sequence was amplified 
from yeast genomic DNA with a 5’ SpeI site and a 3’ HindIII site. HS1 was PCR 
amplified to include a 5’ HindIII site and a 3’ SalI site. The COX4 and HS1 amplicons 
were then sub-cloned into the SpeI and SalI sites of p415-TEF.  
For nuclear targeting, HS1 was PCR amplified using mutagenic primers that 
incorporate the SV40 NLS sequence (5’-CCTAAGAAGAAGAGGAAGGTT-3’) prior to 
the stop codon. The HS1-SV40 amplicon included 5’ SpeI and 3’ HindIII sites for sub-
cloning into p415-GPD.  
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For all expression plasmids, heme binding site mutations of HS1 in which Met7 or 
His102 are mutated to Ala were generated by Quick Change mutagenesis (Agilent 
Technologies). The numbering refers to its position in Cytochrome b562 and is highlighted 
in bold in the sequence for HS1. 
For subcellular targeting: 
Yeast cyto HS1 is p4XX-XXX-[usually SpeI]-HS1-[usually HindIII], depending on the 
construct there are a few different ones made for different subcloning purposes but most 
are 
p4X5-XXX-[SpeI]-HS1-[ HindIII] 
Underlined, bold text is Restriction Enzyme Site 
Start and stop codons are in lower case to distinguish them in the sequences. 






























The p4X5-XXX-[SpeI]-HS1-[ HindIII] plasmids can be amplified using: 
prDH011; GCGAATGCAACTAGTCATATGCACATGG; 5’ to 3’; contains SpeI 
restriction site; Forward Primer 
prRC007; GGATATAAGCTTTCATTTATACAGTTCATCCATACCC; 3’ to 5’; 
Contains HindIII restriction site; Reverse Primer 
 
Mitochondrial targeted plasmid, originally made as, pDH049-3; p415-TEF-[SpeI]-Cox4-
[HindIII]-HS1-[SalI] 






































The ; p415-TEF-[SpeI]-Cox4-[HindIII]-HS1-[SalI] plasmids can be amplified using: 
prDH015; GCCATACAAATAGATAACAACTAGTATGCTTTCACTACG; 5' to 3'; 
contains overlap with Cox4 targeting presequence and SpeI Restriction site; Forward 
Primer 
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prDH034; GGATATGTCGACTCATTTATACAGTTCATCCATACCC; 3' to 5'; 
contains SalI Restriction site; Reverse primer 






































(NLS tag from prDH024) 
The ; p415-GPD-[SpeI]-HS1-NLS-[HindIII] plasmids can be amplified using: 
prDH015; GCGAATGCAACTAGTCATATGCACATGG; 5’ to 3’; contains SpeI 




CCATAC; 3’ to 5’; contains NLS sequence and HindIII restriction site; Reverse primer 
A.6.2 Gene Knockout Construction and Validation 
hem1::HIS3 Knockout Plasmid and hem1∆ Strain Generation. In order to 
generate a hem1::HIS3 knockout plasmid, the 5’ and 3’ untranslated regions (UTR’s) of 
HEM1 were amplified from yeast genomic DNA. The 5’ UTR (-300 to +79) was 
amplified to include 5’ BamHI and 3’ SalI sites. The 3’ UTR (+1695 to +2195) was 
amplified to include 5’ EagI and 3’ BamHI sites. The 5’ and 3’ UTRs were digested with 
the enzymes indicated and ligated in a trimolecular reaction into the HIS3 integrating 
plasmid pRS403 242 digested with EagI and SalI, resulting in pDH001. Transformation of 
BY4741 with pDH001 linearized with BamHI resulted in deletion of HEM1 sequences 
from +80 to +1694. hem1∆ cells were initially selected for on SC-HIS media 
supplemented with 50 μg/mL 5-ALA. After isolation of single colonies, bona fide hem1∆ 
cells were selected for their heme auxotrophy. That is to say, strains that exhibited limited 
growth in YPD or SC media, and robust growth in media supplemented with 50 μg/mL of 
5-ALA or hemin, were deemed genuine hem1∆ cells. 
Primers used for the construction the 5’ UTR of HEM1 include: 
Forward primer: prDH001; contains BamHI site; covers --300 to -273; 
GCCTTGCCCATTGTTCGGATCCATGCG 
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Reverse primer: prDH002; contains SalI site; covers 49 to 79; 
GCTGTCGTCGACAGCCTATTCAGTGTGG 
Primers used for the construction the 5’ UTR of HEM15 include: 
Forward primer: prDH003; contains EagI site; covers 1170 to 1200; 
CCAATATATGCATCGGCCGAGATAGAGGTACAAGG 
Reverse primer: prDH004; contains BamHI site; covers 2163 to 2195; 
CGCTGATGTTCCATTGGATCCAGAGTCTAAGGC 
 hem15::HIS3 Knockout Plasmid and hem1∆ Strain Generation. In order to 
generate a hem15::HIS3 knockout plasmid, the 5’ and 3’ untranslated regions (UTR’s) of 
HEM15 were amplified from yeast genomic DNA. The 5’ UTR (-836 to +218) was 
amplified to include 5’ BamHI and 3’ SalI sites. The 3’ UTR (+1170 to +1648) was 
amplified to include 5’ EagI and 3’ BamHI sites. The 5’ and 3’ UTRs were digested with 
the enzymes indicated and ligated in a trimolecular reaction into the HIS3 integrating 
plasmid pRS403 242 digested with EagI and BamHI, resulting in pDH019. Transformation 
of BY4741 with pDH019 linearized with BamHI resulted in deletion of HEM15 
sequences from +219 to +1. hem15∆ cells were initially selected for on SC-HIS media 
supplemented with 25 μM hemin chloride, 0.16% DMSO. After isolation of single 
colonies, bona fide hem15∆ cells were selected for their heme auxotrophy. That is to say, 
strains that exhibited limited growth in YPD or SC media, and robust growth in media 
supplemented with hemin were deemed genuine hem15∆ cells. 
Primers used for the construction the 5’ UTR of HEM15 include: 
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Forward primer: hem15-1; contains BamHI site; covers -836 to -801; 
GCATTCAGTGGGAAGGATCCCAATAAGCAGATAGC 
Reverse primer: hem15-2; contains SalI site; covers -245 to -218; 
GGCAGCAACTCCGTCGACATATAAGGC 
Primers used for the construction the 3’ UTR of HEM15 include: 
Forward primer: hem15-3; contains EagI site; covers 1170 to 1200; 
CGAATCTACTTGATAACGGCCGTTCATCCC 
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